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Medbche M 
Bi!f-�fhf©en tleh rende bij het proefschrift: Programming of Lipid Metabolism 
Groningen G 
--i--tr?""trO'C'lfflT.,., van LXR in de foetale muizenlever kan worden bereikt door het 
toedienen van een synthetische agonist aan het dieet van de moeder tijdens 
de zwangerschap. (dit proefschrift) 
2. De verhoogde expressie van LXR targetgenen in de foetale muizenlever, als 
gevolg van het toedienen van een synthetische LXR agonist aan het dieet 
van de moeder, heeft geen gevolgen voor het cholesterolmetabolisme in de 
nakomelingen op jongvolwassen leeftijd. (dit proefschrift) 
3. Ondervoeding tijdens de zwangerschap leidt in muizen en mensen niet per 
definitie tot een lager geboortegewicht van de nakomelingen. 
(dit proefschrift en Gluckman PD et al, Nat. Rev. Endocrinol., 2009 Jul;5(7 ):401-
8) 
4. Het geven van een laag-eiwitdieet tijdens de zwangerschap aan muizen 
leidt tot een verschuiving in de methyleringsstatus van het DNA van de 
nakomelingen en niet enkel tot DNA demethylering, zoals Lillycrop et al 
suggereert. (dit proefschrift vs. Lillycrop et al, J Nutr 135: 1382-1386, 2005) 
5. Een laag-eiwitdieet tijdens de zwangerschap leidt in muizen tot 
geslachtsspecifieke verschillen in het glucosemetabolisme van de 
nakomelingen. (dit proefschrift) 
6. Ook met de toegenomen kennis van voeding en stofwisseling op fysiologisch 
en moleculair niveau is het beste advies dot een voedingskundige kan geven 
nog steeds: 'eet gevarieerd en matig'. 
7. When you want to make a lady, start with her grandmother. 
(Catherine Suter, Epigenetics Meeting 2007, Perth, Australia) 
8. The key thing about a forecast is that it is made in advance. 
(Gluckman PD, Hanson M, Mismatch: Why our world no longer fits our bodies, 
Ox Univ Press, 2006) 
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A substantial number of studies show that limited supply of nutrients to 
the fetus, reflected by a low birth weight, is an epidemiological risk factor 
for the development of metabolic diseases at adult age. The limited sup­
ply of nutrients to the fetus could be the result of maternal (under)nutrition. 
This negative relationship between maternal nutrition and health of the 
offspring has lead to several hypotheses on the 'developmental origins of 
health and disease' (DOHaD) , or 'metabolic programming'. The mecha­
nism behind metabolic programming is still largely unknown. 
Developmental origins of health and disease hypotheses - historical over­
view 
During the past decades, several hypotheses on the relation between 
the gestational environment and the development of diseases later in life 
have been postulated (51) . In 1991, the term programming was introduced 
by Lucas, who defined this as "the induction, deletion, or impaired devel­
opment of a permanent somatic structure or the "setting" of a physiologi­
cal system by an early stimulus or insult operating during a "sensitive" pe­
riod, resulting in long-term consequences for function" (44) . This definition is 
consistent with the "thrifty phenotype" hypothesis, proposed by Hales and 
Barker in 1992. This hypothesis suggests that when the fetal environment is 
suboptimal, an adaptive response will occur, which optimizes the growth 
of key organs to the detriment of others and leads to an altered postnatal 
metabolism designed to enhance postnatal survival under conditions of 
intermittent or poor nutrition (18) . 
This is not the only hypothesis that has been put forward to explain asso­
ciations between fetal environment and later disease risk. The thrifty geno­
type hypothesis of Neel (53) proposed that genetic factors could underlie 
the risk of type 2 diabetes. According to the thrifty genotype hypothesis, 
certain genetic variants have provided survival advantage during histori­
cal periods of irregular food supply, and have therefore undergone posi­
tive selection. This hypothesis suggests that the current high prevalence of 
type 2 diabetes and obesity is a consequence of the survival of these gen­
otypes in a period of nutritional overabundance (Southam L, Diabetologia, 
2009 in press) . The thrifty phenotype model, on the other hand, argues that 
an environmental rather than a genetic component predisposes for the 
later development of type 2 diabetes and cardiovascular diseases, e.g. 
the environmental factor poor fetal nutrient supply (18) . However, the thrifty 
genotype hypothesis and the thrifty phenotype hypothesis are not neces­
sarily mutually exclusive, because the former can account for selection 
over many generations and hence population differences in susceptibility 
to diabetes, whereas the latter could be relevant to adaptation within an 
individual's lifespan (40; 75) . 
In 1999, the term metabolic imprinting was coined by Waterland and 
Garza (73). This term is intended to encompass adaptive responses of the 
organism to specific nutritional conditions in early life that are character-
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Cl 
ized by l) a susceptibility limited to a critical ontogenic window early in 
development; 2) a persistent effect lasting through adulthood; 3) a specific 
and measurable outcome, which may differ quantifiably among individu­
als; and 4) a dose-response or threshold relation between a specific expo­
sure and outcome {51). 
It has been proposed in 2004 by Barker that the term developmental 
plasticity would be more appropriate than programming. The formal defi­
nition of developmental plasticity is "the ability of a single genotype to 
produce more than one alternative form of structure, physiological state, 
or behaviour in response to environmental conditions" {l). 
Also in 2004, Bateson et al proposed that the original concept of the 
thrifty phenotype hypothesis, which applied specifically to conditions of in­
trauterine deprivation, may be too limited as an overarching hypothesis for 
the developmental origins of adult disease and that that the adaptive re­
sponses of the embryo or fetus to a range of prenatal environments should 
be viewed in a broader, evolutionary context. They state that humans -like 
many other organisms- are capable of developing in a variety of ways, 
forming characteristics that are often well adapted to the environmental 
conditions in which they find themselves (3). 
Parallel to this hypothesis, Gluckman and Hanson proposed the Predic­
tive Adaptive Response theory in 2004. This theory combined features of 
the thrifty genotype hypothesis and the thrifty phenotype hypothesis. In 
this model, the fetus constantly interprets the environment created by the 
maternal milieu and placental function. Some fetal responses are imme­
diately adaptive; others reflect developmental disruption that might have 
effects throughout life. Still others have little immediate adaptive value, 
but are advantageous by establishing metabolic physiology appropriate 
for the postnatal predicted environment. These responses are appropriate 
if the predicted and actual postnatal environments match, but inappropri­
ate if they do not ( 16). All aforementioned hypotheses are summarized in 
Table l. 
Table 1. Hypotheses of fetal origins of health and disease 
Hypothesis Author Year published Reference 
Programming Lucas et al. 1991 44 
Thrifty Phenotype hypothesis Hales et al. 1992 18 
Thrifty Genotype hypothesis Neel et al. 1969 53 
Metabolic imprinting Waterland et al. 1999 73 
Developmental plasticity Barker et al. 2004 1 
Evolutionary approach Bateson et al. 2004 3 
Predictive Adaptive Response Gluckman et al. 2004 16 
Introduction 
However, in many studies, metabolic programming is still used to de­
scribe effects on metabolism in adult offspring that have their origin in the 
conditions that were present during fetal development. In the studies de­
scribed in this thesis, the terms 'metabolic programming' or 'fetal program­
ming' are used to describe long-term effects of pharmacological or nutri­
tional interference with metabolism during fetal development. 
Metabolic diseases and fetal programming 
Cardiovascular disease and hypertension 
A strong epidemiological association has been demonstrated between 
maternal environment and health of the offspring at a later age. In 1987, 
Barker and colleagues found that birth weight and weight at 1 yr of age 
below average were associated with an increased risk of death from car­
diovascular disease or stroke in a cohort of men and women born in Hert­
fordshire, England between 1911 and 1930 (2). A study in Sweden includ­
ing 15,000 Swedish men and women with a 97% follow-up over a period 
of more than 50 yr showed that individuals in the lower quartiles of birth 
weight compared with those in the highest quartile had increased death 
rates from ischemic heart disease (36). In the Nurses Health Study in the 
United States which includes 121,700 women who have been followed 
since 1976, strong negative associations were found between self-reported 
birth weight and non-fatal coronary heart disease and stroke (66). The as­
sociation between birth weight and higher blood pressure levels has now 
been confirmed in many other studies (11; 37; 49; 65; 67; 71), although not 
in all (69). 
Obesity and metabolic syndrome 
The global prevalence of adult and childhood obesity has markedly in­
creased during the past two decades. Currently over 50% of all adults in 
the United States is overweight, i.e., have a BMI of >25 kg/m2 (9; 55). An 
increase in the prevalence of obesity (BMI >30 kg/m2) is associated with an 
increase in a range of comorbidities including type 2 diabetes, high blood 
pressure and ischemic heart disease (24). A range of epidemiological stud­
ies has shown the relationship between birth weight and BMI in childhood 
and in adult life (10; 26; 47). Central or truncal obesity is associated with 
the clustering of pathologies which defines the insulin resistance or meta­
bolic syndrome (hypertension, dyslipidemia, hyperinsulinemia, impaired 
glucose tolerance or frank diabetes) (62). Whereas people who were small 
babies tend to have a lower BMI in adult life than people who were larger 
at birth, these former individuals tend to have a more abdominal distribu­
tion of obesity, a significantly reduced muscle mass, and a high body fat 
content in adolescent and adult life despite their lower BMI (34; 41; 42; 46). 
Small size at birth has also been associated with parameters of insulin resis­
tance and with the metabolic syndrome. After adjustment for current BMI, 
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there is a negative relationship between birth weight and these outcomes. 
Exposure to a reduced nutrient supply in early pregnancy, as occurred in 
the Dutch Winter Famine in 1944-1945, was associated with increased in­
cidence of obesity in later life. People exposed to this famine during early 
gestation, had a relatively higher body weight, BMI, and waist circumfer­
ence at adult age (63; 70) . 
Animal models for fetal programming 
Despite many human and animal studies investigating fetal program­
ming, the pathophysiological and metabolic mechanisms of fetal program­
ming are still largely unknown. A widely used rodent model to unravel the 
pathophysiological mechanisms underlying programming events involves 
administration of a low protein diet during the gestational period. The goal 
of this dietary regime is to mimic human low birth weight and/or catch-up 
growth. In 1994, Langley and Jackson reported that feeding pregnant rats 
low-protein diets (between 60 and 120 g protein/kg diet, instead of 180g 
protein/kg) resulted in a decreased birth weight and increased blood pres­
sure in the offspring, compared with control animals (30) . Subsequent stud­
ies using this 'Southampton low-protein diet' showed that when rat dams 
are fed low-protein diet (90 g/kg: 9 wt % protein diet) during pregnancy, 
the offspring had higher systolic blood pressure at the time of weaning at 
4 wk of age (30) and developed hypertension by 7 and 18 wk of age (6; 31) . 
Not only undernutrition or an impaired fetal growth, but also fetal over­
nutrition has been associated with negative health effects later in life. Epi­
demiological studies show associations between excessive weight gain in 
pregnancy and the BMI of the adolescent child (57 ) .  Additionally, associa­
tions between maternal hypercholesterolemia and detrimental effects on 
the development of atherosclerosis in their children have been shown (52) . 
A model used for overnutrition during fetal development is adjusting litter 
size immediately after birth. Studies in rats demonstrate that pups from small 
litters were heavier than those from large litters in adult life (58) . The early 
postnatal overnourishment of rats growing up in small litters of only three 
pups per litter leads to increased early weight gain and fat deposition, fol­
lowed by hyperphagia and obesity combined with hyperleptinemia, hy­
perglycemia, hyperinsulinemia, and insulin resistance (43; 60) . Interestingly, 
rats exposed to undernutrition in utero may also develop increased body 
fat mass, but the extent depends on the degree and timing of malnutrition 
and the nature of the postnatal diet. When rats are undernourished (50% 
decrease in energy intake) during the first 2 weeks of pregnancy and given 
a normal diet during the third week, the male offspring develop significant 
hyperphagia and obesity when maintained on a high-fat diet (27) .  Female 
offspring showed hyperinsulinemia and hypertriglyceridaemia (12) . 
As stated above, the pathophysiological and metabolic mechanisms of 
fetal programming are still largely unknown. One possible mechanism in­
volves epigenetic regulation (see below) . Furthermore, these experiments 
show that prenatal nutrition has differential effects on male and female 
offspring. 
Introduction 
In conclusion, the nutritional status of the mother affects the susceptibil­
ity to develop cardiovascular diseases later in life. An important risk factor 
for the development of atherosclerosis -a prerequisite for the majority of 
cases of cardiovascular disease-, is having excess plasma cholesterol con­
centrations. Therefore we were particularly interested in the effects of fetal 
programming on cholesterol metabolism. A short overview of cholesterol 
metabolism and its role during fetal development is given below. 
Cholesterol metabolism 
Cholesterol is a key component of every mammalian cell membrane. It 
is essential to maintain membrane integrity and consequently the structure 
and function of membrane-bound proteins (50). Cholesterol also serves as 
a precursor of steroid hormones, bile acids and other metabolic mediators 
such as oxysterols. During embryogenesis, cholesterol is involved in pattern 
formation in the developing organism: cholesterol is covalently linked to 
hedgehog proteins which are crucial for pattern formation in all animals 
from Drosophila to humans. Finally, cholesterol is essential for the function 
of the myelin sheaths and therefore indispensable for brain development 
(48). 
Cholesterol synthesis 
Cholesterol is synthesized from acetyl-CoA. The liver and intestine are 
considered to be the major sites of cholesterol synthesis in adult life (13; 
72). The enzyme activity of hydroxymethylglutaryl-coenzyme A reductase 
(HMGR) constitutes the rate-controlling step in the cholesterol synthesis 
pathway. Sterols are derived from the circulation in all tissues, with the pos­
sible exception of the brain (14). Cholesterol is carried in the circulation 
in the form of lipoproteins: very-low-density lipoprotein (VLDL), low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL). Lipoprotein choles­
terol is cleared from the plasma by receptor-mediated and receptor-inde­
pendent processes. Receptor-mediated uptake is based on competition 
and saturation kinetics, related to plasma cholesterol concentrations. The 
receptor-independent processes are not saturable and are independent 
of plasma cholesterol concentrations. 
Regulation of cholesterol metabolism 
A key regulator of cholesterol metabolism is the Liver X Receptor (LXR). 
LXR is a nuclear receptor and is a member of the nuclear receptor super­
family of ligand-activated receptors. In humans this family consists of 48 
identified members. Nuclear receptors act as ligand-inducible transcrip­
tion factors by directly interacting with DNA response elements in pro­
moter regions of their target genes. Upon their activation by specific li­
gands nuclear receptors can act as monomers, as homodimers, and as 
heterodimers with the Retinoid X Receptor (RXR). Two isoforms of LXR are 
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known, LXRa, predominantly expressed in liver, intestine and adipose tis­
sue, and LXRl3, that has a more ubiquitously expression pattern (35; 64} . 
LXRs form obligate heterodimers with the retinoid X receptor, RXR. Endog­
enous ligands of LXRs are oxysterols, oxidized cholesterol derivatives with 
24(S} , 25-epoxycholesterol being the most potent one, and 6a-hydroxy bile 
salts. Oxysterol s are formed as by-products during cholesterol synthesis as 
well as by oxidation of dietary cholesterol. Synthetic, highly effective non­
steroidal LXR agonists are available for both in vi tro and animal studies, 
amongst which T0901317 is the best characterized (4) . When activated, 
LXR/RXR complex induces transcription of target genes which encode for 
a variety of proteins that are all involved in cholesterol efflux such as Abcal , 
Abcg5, Abcg8, Abcgl and Cyp7al (in rodents} . Activation of LXR resul ts 
in an increase in plasma HDL-cholesterol, reduced cholesterol absorption, 
increased hepatobi l iary cholesterol secretion and increased neutral sterol 
loss via the faeces. Based on these effects, LXR activation has antiathero­
genic effects. However, LXR does not exclusively activate genes involved 
in cholesterol disposal. Synthetic activation of LXR also induces sterol regu­
latory element binding protein l e  (SREBPl c} that subsequently activates 
the lipogenic genes acetyl-CoA carboxylase (ACC} , fatty acid synthase 
(FASN} and stearoyl-Coenzyme A desaturase 1 (SCDl } (77} ,  genes involved 
in lipogenesis, leading to hypertriglyceridaemia through production of 
larger VLDL particles, and hepatic steatosis (17 } .  
Fetal cholesterol metabolism 
Theoretically, a fetus could derive cholesterol either from the mother via 
transport across the placenta, or via de novo synthesis in the embryonic 
or fetal organs. Unlike the adult, the cholesterol homeostasis is not (yet} in 
steady state because of rapid growth and development, the fetus accrues 
cholesterol. Not surprisingly, the rates of sterol synthesis are much greater in 
the fetus than in the adult ( 1 4} .  I n  addition to increased biosynthesis, several 
lines of evidence support the concept that the fetus also acquires choles­
terol from an exogenous source, i .e. from placenta and/or maternal supply. 
Defects in cholesterol synthesis or in its intracellular routing can have 
devastating consequences for the individual. In humans, several inborn 
errors of cholesterol metabolism are known. The inabi li ty to convert 7-de­
hydrocholesterol (7-DHC} to cholesterol, which represents the final step 
in cholesterol biosynthesis (61} , is the biochemical basis of the Smith Lemli 
Opitz syndrome (SLOS} . SLOS is an autosomal recessive syndrome caused 
by mutations in the DHCR-7 gene which encodes for the enzyme that con­
verts 7-dehydroxycholesterol to cholesterol, which is an obligate step in 
cholesterol biosynthesis. Despite this defect in cholesterol biosynthesis, 
newborns with SLOS do have a small amount of cholesterol in plasma and 
tissues. Importantly, investigators found measurable amounts of cholesterol 
in infants with the null/null genotype (39; 54} . By inference, patients must 
have had at least some access to a source of cholesterol in utero. 
I ntroduction 
Since the Liver X Receptor is a key regu lator of adult cholesterol trans­
port and metabol ism, it presumably a lso has a major role in regu lating feta l 
cholesterol transport and metabol ism. We therefore a imed to investigate 
the role of LXR during different stages of feta l development, and examined 
whether synthetical ly activating LXR during feta l development wou ld influ­
ence feta l cholestero l  transport and metabol ism. 
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Figure 1 .  Schematic overview of the Liver X Receptor and Its methods of action. Within the nucleus, LXR/RXR 
heterodimers are bound to LXREs in the promoters of target genes and in complex with corepressors. In response 
to the binding of oxysterol (LXR) and retinoic acid (RXR) ligands, the corepressor complexes are exchanged for 
coactivator complexes, and target gene expression is induced. Upon activation, LXR promotes net cholesterol 
excretion. LXR induces ABCA 1 expression in liver and intestine. ABCA 1 mediates the efflux of cholesterol to HDL. 
LXR also induces the halftransporters ABCGS and ABCG8, which secrete cholesterol into bile in the liver and limit 
dietary cholesterol uptake in the intestine. Furthermore, LXR activation leads to activation of the fatty acid syn­
thesis pathway, leading to the formation of trigylcerides in the liver. ABCA 1 /GS/G8, Abe-transporter a 1 ,  gS and 
g8; Fas, Fatty acid synthase; HDL, High density lipoprotein; Srebp 1 c. Sterol regulatory binding protein 1 c .  
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Embryonic and fetal development 
The human zygote undergoes multiple cleavages during the first week 
after fertilization (33). In the second week, the trophoblasts that make up 
the outer cells of the newly formed blastocyst invade the uterine endome­
trium; the inner cell mass, or embryoblast, gives rise to the embryo. Dur­
ing this time, maternal blood and remnants of cells digested from tropho­
blast invasion bathe the conceptus. As development progresses, maternal 
blood flows into lacunae (large vacuoles) within the uterus, forming the 
uteroplacental circulation and coming into direct contact with syncytiotro­
phoblasts. Between approximately the fourth week and the eighth week 
of gestation, only small amounts of maternal blood leak into the lacunae 
or intervillous space of the placenta, as spiral arteries are plugged early 
in gestation (7; 21 ). The uterine glands secrete nutrients, including lipids, 
to the intervillous space as well (8; 20). Nutrients in the intervil lous space 
thus contain components of maternal blood, such as cholesterol-carrying 
lipoproteins, and uterine gland secretions, such as lipids and presumably 
cholesterol. As development proceeds, a more efficient method of nutri­
ent exchange develops and the placenta becomes the primary route of 
transport. The maternal blood enters the intervillous space and bathes the 
syncytiotrophoblasts of the chorionic villi. By this time, there is an extensive 
fetal vascular network at the basal membrane of the trophoblasts (25). Ma­
ternal nutrients, such as lipids and presumably cholesterol, are taken up by 
the syncytiotrophoblasts by receptor-mediated as well as receptor-inde­
pendent processes. Once taken up, nutrients cross cells and pass through 
or between endothelial cells to enter the fetal circulation. Because the ma­
ternal blood within the intervillous space exchanges three to four times per 
minute, it is an excellent source of nutrients for the developing fetus. 
Rodents, like rats and mice, are popular models to study vertebrate de­
velopment and metabolism. The differentiation and growth of the embryos 
and fetuses of the rodent and the human follow the same general pattern. 
In the rat and mouse the gestation takes about 21 days. Implantation of 
the zygote takes place around day 5. Rats and mice are born relatively im­
m ature compared to humans. The placentas of the rodent and the human 
have a very similar physiology. All have hemochorial placentas; i.e., mater­
nal blood is in direct contact with the trophoblasts. However, differences 
do exist: for example, the exchange between the maternal and fetal circu­
lations within the rodent is based on a labyrinthine matrix of blood vessels, 
whereas the human exchange is based on villi protruding into pools of ma­
ternal blood. Simply put, in the rodent placenta, maternal and fetal blood 
circulates in vessels that are in close proximity to one another, and nutrients 
pass between trophoblasts separating the two vessels. In the human pla­
centa, the fetal vessels are layered under a layer of syncytiotrophoblasts, 
which is bathed in a pool of maternal blood (76). 
I ntroduction 
Epigenetics 
As stated above, epigenetic effects constitute one mechanism along 
which the fetal environment may have long lasting effects on an individu­
al's health later in life. The term 'epigenetics' is currently used to describe 
the study of stable alterations in gene expression potential that arise dur­
ing development and cell proliferation, without alterations in the DNA se­
quence (23). The two best-documented forms of epigenetic regulation 
include histone modifications and DNA methylation. 
In eukaryotes, DNA is packaged as chromatin in the nucleus (28). Chro­
matin is further organized into two different levels of general structure, 
heterochromatin ( ' silent') and euchromatin ( 'active' ). Heterochromatin re­
gions correspond to the bulk of nuclear material and constitute both telo­
meres and pericentric regions and these areas tend to be rich in repeti­
tive sequences and low in gene content. The remainder of the genome is 
considered to be euchromatin that contains most of gene-encoding DNA 
and is considered transcriptionally active. The nucleosomes are the basic 
unit of chromatin consisting of 147 bp of DNA wrapped around a histone 
octamer. Two copies of each of the following core histones are present 
in a mononucleosome: H2A, H2B, H3 and H4. All of them have a globular 
C-terminal domain and an unstructured N-terminal tail (45). A variety of 
modifications are associated with these tails. Histone modifications include 
methylation of arginine (R), methylation, acetylation, ubiquitination and 
sumoylation of lysines (K), and phosphorylation of serine (S) and threonine 
(T) (29; 68). Acetylation/deacetylation of lysines correlates with chromatin 
accessibility and transcription, whereas lysine methylation exerts a differ­
ent effect depending on the number of the methyl groups and position of 
lysine residues (29). Plasticity of euchromatin keeps DNA open for biologi­
cal activity, thus genes can be transcriptionally turned on or off. 
DNA methylation occurs by covalent modification of the fifth carbon 
(C5) in the cytosine base, and in vertebrates almost exclusively in cyto­
sine-guanine (CpG) dinucleotides. Most CpGs are methylated, meaning 
that they contain cytosine-coupled methyl groups (5). The extent of DNA 
methylation during mammalian development starts with almost complete 
demethylation during cleavage, after which de novo methylation takes 
place. Several DNA methyltransferases (DNMTs) regulate maintenance of 
DNA methylation (Dnmtl )  and de novo DNA methylation after implanta­
tion (Dnmt3a and 3b). Deletion of these DNMTs in mice results in embryonic 
lethality (38; 56), stressing that DNA methylation is essential for vertebrate 
development. 
In non-embryonic cel ls, about 80% of CpGs are methylated. However, 
certain short stretches of DNA enriched in C-G areas (CpG islands) gener­
ally remain unmethylated (15; 32). Most CpG islands are associated with 
gene promoters, possibly controlling in this way transcription factors and 
CpG-binding proteins. In a few specific cases, CpG islands do become 
methylated during development, leading to long-term shutdown of the as­
sociated gene (22). Animal studies indicate that DNA methylation status 
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of certain regions is susceptible to nutritional influences during fetal devel­
opment and that these epigenetic changes have life-long consequences 
(74) . It has been demonstrated in rats that administration of the Southamp­
ton low protein diet during gestation decreases methylation of the promot­
er of selected genes involved in metabolic processes including peroxisome 
proliferator activated receptor alpha (Ppara) and glucocorticoid receptor 
(Gr) , and causes upregulation of expression of these genes. 
In humans, it recently has been shown that people prenatally exposed 
to famine during the Dutch Famine have less DNA methylation of the IGF2 
gene compared with their unexposed, same-sex siblings (19 ) .  DNA methyl­
ation might therefore partly explain the permanent changes in physiology 
and metabolism of the fetus that lead to certain diseases at a later age. 
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Figure 2 Schematic representation of DNA Methylation 
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Scope of this thesis 
Human and animal studies indicate that the nutritional status of the 
mother during pregnancy affects long-term health of the offspring. This 
process, in which early adaptations to specific nutritional conditions per­
manently change the physiology and metabolism of the organism and 
continue to be expressed even in the absence of the condition that initi­
ated them, is termed "metabolic programming" {59) . The molecular mech­
anisms of metabolic programming are largely unknown. 
The aim of the research described in this thesis was to unravel molecular 
mechanisms and physiological consequences of metabolic programming. 
We have chosen to obtain metabolic programming by pharmacologically 
or nutritionally influencing the status of the mother during gestation. 
First, we investigated the role of the Liver X Receptor during fetal de­
velopment by means of a pharmacological LXR agonist. The nuclear re­
ceptor LXR is a major player in regulating cholesterol efflux and fatty acid 
synthesis. It has been suggested that LXR also plays a role in glucose me­
tabolism. The role of LXR in fetal cholesterol and lipid metabolism had not 
been defined so far. In Chapter 2 we review potential means of cholesterol 
transport across the placenta and discuss how the Liver X Receptor might 
be involved in maternofetal cholesterol transport. In Chapter 3 we describe 
experimental studies in which pharmacological activation of LXR influenc­
es placental cholesterol transport in human placenta's, human placental 
cell lines and in rodent placenta's. In Chapter 4, we describe the effects of 
pharmacologically activating Lxr during fetal development on cholesterol 
metabolism of the mouse fetus by administration of a synthetic Lxr ligand 
to the diet of the dam. 
In Chapter 5 we evaluated how this pharmacological activation of Lxr 
during fetal development affected fetal fatty acid and g lucose metabo­
lism in the mouse. In Chapters 4 and 5 we also investigated whether the 
pharmacological activation of Lxr during fetal development also affected 
cholesterol or fatty acid metaboli sm, respectively, into adulthood. 
In human physiology, nutritional conditions during gestation may ex­
ert a more common programming influence, compared to pharmaco­
logical interventions. We investigated metabolic programming in mice by 
nutritionally changing the status of the mother during gestation. A well­
known model to investigate metabolic programming is by providing the 
dam with a mild protein deficient diet containing 9% casein instead of 1 8% 
casein. A limited number of recent studies describe epigenetic changes, 
e.g .  changes in DNA methylation status of selected genes, in fetuses from 
dams receiving a protein deficient diet. In Chapter 6 we assessed genome­
wide changes in DNA methylation in livers from pups born from low protein 
dams, and whether epigenetic changes influenced hepatic RNA expres­
sion levels of genes involved in lipid metabolism. 
Chapter 1 
Since protein restriction in dams led to lower expression levels of sev­
eral genes involved in cholesterol metabolism in the fetal liver, we evalu­
ated in Chapter 7 whether a maternal low protein diet during gestation 
influenced cholesterol fl uxes from dam to fetus. Finally, we determined the 
long-term effects of receiving a diet low in protein during the gestational 
period (Chapter 8}. We evaluated effects at a physiological level, e.g. on 
insulin sensitivity and lipid metabolism, and at a molecular level, e.g. on 
gene expression patterns. 
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Abstract 
Cholesterol is an important sterol in mammals. Defects in cholesterol syn­
thesis or intracellular routing have devastating consequences already in 
utero: the Smith-Lemli-Opitz syndrome, desmosterolosis and Niemann-Pick 
Cl disease provide examples of severe human inherited diseases caused 
by mutations in cholesterol metabolism genes. On the other hand, elevated 
plasma cholesterol concentrations are associated with the development 
of atherosclerosis which represents a major health risk in Western societ­
ies. Moreover, several studies indicate that development of atherosclerosis 
may already start during fetal life. Hence, a carefully balanced regula­
tion of cholesterol metabolism appears of critical importance for both the 
development of the fetus and health of the adult. In the adult, the Liver 
X Receptor is a key regulator of cholesterol metabolism. Its target genes 
regulate cellular cholesterol efflux and thereby modulate whole-body 
cholesterol fluxes. LXR and several of its target genes have recently been 
demonstrated to be expressed in the placenta, which would provide a 
means to control delivery of maternal cholesterol to the fetus. Here we dis­
cuss the potential role of the placenta in the regulation of fetal cholesterol 
homeostasis and strategies to influence maternal-fetal cholesterol transfer. 
Cholesterol transport by the placenta 
The importance of cholesterol for intrauterine growth and 
development 
Stero ls fulfi l l  severa l indispensable roles in a l l  eukaryotic cel ls .  Cholestero l  
i s  an important sterol in mammals in quantitative terms. I t  i s  an  integra l  part 
of both plasma membrane and organe l le  membranes as wel l  as a precur­
sor for important molecules l ike bi le sa lts and steroid hormones. The impor­
tance of cholesterol for the organism is most obvious during ontogenesis, 
when the growing embryo and fetus require large amounts of cho lestero l  
for their rapidly g rowing ce l l  mass. 
During embryogenesis, cholestero l is i nvolved in pattern formation in the 
developing organism: cholesterol is covalently l inked to hedgehog proteins 
which are crucial for pattern formation in a l l  an imals from Drosophi la to hu­
mans (26) . I n  addition ,  cholesterol i s  essential for the function of  the myel in  
sheaths and therefore indispen•sable for brain development (5) . Defects in  
cholestero l  synthesis or intracel lu lar routing have devastating consequenc­
es for the individual .  I n  humans, the Smith-Leml i-Opitz syndrome, desmo­
sterolosis and N iemann-Pick C l  disease are wel l-documented examples 
for inherited diseases caused by mutations of genes invo lved in cholestero l  
metabol ism. 
I n  Smith-Lemli-Opitz syndrome, 7 dehydrocholesterol reductase activity 
is impaired which leads to abnormal low cholestero l  synthesis and accu­
mulation of the u ltimate cholestero l  precursor 7 dehydrocholesterol (52) . 
The Smith-Leml i-Opitz syndrome is characterized by menta l retardation ,  
microcephaly, and pattern defects as misplaced thumbs and congenita l 
cardiac abnormal ities. In desmostero losis, a defect in 24 dehydrocholes­
tero l  reductase (DHCR24) leads to accumulation of desmosterol in p lasma 
and various tissues, accompanied by mu ltiple congenita l anomal ies with 
deleterious effects in humans ( 1 8, 57) . N iemann-Pick Cl disease, in con­
trast, is caused by a mutation in the N PC l  gene which affects intracel lu lar  
cholesterol hand l ing and storage. Therefore, i t  i s  characterized by intracel­
lu lar cholestero l  accumulation, fol lowed by neurodegeneration startin g  
early in l ife. ( 1 0, 1 4, 31 ) .  
O n  the other hand, excess cholesterol a lso poses severe health burdens 
as it i s  an important risk factor for the development of atherosclerosis. Ath ­
erosclerosis i s  a pre·requisite for the  majority o f  cases o f  coronary heart 
disease, which is the most prevalent cause of death in industrial ized coun­
tries (47 ) .  I n  the pathogenesis of atherosclerosis, l ipids such as cho lestero l 
accumulate in macrophages in the vessel wal l  (29) . Cholesterol- loaded 
macrophages, so-cal led foam cel ls ,  form fatty streaks in the endothel ium 
of the vessel .  Due to the interaction with inflammatory blood cel ls, an  ath­
erosclerotic plaque may develop which subsequently can b lock the ves­
sel at its site of development or rupture and b lock smal ler vessels at other  
p laces, e.g. ,  the  heart or the  brain (47) . I nteresting ly, there i s  convincing 
evidence that the development of atherosclerosis is a process that starts 
a l ready early in l ife. It has been demonstrated that materna l  hypercholes­
terolemia leads to fatty streak formation,  i .e., pre-atherosclerotic lesions,  
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already in utero (35) . Furthermore, the size of atherosclerotic lesions in nor­
mocholesterolaemic children under 14 years was increasing faster in chil­
dren of hypercholesterolaemic mothers (36). Therefore, exposure to high 
levels of cholesterol in fetal life is most likely a risk factor for the develop­
ment of cardiovascular disease in the adult. 
Obviously, both a surplus and a shortage of cholesterol have detrimen­
tal effects in the embryo and the fetus. Consequently, sophisticated mech­
anisms exist to fine-tune cholesterol metabolism on the cellular level on the 
one hand and cholesterol homeostasis of the developing organism on the 
other hand. We propose a vital role of the Liver X Receptor (LXR) for the 
regulation of cholesterol metabolism in utero and discuss potential s trate­
gies to interfere with the processes involved as prevention of the burden of 
cardiovascular diseases or, on the other hand, as a means to ameliorate 
the consequences of inherited defects of cholesterol synthesis . 
Molecular regulation of cholesterol metabolism in the adult 
Cholesterol is of crucial importance for all cells in the body, but dietary 
intake and cellular demands vary widely, e.g. , during development and in 
different nutritional s tates. Therefore, considerable quantities of cholesterol 
are circulating in the blood compartment at all times to provide a s teady 
supply to cells ( 1 6, 17 ) :  in adult, non-pregnant humans, approximately 10 
mg cholesterol per kg body weight are on average synthesized per day. 
This amount is carefully adapted to dietary intake, i.e. , is high when intake 
is low and vice versa. 
During the last decade, transcription factors have been identified that 
control cellular cholesterol metabolism. The sterol regulatory element-bind­
ing proteins (SREBPs) are transcription factors heavily involved in the regu­
lation of lipid homeostasis .  Three SREBP isoforms are known, i.e. , SREBP-1 a, 
SREBP-1 c, and SREBP-2. When cells are depleted from cholesterol, SREBP-2 is 
proteolytically cleaved in a two-step process and escorted to the nucleus 
(7) .  Cleavage of the SREBPs is controlled by the SREBP cleavage-activating 
protein (SCAP) , a protein that is regulated by the level of s terols present 
inside the cell (8) . Target genes activated by SREBP-2 are mainly genes in­
volved in cholesterol synthesis, e.g., 3-hydroxy-3-methylglutaryl-coenzyme 
A (HMG-CoA) reductase (23) . It has been speculated that increased ex­
pression of the SREBPs is responsible for the accelerated synthesis of cho­
lesterol in fetal tissues (63) . However, time- and tissue-specific expression of 
this transcription factor has not been defined so far. 
The major player in regulation of cholesterol metabolism at the level of 
uptake and secretion - rather than synthesis - is the Liver X Receptor LXR. 
Two LXR isoforms are known, i.e. , LXRa (NRl H3) , which is highly expressed 
in the liver, and LXRB (NRl H2) with a more ubiquitous distribution (25, 41, 41, 
42, 60) . From these two, LXRa has been studied in most detail. LXR forms 
obligate heterodimers with the Retinoid X Receptor, RXR. Physiological li­
gands of LXR are oxysterols , oxidized cholesterol derivatives with 24(S) ,25-
epoxycholesterol being the most potent one, and 6a-hydroxy bile salts (24, 
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25, 25) . Oxysterols are formed as by products during cholesterol synthesis as 
well as by oxidation of dietary cholesterol. Synthetic, highly effective non­
steroidal LXR agonists are available for both in vitro and animal studies, 
amongst which T0901317 is best characterized (45) . 
The SREBP and LXR systems provide a means for cells to "sense" intracellu­
lar cholesterol concen,trations. When cells are depleted from cholesterol, 
cholesterol synthesis is activated in an SREBP-2-dependent manner. When 
cholesterol and its metabolites accumulate in cells, LXR becomes activat­
ed and the LXR/RXR heterodimer induces transcription of genes involved in 
cholesterol disposal from cells. Well-known target genes of LXR are Cyp7al 
(12) (encoding for cholesterol-7a-hydroxylase and consequently leading to 
increased catabolism of cholesterol to bile acids in the liver) , Srebpl c (43) 
(resulting in increased lipogenesis required for formation of cholesteryl es­
ter) and the adenosine triphosphate-binding cassette (ABC) transporters 
Abcal , Abcgl , Abcg5 and Abcg8 (leading to increased removal out of the 
cell) (27, 49, 54, 67) .  Both LXRa and LXRB have been shown to be expressed 
in the placenta as well as in BeWo cells, a widely used in vitro model of tro­
phoblasts; this will be discussed below (59) . 
Cellular cholesterol uptake and secretion 
Typical mammalian peripheral cells (non-hepatocytes) possess several 
ways to take up cholesterol from the blood. In the circulation, cholesterol 
destined for the periphery is present as Very-Low-Density Li po protein (VLDL) 
particle which is secreted by hepatocytes. Hydrolysis of VLDL-triglycerides 
by lipoprotein lipase leads to formation of Intermediate-Density Lipopro­
tein (IDL) . IDL can be further hydrolyzed to Low-Density Lipoprotein (LDL) or 
be cleared by the liver. LDL is finally taken up by the liver or by peripheral 
cells, including macrophages. Uptake of cholesterol and cholesterol esters 
in peripheral tissues is mediated by members of the LDL receptor family 
(i.e., LDL receptor, LDL receptor receptor-related protein) and scavenger 
receptors (6, 13) .  
Peripheral cells, in contrast to hepatocytes and enterocytes, are limited 
in the number of cholesterol removal pathways: they can only secrete ex­
cess cholesterol to the blood stream. The most important routes for cellular 
cholesterol secretion involve HDL particles. First, cholesterol and phospho­
lipids are transferred to lipid-poor HDL particles (pre B- HDL) via the action 
of the ABC transporter Al (Abcal ) (2, 56) . Cholesterol in the HDL particle is 
esterified by the action of lecithin:cholesterol acyltransferase (LCAT) , result­
ing in cholesteryl ester-rich, mature HDL particles. In humans, cholesteryl 
esters can be transferred to ApoB-containing particles, e.g. , LDL and VLDL 
particles, in a process mediated by the cholesteryl ester transfer protein 
(CETP) (3, 9) . In exchange, the HDL particle receives triglycerides which are 
subsequently hydrolyzed. In this way, a cholesterol-poor particle is regener­
ated which can function as a cholesterol acceptor in the periphery again 
(3, 9) . An alternative fate for the mature HDL particle is binding to scav­
enger receptor Bl (SR-Bl) at the membrane of the target cell, followed by 
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transfer of mainly cholesteryl esters to the accepting plasma membrane, a 
process commonly referred to as selective uptake (1) .  
A second, ABCAl -independent pathway has recently been proposed. 
ABCGl , at least in macrophages, is thought to transfer cholesterol and 
phospholipids to mature HDL particles (55) . As the majority of plasma HDL 
is in the form of mature HDL, this would be an important new route for cho­
lesterol disposal from cells. The expression of both ABCAl and ABCGl are 
regulated by LXR, which in this way is able to promote cholesterol efflux 
from cells. A similar role could putatively be played by ABCG4 in the brain 
where it is highly expressed (39) , but detailed data are still lacking. 
Putative mechanisms for cholesterol transport in the placenta 
The placenta is considered to separate the maternal from the fetal cho­
lesterol pool. Fetal synthesis can, in principle, accommodate a significant 
part of the demand of the growing fetus, at least in a variety of animal 
models (4, 11, 15, 62, 66) . Whereas all these studies suggest that the con­
tribution of maternal cholesterol to fetal cholesterol metabolism is limited, 
they do not rule out that maternal-fetal cholesterol transfer may be impor­
tant in specific physiological situations. Indeed, both clinical observations 
as well as in vivo and in vitro studies suggest that cholesterol transport from 
the mother to the fetus actually takes place. First, the presence of fatty 
streaks in fetal aortas is depending on cholesterol levels in the mother (35, 
36); second, cholesterol concentrations in fetal hamsters have been dem­
onstrated to correlate with maternal plasma cholesterol concentrations 
(33) ; third, in mice exchange of labeled cholesterol between mother and 
embryo or fetus has been demonstrated (65) and cholesterol has been 
quantified in fetuses unable to synthesize cholesterol (53). Last but not least, 
in vitro studies have demonstrated transport across monolayers of tropho­
blast-like cells (48) . 
Trophoblasts express all factors for allowing cholesterol transport from 
the maternal (apical) to the fetal (basolateral) side to occur. They express 
the LDL receptor, class A scavenger receptors and SR-Bl for uptake of ma­
ternal cholesterol from LDL and HDL particles, respectively (19, 22, 64) .  They 
furthermore express high levels of the ABC-transporters ABCAl and ABCGl , 
which could facilitate transfer of cholesterol to acceptor lipoproteins pres­
ent in fetal blood (30, 38) . Moreover, it has been demonstrated that also 
apolipoprotein genes (e.g. ,  ApoA-1, ApoB, ApoE) are expressed in the pla­
centa (32, 46) .  
SR-Bl has been demonstrated to be localized at the apical membrane in 
murine trophoblasts, deciduas endothelial cells, yolk sac and chorionic villi 
(22) . Its localization in human placenta has not yet been elucidated. Until 
now, the intracellular localization of ABCA 1 and ABCG 1 in trophoblasts has 
not been demonstrated. ABCAl and ABCGl are localized at the basolat­
eral membrane of all polarized cells investigated so far. It is tempting to 
speculate that, in analogy to other tissues, these transporters are situated 
at the basolateral membrane of trophoblast cells of the placenta as well. 
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In that case, a mechanism would exist to transport cholesterol across the 
trophoblast and transfer it to suitable acceptor particles, e.g., pre-B-HDL or 
mature HDL in the fetal circulation. This situation is schematically depicted 
in Figure 1. However, it should be noted again that no direct evidence con­
cerning the localization of ABCGl , ABCAl and SR-Bl in the trophoblast is 
currently available. 
Besides the pathways potentially mediated by ABCA 1 and ABCG 1, it 
should be mentioned that an important LXR-independent way of maternal­
fetal cholesterol transport exists. In the placenta as well as in the yolk sac of 
mice, all compounds of the microsomal triglyceride transfer protein (MTP)/ 
ApoB pathway are expressed. In short, the native ApoB protein is translo­
cated via the membrane of the endoplasmic reticulum. During transloca­
tion, it is folded and lipidated with phospholipids and some triglycerides 
by the action of MTP. Subsequently, it gathers lipid droplets present in the 
endoplasmic reticulum and/or the Golgi com·partment and thereby col­
lect the majority of its lipids. This process would lead to secretion of VLDL­
like particle to the fetus either by the placenta or the yolk sac (32, 32, 51). 
Mother 
Fetus 
Figure 1: Schematic overview of the hypothesized pathways of Liver X Receptor (LXR) regulated maternal-fetal 
cholesterol transport. 
LXR can be activated by endogenous ligands, the oxysterols, or by administration of specific synthetic LXR 
ligands, like T0901 3 1 7 (45). Upon activation, LXR forms a heterodimer with the Retinoid X Receptor (RXR) . This 
heterodimer, together with a plethora of co-regulators, binds to LXR response elements in the promoters of target 
genes, which leads to induced transcription of these genes. In the trophoblast, cholesterol is putatively taken up 
from maternal lipoproteins, i.e. LDL and HDL, by means of the LDL receptor and SR-B 1, respectively. Upregulation 
of the LXR target genes ABCG 1 and ABCA 1 in the trophoblast would subsequently result in increased cholesterol 
transport to the fetus. Please note that only putative localizations of transport proteins are given. 
The role of LXR in maternal-fetal cholesterol transport 
LXR has been demonstrated to be expressed in the placenta and in tro­
phoblast-like cell lines, e.g., JAR and BeWo (40, 41, 59). Schmid et al. have 
added oxysterols, the natural LXR ligands, to BeWo cells to measure LXR-
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dependent stimulation of cholesterol transport to ApoA-1 (48). In their ex­
periments, enhanced cholesterol transport was not observed, in line with 
unaffected ABCAl expression levels. However, pharmacological agonists 
of LXR are available which have been well-characterized in other cell lines. 
And indeed, treatment of BeWo and JAR cells with these agonist resulted 
in increased expression of LXR target genes in vitro (59). Consequently, it 
would be highly relevant to establish their putative influence on the LXR­
mediated cholesterol flux in trophoblasts s well as in animal model systems. 
We postulate that, in analogy to the regulatory actions of LXR in other 
cell types, LXR activation in trophoblasts in vivo would lead to increased 
expression of its target genes, e.g., ABCGl and ABCAl. Based on the spec­
ulative localization of the ABCGl and ABCAl proteins to the basolateral 
(fetal) side of the trophoblast, one could assume that LXR activation would 
increase cholesterol flux from the maternal to the fetal circulation. De­
pending on the lipidation status of acceptor particles in the fetal circula­
tion, both ABCGl- or ABCAl -dependent pathways seem to be possible, or 
even a combination of both. Therefore, LXR activation may be considered 
as a stimulus for increased transport of maternal cholesterol via the pla­
centa to the fetal circulation. 
Clinical relevance of placental LXR activation 
The question whether LXR activation will stimulate cholesterol transfer 
from the mother to the fetus is not a purely academic one but clearly has 
clinical impact. The use of (second-generation-) LXR agonists to remove 
cholesterol from the body as a tool against atherosclerosis is currently un­
der discussion (34, 37, 44). On the background of LXR expression in the pla­
centa, the potential use of those agonists during pregnancy needs careful 
evaluation. On the other hand, the mechanisms of maternal-fetal choles­
terol transfer we proposed above could possibly be a valuable means to 
direct cholesterol to fetuses with a known inherited deficit in cholesterol 
synthesis. Obviously, adequate in utero diagnostics or familial history of 
such defects would be required to initiate such an intervention . 
The underlying idea of the pharmaceutical use of LXR agonists is that 
LXR activation would promote reverse cholesterol transport, the removal 
of cholesterol from the periphery to the feces, and thereby lower the risk 
of atherosclerosis. First-generation-LXR agonists, like T0901317, have indeed 
been shown to stimulate cholesterol transport from the liver into bile and 
from intestinal cells into the intestinal lumen (28, 45). However, until now 
they have strong adverse effects, i.e., induction of hepatic steatosis (21). 
Therefore, strategies are sought to guide the LXR agonist to its target tissue, 
e.g. , intestinal cells or macrophages, to selectively stimulate cholesterol 
excretion without adverse hepatic effects. In the context of this review we 
would like to draw the attention to the possibly deleterious effects the use 
of LXR agonists could have on the fetus. 
It has been demonstrated (as discussed above) that fetal cholesterol 
levels correlate with those of the mother. Moreover, studies show that ath-
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erosclerotic plaques may already develop in utero. We here propose that 
LXR activation may stimulate cholesterol transport to the fetus. Conse­
quently, the use of unselective LXR agonists may influence the develop­
ment of atherosclerotic plaques already in the unborn, depending of the 
acceptor lipoproteins in fetal serum. It is therefore necessary to carefully 
analyze the consequences of placental LXR activation on fetal l ipoprotein 
profi les, namely if a more atherogenic profile is created. Thus, a critical 
evaluation of the use of LXR agonists during pregnancy is required. 
In  some cases, however, it would be favorable to promote cholesterol 
flux from the maternal to the fetal circulation. This is the case in inherited 
disorders of cholesterol synthesis, namely the Smith-Lemli-Opitz syndrome 
and desmosterolosis (18, 52, 57) . In those diseases, it is desirable to substi­
tute the deficit in cholesterol synthesized by the fetus with cholesterol from 
the mother: in the Smith-Lemli-Opitz syndrome, for example, it has been 
demonstrated that the severity of the impact on the child is correlated with 
the maternal apolipoprotein E genotype which may be indicative for the 
rate of cholesterol uptake by the placenta (61) and, potentially, for its efflux 
capacity to the fetus since ApoE stimulates cholesterol efflux from macro­
phages (20) . Secondly, although cholesterol-rich diets have been shown to 
be ineffective in children with Smith-Lemli-Opitz syndrome (50) , this inter­
vention may be too late in development and, therefore, inferior to an inter­
vention in utero. Similarly, it has been shown that in human desmosterolosis, 
patients are more severely affected than postulated based on a mouse 
model of the disease (58). This could be due to a higher transfer of mater­
nal cholesterol in mice than in human. Based on the assumption that LXR­
mediated processes are involved in maternal-fetal cholesterol transport, it 
is tempting to speculate that LXR activation could possibly ameliorate the 
symptoms in patients with the Smith-Lemli-Opitz syndrome or desmostero­
losis. Activation of LXR in the placenta would increase the expression of 
putative cholesterol transport genes, i.e. , ABCAl and ABCGl , and thereby 
provide a means to transfer cholesterol to the fetus. This, hopefully, would 
limit the severity of symptoms caused by the lack of fetal cholesterol syn­
thesis. 
Conclusions 
During the last decade, a vast amount of information became avail­
able about the molecular regulation of cholesterol homeostasis in the 
adult. It is now time to proceed with the next step, which in our opinion is 
the in-depth-study of the ways in which cholesterol homeostasis in the em­
bryo and fetus, involving maternal -fetal-cholesterol transfer, is regulated. 
We here propose LXR to be a key player in this game and a valuable target 
for potential interventions. 
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Abstract 
The Liver X receptors ( LXR) a lpha and beta have been shown to be crucial­
ly involved in the regu lation of cel lu lar cholesterol homeostasis, unti l  now 
namely in the liver. On ly l imited information is avai lable about their role in 
the human placenta and in the pregnancy-disease preeclampsia . The aim 
of our study was to investigate the expression pattern of the LXRs and their 
target genes in murine and human placenta during normal pregnancy 
and in preeclamptic placentae. In mouse placentae, Lxra and Lxrb were 
expressed at unchanged levels from 1 3.5 unti l 1 9 .5 post coitum.  The pro­
totypic LXR target genes Abca 1 and Srebp 1 c showed a similar expression 
pattern compared to the control group.  However, expression of all LXR tar­
get genes studied was dramatical ly increased in placentae from dams fed 
with the pharmacological LXR agonist T090 1 3 1 7 . In the human placenta 
LXRA and LXRB expression increased during normal  pregnancy. Treatment 
of Jeg3, JAr and BeWo trophoblast cel ls and human first trimester placental 
explants with T090 1 3 1 7 lead to increased expression of LXR target genes. 
Interestingly, early-onset preeclamptic placentae and placental explants 
cultivated under hypoxia revealed a significant upregulation of ABCA 1 ,  
which is involved in cholesterol efflux. I ncreased expression of ABCA 1 in 
early preeclampsia might be the result of fetal oxygen undersupply. We 
here show that pharmacological activation leads to increased expression 
of LXR target genes both in vitro and in vivo. This indicates that LXR and its 
target genes play an important role not only in murine but also in human 
materna l-fetal cholesterol transport. 
Liver X receptor in the murine and human placenta 
Introduction 
Cholesterol is of crucia l  importance for a l l  cel ls in the human body, but 
dietary intake and cel lu lar demands vary widely, e.g. ,  during development 
and in different nutritional states. To maintai n  cholesterol homeostasis un­
der al l  metabolic circumstances, sophisticated mechanisms exist to fine­
tune cholesterol metabol ism on the cel lu lar  level on the one hand and 
cholestero l  homeostasis of the embryonic and adult organism on the other 
hand.  The Liver X receptors (LXR)  a lpha and beta have been shown to be 
crucia l ly involved in the regu lation of cel lu lar cholesterol homeostasis in  
adult mammals ,  namely in the l iver, the intestine and in macrophages .  
I n  short, the LXRs are activated by oxystero ls (oxidized cholesterol deriv­
atives) , bind to their heterodimer partner Retinoid X-Receptor (RXR) and 
activate transcription o f  their target genes. Important LXR  targets are ATP­
binding cassette (ABC) transporters involved in cholesterol efflux from cel ls  
to the intestina l  lumen or bi le (ABCG5/ABCG8) , or to high-density l ipopro­
teins (HDL) (ABCAl , ABCG l ) .  Moreover, the LXRs activate transcription of 
genes responsib le for de nova l ipogenesis (SREBP l  C, FASN)  which provides 
a mean to detoxify cholesterol by the formation of cholesterylesters. 
Less is known about the role  of LXRs during embryonic and feta l devel­
opment. LXR has been demonstrated to be expressed in the placenta and 
in mal ignant trophoblast ce l l  l ines, e .g . ,  JAr  and BeWo (21 -23) .We have re­
cently discussed a vita l ro le of the LXRs for the regu lation of intrauterine 
cholesterol metabolism (25) and proposed LXR-dependent processes as  
potential targets to direct cholesterol to  the  fetus. This would provide po­
tentia l  therapeutic tools to ameliorate the cl in ical outcome in patients with 
inborn errors of cholesterol metabolism, namely the Smith-Leml i-Opitz syn­
drome. I n  a series of elegant studies in a mouse model of the Smith-Leml i­
Opitz syndrome, the Dhcr7-/- mouse, Tint and col leagues have shown that 
a significant proportion of feta l cholesterol orig inates from the mother (28) . 
In addition,  Lindegaard et a l .  demonstrated that activation of the LXR 
pathways by the pharmacological LXR agonist T0901 31 7  increases the ex­
pression of Abca l in the mouse placenta and enhances maternal-feta l 
cholesterol transfer ( 1 6) .  
Until now, on ly l imited information i s  avai lab le a bout the ro le of  LXR in  the 
human placenta . Rodents and human placentae belong both to the he­
mochoria l  type, where the materna l  blood directly faces the trophoblast 
barrier, which separates the feta l from the materna l  compartment (4) . I n  ro­
dents the barrier is composed of the three layered labyrinth ine trophoblast 
and in humans of the vi l lous trophoblast which contains one syncytial layer 
with an underlying cytotrophoblast layer. The vil lous trophoblast expresses 
all factors for ensuring cholesterol transport from the maternal (apica l) to 
the fetal (basolateral )  side.  The trophoblast cells express the low-density 
l ipoprotein (LDL) receptor, c lass A scavenger receptors and scavenger re­
ceptor Bl (SRB I )  for uptake of maternal cholesterol from LDL and HDL  par­
ticles, respectively (7, 1 3, 30, 32) . Furthermore, they express h igh levels of 
the ABC-transporters ABCAl and ABCGl , which faci l itate transfer of cho-
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lesterol to acceptor lipoproteins present in fetal blood (15, 20} . 
The pregnancy disease preeclampsia, a multisystemic disorder affect­
ing about 5-10% of pregnancies towards the end of the second trimester of 
gestation, is still one of the leading causes of pregnancy-related maternal 
and fetal morbidity and mortality (14, 17, 26}. Among its complications, in­
trauterine growth restriction (IUGR} and premature birth play an important 
role. Maternal predisposing factors such as diabetes, hypertension and 
obesity contribute to the consequences of this pathological disorder. Se­
vere forms of placental insufficiency result in iatrogenic preterm birth. Al­
though the pathophysiology of preeclampsia is still unknown, the placenta 
is considered to play a key role in this disease. Strong evidence supports 
that preeclampsia is generated by shallow invasion of the extravillous tro­
phoblast into the decidua and vessels followed by an incomplete remod­
elling of the maternal vascular structures. This phenomenon leads to an 
impairment of oxygen and nutrition supply at the feta-maternal interface 
and influences fetal growth (5, 9, 11} . Data about the role of LXR and its 
target genes in preeclampsia are restricted. Albrecht et al. analyzed the 
expression of ABCAl in preeclamptic pregnancies compared to third tri­
mester controls and found no differences in ABCA 1 expression, but without 
discriminating early-onset and late-onset preeclampsia (1) .  
The aim of this study was to characterize the expression pattern of LXR 
and its target genes in murine and human placenta, especially with re­
gard to its sensitivity to the pharmacological LXR agonist T0901317. Here we 
present data that Lxra and Lxrb and their target genes relevant for choles­
terol transfer are expressed in the murine and human placenta through­
out pregnancy. In accordance with results presented by Lindegaard and 
colleagues (16} , we show that the LXR system can be activated in mice in 
vivo. In addition, we could also detect a reaction to pharmacological LXR 
activation in human trophoblast cell lines (Jeg3, BeWo and JAr} as well as in 
human placental explants from first trimester pregnancies by an increased 
expression of genes involved in cholesterol transfer. Interestingly, we found 
a significant upregulation of ABCA 1 in early-onset preeclamptic placentae 
and an upregulation of this LXR target gene in placental explants upon 
hypoxic treatment. Therefore, our study provides new insights into LXR and 
ABCAl regulation in the human placenta which is one more step towards 
a placenta-mediated manipulation of maternal-fetal cholesterol trans­
port. Moreover, we detected a change in cholesterol metabolism by an 
increase in ABCA 1 expression upon hypoxia in preeclamptic placentae. 
Material and Methods 
Human Placental Tissue, Placental Explant Culture and Cell Lines 
Placental tissues were obtained from the Department of Gynecology 
and Obstetrics of the University Hospital Essen, Germany, and the Depart­
ment of Obstetrics and Gynecology, Samuel Lunenfeld Research Institute, 
Mount Sinai Hospital, Toronto, Canada. First trimester placental tissues from 
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induced abortions were received from the cl inic from T. R ing, Essen, Ger­
many, and the Morgenta ler Cl inic, Toronto, Canada. Written consent was 
received from women before surgery. The respective ethics committee ap­
proved consent forms and protocols to use the tissue. For  detai led cl in ical  
information see Gel lhaus et a l .  (8, 8) . P lacenta l tissue was obtained at the 
time of vaginal  del ivery, Caesarean section or as abortion materia l ,  as de­
scribed earl ier (8) . Gene expression during normal  pregnancy was mea­
sured in the fol lowing  four groups: first trimester (6-1 3 weeks, n=8) , second 
trimester ( 1 4-26 weeks, n=6) , preterm (27-36 weeks, n=9) and term (37-41 
weeks, n= l O) .  Preeclampsia was diagnosed according to international cri­
teria of the I nternationa l  Society for the Study of Hypertensive Disorders i n  
Pregnancy. Fo r  this study the  fol lowing groups were ana lyzed: pregnancies 
compl icated by a severe form of preeclampsia, early-onset preeclampsia 
(25-33 wk, n= l 6) and late preeclampsia (34-39 wk, n = l 5) as wel l  as their 
respective gestationa l  age-matched control groups (control 1 :  23-33 wk, 
n= 1 6; control 2: 34-39 wk, n= 1 2) .  
For RNA a n d  protein isolation,  on ly placenta l  tissue from the centra l part 
of the placenta was col lected, to avoid contamination with materna l de­
cidua and amniotic membranes. Tissue process ing was equal ly performed 
in the participating cl in ical  centers involved in this study. Tissues were fro­
zen in l iquid n itrogen and stored at 80°C until extraction of matched RNA 
samples .  
First trimester placenta l explant cultures were established from first tri­
mester human placenta l tissues with a modification of the method of Gen­
bacev et a l .  ( 1 0) .  P lacenta l tissue was washed in ice-cold PBS ( l nvitrogen ,  
Carlsbad, Cal ifornia) , and a mnion and umbi l ical  cord were dissected 
away. Smal l  fragments of placenta l  vi l l i  were dissected from the placenta, 
teased apart, and selected for the presence of trophoblast cel l  columns. 
P lacenta l  explants were placed in Mi l l icel l -CM cu lture dish inserts (pore 
size 0.4 µm,  Mi l l ipore Corporation ,  Bedford, Massachusetts) precoated 
with 0.2 ml  undi luted phenol red-free matrigel  (Becton Dickinson,  Bedford, 
Massachusetts) . Explants were cu ltured in 1 0% FBS DMEM/F- 1 2  media ( l n ­
vitrogen) supplemented with 1 00 µg/ml Normocin at 37°C, 5% CO2 in an  
atmosphere of  3% 02 for hypoxic treatment and for control in 20% 02. P la­
centa l explants were maintai ned in culture for up to 7 days . For the treat­
ment with T090 1 31 7, explants were incubated for 1 week under 3% 02 with 
and without 1 µM T090 1 3 1 7  (Cayman Chemicals, Ann Arbor, Michigan) . For 
the hypoxia experiments, explants were cultured under 3% 02 or 20% 02, 
respectively. 
Cel l  cu lture studies were performed with the human choriocarcinoma 
cel l  l ines J EG3, JAr and BeWo purchased from the American Type Culture 




Pregnant C57BL/6J mice were obtained from Harlan (Horst, The Nether­
lands) at 2 days pc.  Animals were housed in temperature-contro l led rooms 
(23°C) with 12 hours l ight cycl ing and received standard mouse chow (Arie 
Blok BV, Woerden,  The Netherlands) and water ad  l ibitum. From day 10 pc 
ti l l  day 17 pc,  C57BL/6J females received a diet contain ing 0.01 5% T090 1 3 1 7  
(Cayman Chemica ls) o r  chow diet. At stages 1 3.5, 1 5.5, 1 7.5 a n d  1 9.5  p c  
pregna nt C57BL/6J mice were anaesthetized with isoflurane a n d  sacrificed 
by heart puncture. 
To investigate if LXR induction in the placenta is related to LXR a lpha,  
Lxra+/- female  mice on a C57BL/6J background were crossed with LXRa+/­
male mice on  the same background to obtain nests with a l l  LXR geno­
types. LXRa+/- females received a d iet contain ing T090 131 7  from day 1 0  
pc t i l l  day 1 9  pc.  Pregnant LXRa+/- females were sacrificed at day 1 9.5 pc.  
I n  a l l  an imal  experiments, maternal blood was co l lected in EDTA con­
taining tubes . P lacentae were removed, weighed,  measured and snap­
frozen in l iquid n itrogen and stored at 80°C for m RNA isolation and bio­
chemical ana lysis. Experimenta l procedures were a pproved by the local  
Ethical Committee for Animal Experiments. 
Analytical Procedures 
Placenta l l ipids from murine placentae were extracted using the B l igh 
and Dyer method as previously described (29) . Commercial ly avai lab le 
kits were used for  the determination of  tota l cholesterol and trig lycerides 
(Roche, Mannheim, Germany) . 
RNA Isolation and PCR Procedures 
Tota l RNA was extracted from frozen tissues with TriReagent (Sigma, St. 
Louis ,  MO) , and quantified using a NanoDrop N Dl O00 spectrophotometer 
(NanoDrop Technologies Inc. ,  Wi lmington ,  D E) .  cDNA synthesis was per­
formed using recombinant M-MLV reverse transcriptase ( 1 0  U/µ I) ,  the ap­
propriate buffer, d NTPs (500 µmol/L) , random nonamers ( 1  µmol/L) , R NAse 
inh ib itor (2U/µ I ;  al l  from Sigma) and tota l RNA (50 ng/µ L) . The reaction mix 
was incubated for 1 0 min at 25°C for primer a nneal ing,  60 min at 37°C for 
synthesis and 5 min at 94°C to denature the RT enzyme. Real t ime quan­
titative PCR was performed us ing an Applied B iosystems 7900HT FAST se­
quence detector and Appl ied Biosystems reagents according to the man­
ufacturer's instructions. Primers and probes were obtained from l nvitrogen .  
Primer sequences can be obtained onl ine (www. labpediatricsrug .n l) or 
are avai lable on request. Express ion levels were normal ized to those of 1 8S 
ribosomal  RNA which was analyzed in separate runs .  
Statistics 
Statistica l  ana lyses were performed using S PSS 1 6.0 for Windows (SPSS 
I nc . ,  Chicago, USA) . Differences between the g roups were ana lyzed by 
Kruska l  Wal l is test fol lowed by Mann-Whitney-U-test. The Wilcoxon Signed 
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Ranks test was used for pairwise comparison of placenta l explants. Data 
presented are means ± SD. A p-va lue smal ler than 0.05 was considered 
statistical ly s ign ificant. 
Results 
LXR is Expressed in the Murine Placenta and can be Activated by 10901 31 7 
To characterize the ro le of LXR during feta l development, fema le  
C57BL/6 mice received a diet contain ing the  pharmacological LXR  agonist 
T0901 31 7 (0.0 1 5%) from day 1 0  pc ti l l  day 1 9.5 pc.  Figures la - c show that 
both LXR alpha and LXR beta as wel l  as their obl igate heterodimer partner 
RXR are constitutively expressed in the placentae of mice fed the control 
d iet. To investigate the physiologica l relevance of the placenta l expression 
levels ,  Lxra, Lxrb and Rxr mRNA were a lso analyzed in the l iver of female,  
non-pregnant mice. P lacental expression levels a re around 10 to 20%, 80%, 
and 60 to 80% of those in  the liver for Lxra , Lxrb, and Rxr, respectively. Feed­
ing the T090 13 17-contain ing d iet had no effect on expression level and pat­
tern of these genes .  
The LXR target genes Abcal and Abcg l , encoding for the transporters 
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Figure 1. Influence of LXR activation on gene expression in the murine placenta. Bars show mRNA expression nor­
malized to 1 8S rRNA from day 1 3.5 pc till day 1 9  .5 pc. Liver cDNA was used for comparison and set to 1 .00. Filled 
bars, untreated; open bars, treated with the LXR agonist T0901 3 1 7. mRNA expression of: (A) Lxra; (B) Lxrb; (CJ 
Rxr; (DJ Abca l ;  (El Abcg l ;  (Fl Abcg4. • indicates significant difference compared to untreated control (p!,Q.05; 
n=5-8). 
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pressed in the placenta (Figure l d, e). Abcal was expressed twice as high 
as in the liver from day 13.5 till 19.5 pc. Expression of Abcgl rose from 5. 6 
to 14-fold compared to the level of liver in the same period. Feeding the 
LXR agonist T090131 7 to the dam induced a l to 3-fold increase of Abcal 
and Abcgl. Abcg4 is highly expressed at day 13.5 pc (690-fold higher than 
in the liver). Its expression declines during gestation to 200-fold. T090131 7 
feeding to the female mouse suppressed the expression of Abcg4 at day 
13.5 pc but not later. 
Genes encoding for other proteins involved in cholesterol transport, i.e., 
Ldlr, Srbl, and Apoal, are constitutively expressed from day 13.5 till 1 9.5 
pc in levels comparable to those in the liver, but their expression is not 
changed upon T0901317 administration (data not shown). 
Placental LXR Activation Leads to Triglyceride Accumulation 
To differentiate between LXR alpha and LXR beta function, we cross­
bred Lxra knock-out mice heterozygously to obtain placentae represent­
ing an Lxra+/+, Lxra+/- and Lxra-/- genotype and treated the dams with 
the LXR agonist T0901 317. Lxra m RNA was found to be reduced to present 
at 11 % and 6% of wild-type levels in untreated and T0901 31 7-treated Lxra-/­
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Figure 2. LXR activation in the murine placenta in relation to the Lxra genotype. Lxra knock-out mice were cross­
bred heterozygously to obtain placentae representing an Lxra+/+, Lxra+/- and Lxra-/- genotype. Filled bars, 
untreated; open bars, treated with the LXR agonist T090 1 3 1 7. mRNA expression of: (A) Lxra; (B) Lxrb; (C) Srebpl c. 
(D) triglyceride concentration (µmol/g tissue); • indicates significant difference compared to untreated control 
(pS0.05; n=6-8). 
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The remaining low levels of Lxra represent probably decidual  cel ls de­
rived from the (heterozygous) mothers. Lxrb expression was s l ightly re­
duced in T0901 31 7-treated Lxra-/- placentae when compared to untreated 
counterparts; this effect was not present in  placentae of the other geno­
types (Fig . 2b) . Expression of the prototypic LXR-target gene Srebpl c was 
induced by T090 13 1 7  administration in all three genotypes, with highest 
induction in wildtype placentae ( 1 1 . 7-fold) , intermediate in heterozygous 
placentae (8 . 1 -fold) and lowest in Lxra-/- p lacentae (4.2-fo ld) (F ig. 2c) .  Ac­
tivation of the LXR/SREBPl  C pathway is known to induce hepatic steato­
sis in mice ( 1 2) .  We therefore measured trig lyceride concentrations in the 
placenta as a surrogate marker for de nova l ipogenesis. As shown in Fig . 
2d, LXR activation indeed led to severely increased trig lyceride concen­
trations in p lacentae belonging to fetuses of a l l  three genotypes (+ 1 1 0%, 
+231 %, and + 1 03% in  Lxra+/+, Lxra+/- and Lxra-/- placentae, respective ly) . 
This phenomenon can be explained by a compensatory action of LXRB .  
LXR alpha and LXR beta Expression Increased in the Human Placenta 
In the human p lacenta, both LXRA and LXRB can be detected through­
out gestation . I n  contrast to murine placenta, as depicted in Figure 3a and 
b, mRNA expression is lowest in  the first and second trimester of pregnancy 
(25 and 24% of term for LXRA, 33 and 1 6% for LXRB, respectively) . Expression 
levels in preterm and term placentae are s imi lar to each other, but sign ifi­
cantly higher than in the first two trimesters of gestation (p<0.05) . The ob l i­
gate heterodimer partner of the LXRs, RXR, was found to be constitutively 
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Figure 3. Expression of LXRA and LXRB in the human placenta during pregnancy. Bars show mRNA expression 
normalized to beta actin mRNA in placental tissues of all trimesters of pregnancy. mRNA expression of: (A) LXRA; 
(BJ LXRB. • denotes significant difference to the preceding age group (pS0.05; n=6-10) .  
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LXR Target Genes are Expressed in the Human Placenta 
Figure 4 visualizes the ontogenetic changes of gene expression levels 
of key genes involved in cellular cholesterol uptake and secretion in the 
human placenta. Expression of the gene encoding the HDL receptor SRBI 
is lowest in the first and second trimester and highest in preterm and term 
placenta (Fig. 4a}. The gene encoding the LDL  receptor, LDLR, is expressed 
at constant levels throughout gestation, with a reduced expression in the 
second trimester (Fig. 4c}. ABCAl and ABCGl, encoding proteins which fa­
cilitate cholesterol excretion, show expression patterns very similar to those 
of the LXRs, with increased expression levels throughout pregnancy (Fig. 
4b,d}. Finally, the genes encoding the ABC transporter ABCG4 (Fig. 4e} and 
the cholesterol acceptor APOAl (data not shown} are constitutively ex­
pressed during gestation. 
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Figure 4. Cholesterol transporter gene expression in the human placenta during pregnancy. Bars show mRNA 
expression normalized to beta actin mRNA in placental tissues of all trimesters of pregnancy. mRNA expression 
of: (A) SRBI; (B) ABCA l ;  (C) LDLR; (D) ABCG l; (E) ABCG4. • denotes significant difference to the preceding age 
group (p:50.05; n=6-1 0) .  
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The LXR Target Gene ABCA 1 is significantly Increased in Early-onset 
Preeclamptic Placentae and Human Placental Explants Cultivated under 
Hypoxia 
LXRA and ABCA 1 mRNA expression were measured in early-onset pre­
eclamptic and age-matched control placentae (29.0±1.7 vs 28.8±2.9 
weeks of gestation). The expression level of LXRA was not significantly dif­
ferent in control and preeclamptic placentae (Figure Sa). Interestingly, 
expression of ABCA 1 was found to be almost twofold increased in early­
onset preeclampsia, although with notable variation (P=0.02S; Figure Sa). 






(/) (/) � � 
� 3.0 � 3.0 
C: 0 0 
·� 0 0 -� 
[ 2.0 9 i 2.0 0 
X B � a, 0 a, el 
a, 0 0 � .2: t � .lii 1 .0 .!. -e- � 1 .0 . -0-a, I § a, � ..&. er 0 ! 0 0 � 0.0 0.0 
control earlyPE control earlyPE control late PE control late PE 
LXRA ABCA1 LXRA ABCA1 
Figure 5. LXRA and ABCA 1 mRNA expression in human placentae of preeclomptic patients compared to age­
matched controls. (A) mRNA expression of LXRA and ABCA 1 in early-onset preeclomptic placentae (25-33 wk, 
n=l 6) and their respective gestational age-matched controls (23-33 wk. n= l 6); (B) mRNA expression of LXRA and 
ABCA 1 in late-onset preeclamptic placentae (34-39 wk. n= 1 5) and gestational age-matched control groups 
(control 2: 34-39 wk. n= l 2) .  • indicates significant difference compared to control (MWU-test. p�0.05) . - indicates 
the overage per group. 
and HMGCR was not significantly different comparing preeclamptic and 
control placentae (data not shown). In late-onset preeclampsia (week 34-
39 of gestation), no significant difference in the expression levels of LXRA 
or ABCAl were detected (Figure Sb) when compared to age-matched 
controls probably caused by the high variation in the expression pattern 
of the different samples. Also at this time of gestation no difference in the 
expression of LXRB, SREBP l A, SREBPl C, ABCGl , ABCG4, LDLR, FASN, SRBl 
and HMGCR was found (data not shown). 
To investigate whether the observed increase in ABCA 1 expression is 
related to the hypoxic situation in the placenta during preeclampsia, we 
cultivated human placental explants under conditions of high (20%) and 
low (3%) oxygen. As shown in Fig. 6, in 6 out of 7 explants from different do­
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Figure 6. Expression of ABCA l in human placental explants under hypoxic conditions. Human placental explants 
from 7 different donors were incubated under normoxic (20% 02) and hypoxic conditions (3% 02) . mRNA expres­
sion of ABCA l was corrected for that of beta-actin. Data were analyzed in a pairwise way by Wilcoxon Signed 
Ranks Test. 
The LXR Pathway can be Pharmacologically Activated in Human Tropho­
blast Cell Lines and in Human Placental Explants 
The malignant trophoblast cell lines Jeg3, BeWo and Jar, which do ex­
press both receptor isoforms (data not shown), were used to answer the 
question whether LXR can be activated in human trophoblast cells in a 
similar way as in the mouse placenta. All three cell lines were incubated 
with 0.1 and l µM of the synthetic LXR agonist T091317 or the solvent only. 
Expression of the prototypical LXR target gene SREBP l  C was induced in 
all three cell lines (+494%, + 1 010%, and +285% in Jeg3, Bewo and JAr cells, 
respectively) (Figure 7). 
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Figure 7. Expression of the LXR alpha target gene SREBP l c in human trophoblast cell lines treated with T090 1 3 1 7. 
Jeg3, BeWo and JAr cells were treated with the LXR agonist T090 1 3 1 7  in different concentrations (open bars, 0 
µM; striped bars, 0. 1 µM; filled bars, l .0 µM) . mRNA expression was corrected for that of 1 8S rRNA. • Different from 
control, # different from 0. 1  µM. 
Liver X receptor in the murine and human placenta 
Moreover, we incubated human p lacental explants from first trimester 
pregnancies with the LXR agonist  T090 1 31 7 1  ( 1  µM) a nd measured mRNA 
expression of ABCAl . As depicted in Figure 8, expression of ABCAl varied 
considerably between the para l le l  experiments, but was on average 6 
times higher in T0901 31 7-treated explants compared to contro l s  (p=0.029, 
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Figure 8.  ABCA l mRNA expression in human placental explants treated with T090 1 3 1 7. mRNA expression was 
corrected for that of 1 8S rRNA. Human placental explants (n=4) were treated with 1 µM T090 1 3 1 7. Data were 
analyzed by MWU, single-sided significance. 
Discussion 
Cholestero l homeostasis is a tightly regulated process capable to cope 
with d ifferent levels of externa l  cho lesterol v ia the d iet and different de­
mands, e.g., du ring g rowth and p regnancy. The nuclear receptors LXR a l­
pha and LXR beta have been identified as intracel lu lar  sensors for oxyster­
ols ,  cholesterol derivatives. Upon binding of oxysterols, LXR activates the 
transcription of genes involved in  ce l lu la r  cholesterol remova l :  LXR  activa­
tion leads to increased excretion of cholesterol from the cells via transport 
proteins (ABCA 1 ,  ABCGS, ABCG8) , de-toxification to bi le acids (cholesterol 
7-a lpha-hydroxylase, CYP7Al ) ,  o r  storage as cholesterol esters (SREBP l C) . 
Both LXR a lpha and LXR beta have been demonstrated to be expressed 
in the murine p lacenta, as wel l  as many of  the i r  target genes encoding for  
proteins involved in cholesterol transport. Specifica l ly, trophoblasts express 
the LDL receptor, c lass A scavenger receptors and scavenger receptor B l  
for uptake o f  cholesterol from t h e  materna l  compartment. Moreover, the 
ABC transporters ABCGl  and ABCA 1 a re expressed, both of wh ich l inked to 
transfer of cholesterol to acceptor l ipoproteins .  We have therefore recently 
proposed that LXR-mediated processes may be involved in materna l-feta l 
cholesterol tra nsport (25) . L indegaard and col leagues have indeed dem­
onstrated that  pharmacological LXR  activation in a mouse model of  the 
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Smith-Lem li-Opitz syndrome promotes materna l-feta l cholesterol transport 
( 1 6) .  Very recently, also endothel ia l cel ls  isolated from the human placenta 
have been shown to be capable of excreting cholesterol (27) . 
I n  our cu rrent study we ana lyzed the expression pattern of LXRA and  
LXRB and  their target genes du ring fetal development in t he  mouse p la­
centa compared to the human p lacenta . I n  the mouse placenta we could 
demonstrate that both Lxra and Lxrb and their  heterodimer partner Rxr  
are constitutively expressed throughout the second ha lf of pregnancy. In­
teresting ly, when compared to expression in the mouse l iver, Lxra is  lower 
expressed tha n  Lxrb. This indicates that, in turn , LXR beta may be more 
critical in the placenta than in the l iver. It is further supported by our find­
ing that placentae derived fro m  Lxra-/- fetuses show comparable mRNA 
levels o f  LXR target genes when  compared to  wildtype or Lxr+/- p lacentae. 
Thus, LXR alpha deficiency can be at least partia l ly compensated by other 
mechanisms, most l ikely LXR beta . 
Cholesterol transfer to p lasma l ipoproteins is genera l ly  bel ieved to rely  
on the ABC transporters ABCAl and  ABCGl (24) . ABCAl , deficient in Ta ngi­
er Disease, is responsible for transfer of cholestero l  to nascent HDL, whereas 
ABCGl is invo lved in cho lesterol transport to mature H DL. Functiona l  loss of 
ABCA 1 in mice causes severe p lacenta l  ma lformatio n  resulting in severe 
embryo growth retardation,  feta l loss and neonata l d eath (3) . 
We could here show that Abcal and Abcg l a re constitutive ly expressed 
in the mouse placenta at levels  comparable to the expression in adu lt l iver 
(Abca l )  or 5- 1 0  times higher (Abcg l ) ,  meaning that they a re expressed at 
physio logica l ly relevant levels .  Expression of both genes could be d ramati­
ca l ly increased by pharmacological  activation of LXR via the d iet of the 
mother. I nteresting ly, we found another transporter putatively involved in 
transport of cholesterol and other sterols, Abcg4, a lso at high levels  in the 
mouse and human placenta .  Abcg4 is genera l ly  bel ieved to be active in 
the brain and the testis in adult mice (31 ) ,  but has very recently be shown to 
be temporari ly expressed in hemato poietic cel ls  and enterocytes in the de­
veloping fetus (2) . Its mechanism of action in the p lacenta has not yet been 
elucidated; it therefore remains unclear whether or n ot ABCG4 is invo lved 
in maternal -feta l cholesterol transport. Comparab le to resu lts obtained by 
Stefulj and col leagues (27, 27) , we could neither fi nd A BCG4 activation by 
the LXR agonist  T0901 31 7 nor changes in expression in preeclampsia.  
Epidemiological studies have provided evidence that materna l  hyper­
cholesterolemia is associated with atherosclerotic lesion development in 
the fetus ( 1 8, 1 9) .  We therefore studied processes potentia l ly involved in the 
reg u lation of materna l-feta l cho lesterol transport, i .e . ,  LXR expression in  the 
human placenta . We here demonstrate that both LXRA and LXRB a re ex­
pressed throughout gestation ,  with higher levels of expression towards the 
end of pregnancy. Gene expression  of target genes fol lowed that of the 
LXRs and increased during gestation .  It is tempting to speculate that these 
expression patterns provide a means to adapt the maternal-feta l supply to 
the demands of the growing fetus.  
Obvious ly, we cou ld not support this hypothesis experimenta l ly in hu-
Liver X receptor in the murine and human placenta 
mans. However, activation of LXR by the pharmacological LXR agonist 
T0901317 in three human trophoblast cell lines showed that the LXR system 
is indeed inducible in these cell lines. Incubation of human placental ex­
plants with T0901 317 clearly demonstrated that LXR activation leads to a 
significant increased ABCA 1 expression. We therefore postulate that the 
LXR-mediated pathway of transplacental cholesterol transport is very likely 
also active in the human placenta. 
Since maternal predisposing factors such as diabetes and obesity con­
tribute to the consequences of preeclampsia and the main hypothesis 
of this disease is a shallow invasion of the extravillous trophoblast and an 
incomplete vascular remodeling leading to an undersupply of the fetus, 
we investigated whether maternal-fetal cholesterol transport would be af­
fected in preeclampsia. We compared the expression pattern of genes 
potentially involved in this pathway in preeclamptic placentae and age­
matched controls. Only ABCAl mRNA was found to be significantly in­
creased in early-onset preeclamptic samples compared to normal age­
matched controls. Interestingly, in late-onset preeclampsia with a mild 
course of disease no differences compared to controls was found. This 
observation is different from data published by Albrecht et al. who found 
similar levels of ABCAl in preeclampsia and healthy controls (1). However, 
subjects used in their study were on average in a later stage of gestation, 
even more late-onset preeclamptic samples, than the subjects used in our 
study. An involvement of LXR and its target genes in human trophoblast 
invasion is already shown in recent studies from Pavan et al. who reveal 
an involvement of LXR beta in the control of human trophoblast invasion 
(6, 21, 21). Activation of LXR beta by specific agonists inhibited human tro­
phoblast invasion in vitro. Our observations in the preeclamptic placentae 
were confirmed by the finding that ABCA 1 can be activated by hypoxia in 
placental explants which might represent a first step for follow-up experi­
ments. However, the physiological relevance of increased levels of ABCA 1 
expression observed in preeclamptic placentae and hypoxic placental 
explants clearly needs further investigation. 
We have previously postulated that LXR-dependent processes may be 
involved in maternal-fetal cholesterol transport (25). This has been extend­
ed by studies in specific mouse models (16). In the current study we have 
demonstrated that these observations may most likely be extended to the 
human situation. Our study provides information which may give us op­
portunities to influence maternal-fetal cholesterol transport and thereby 
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Abstract 
Cholesterol is critical for several cellular functions and essential for nor­
mal fetal development. Therefore, its metabolism is tightly controlled during 
all life stages. The Liver X Receptors a (LXRa; NRl H3) and 13 (LXRl3; NRl H2) 
are nuclear receptors that are of key relevance in coordinating cholesterol 
and fatty acid metabolism. The aim of this study was to elucidate whether 
fetal cholesterol metabolism can be influenced in utero via pharmaco­
logical activation of LXR and whether this would have long-term effects 
on cholesterol homeostasis. Administration of the LXR agonist T0901317 to 
pregnant mice via their diet (0.015% wt/wt) led to induced fetal hepatic ex­
pression levels of the cholesterol transporter genes Abcg5/g8 and Abcal , 
higher plasma cholesterol levels and lower hepatic cholesterol levels com­
pared to controls. These profound changes during fetal development did 
not affect cholesterol metabolism in adulthood, nor influence coping with 
a high fat/ high cholesterol (HFHC) diet. This study shows that the LXR sys­
tem is functional in fetal mice and susceptible to pharmacological activa­
tion. Despite massive changes in fetal cholesterol metabolism, regulatory 
mechanisms involved in cholesterol metabolism return to a 'normal ' state 
in offspring and allow coping with a high fat/high cholesterol diet. 
Lxr activation during fetal development 
Introduction 
Cholesterol is an integral part of mammalian cell membranes and or­
ganelles and serves as a precursor of steroid hormones, bile acids and 
other metabolic mediators such as oxysterols. During fetal development, 
cholesterol is essential for the activation and propagation of hedgehog 
signaling: activation of sonic hedgehog by covalent binding of cholesterol 
is crucial for development and patterning of the central nervous system 
(13). Inborn errors of de nova cholesterol synthesis are associated with a 
variety of birth defects. Of the seven known defects in the human 
cholesterol biosynthesis, six are extremely rare and often lethal. The 
inability to convert 7-dehydrocholesterol to cholesterol, which represents 
the final step in cholesterol biosynthesis (18), leads to the Smith Lemli Opitz 
(SLO)-syndrome. Subjects with SLOS are nonetheless born with cholesterol 
(although in very low concentrations) in blood and tissues and therefore 
must have had access to an exogenous source of cholesterol in utero (24). 
The biosynthesis of cholesterol and its conversion into bioactive 
steroids are regulated by a complex network of enzymes which are tightly 
controlled by several hormones, by cholesterol itself and by oxysterols. 
Several oxysterols, in particular 22(R)-, 24(S)-, 27-, and 24(S), 25-hydroxy­
cholesterol, are natural ligands of the Liver X Receptors a (LXRa; NRl H3) 
and 13 (LXRl3; NRl H2), two members of the nuclear receptor superfamily of 
ligand-activated receptors (12). LXRa and 13 are key players in coordinating 
cholesterol and fatty acid metabolism in mammals. LXRa is mainly 
expressed in the liver, adrenal, intestine, adipose tissue and macrophages, 
while LXRl3 is ubiquitously expressed (19). Both LXR isoforms are activated 
by oxysterols with no specificity documented. Several synthetic LXR ligands 
have been generated during the past years (6). Activated LXRs heterodi­
merize with ligand-activated retinoid X receptor (RXR) at LXR response 
elements present in the promotors of target genes to induce their 
transcription. General activation of LXRs by synthetic agonists such as 
T0901317 induces transcription of multiple genes involved in cellular ste­
rol efflux (ABCA 1, ABCGS and ABCGB) ,  bile acid synthesis (CYPla l ) ,  and 
de novo lipogenesis (SREBPlc and FASN) in a variety of cell types (29). 
Treatment of C57BL/6 mice with T0901317 increases HDL-cholesterol 
concentrations in plasma and induces fecal sterol excretion while at the 
same time hepatic steatosis develops (21) (15) (8). In addition, LXRs repress 
inflammatory genes like NOS2 (Nitric Oxide Synthase), PTGS2 (Cytochrome 
c oxidase II), IL6 (Interleukin 6) and /L lb  (Interleukin 1 beta) in macrophages 
(11). 
Since the LXRs are fundamental regulators of cholesterol fluxes in the 
adult, it is tempting to speculate that they may have important roles in 
the development of fetal cholesterol metabolism as well. Expression of 
Lxra and Lxrb has been demonstrated in mouse fetuses from day 11.5  
post coitum onwards (2), however, the functional role of  LXRs in  fetal 
development in the newborn has not yet been defined. It has been stated 
that LXR is important but not essential for normal fetal development, as is 
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also evident from studies with Lxra-, Lxrb-, and Lxrab-null mice (1; 1 7; 22). 
Specifically activating LXR during fetal development might alter lipid and 
cholesterol metabolism in the developing fetus and have long-term effects 
into adulthood, especially when the animal receives a cholesterol-rich 
diet. 
The aim of this study was to elucidate whether LXR is functionally active 
in the regulation of cholesterol metabolism in utero and whether activating 
LXR during fetal development influences the coping with a high fat/high 
cholesterol diet in the offspring at a later age. We show that when the LXR 
agonist T0901317 is administered to pregnant mice via the diet, cholesterol 
metabolism in fetuses is strongly affected in an Lxr-dependent manner. 
However, massive changes in fetal lipid homeostasis induced by T0901317 
did not have an impact on the response to a high fat/ high cholesterol diet 
in the offspring at an age of 8 weeks. 
Materials and Methods 
Animals 
Pregnant C57BL/6J Sv129/Ola Hsd mice were obtained from Harlan (Horst, 
The Netherlands) at 2 days post coitum (dpc). Lxra+t- female mice (26) on 
a C57BL/66J Sv1 29/OlaHsd background were crossed with Lxra+t- male 
mice on the same background in our laboratory to obtain offspring with 
Lxra+t+ , Lxra+t- and Lxra+ genotypes. Animals were housed in temperature­
controlled rooms (23 °C) with 12 hours light cycling and received standard 
RM H-B mouse chow (Arie Blok BV, Woerden, The Netherlands) and water 
ad libitum. Experimental procedures were approved by the local Ethical 
Committee for Animal Experiments of the University of Groningen. 
Experimental procedures 
From day 10 post coitum until day one after delivery, C57BL/6J Sv1 29/ 
Ola Hsd wild-type females received standard chow only or chow supple­
mented with 0.01 5% w/w T0901317 (Cayman Chemicals, Ann Arbor, Michi­
gan). At days 13.5, 1 5.5, 17.5 and 19.5 post coitum pregnant C57BL/6J mice 
were anaesthetized with isoflurane and terminated by heart puncture. 
Lxra+t- females received the T0901317 diet from day 10 pc till day 1 9. 5  pc 
and were terminated at day 19.5 pc. Blood was collected in EDTA contain­
ing tubes. Liver samples of the dams were snap-frozen in liquid nitrogen. 
Fetuses were removed from uteri, their weight and length were measured, 
they were terminated by decapitation and dissected. Pups were sacrificed 
at day 1 post partum. Blood samples were taken by exsanguisation. Livers 
and intestines of fetuses and pups were collected, immediately snap-frozen 
in liquid nitrogen and stored at -80 °C until m RNA isolation or biochemical 
analysis. Samples for microscopic evaluation were fixed in paraformalde­
hyde for hematoxylin/eosin staining. Pups were genotyped by PCR using al­
lele-specific primers (wild-type: sense 5'-CACCCATTCTCCCGTGCTTCTCTT 
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G-3';  knockout: sense, 5 '-GGGCCAGCTCATTCCTCCCACTCAT-3' ;  antisense 
for both, 5'-GTTTCTCTCCCCTATCTAGGGAGAC-3' ). 
In another group of pups from chow-fed dams, the pups were taken 
away from the dam immediately after delivery, i.e. before the first suckling, 
and hand-fed for 1 4  hours with either Orisel-Junior (composition: glucose 
0.2 mmol/L, Na 1 4  mg/L, K 1 0  mg/L, Cl 20 mg/L; osmolarity 21 6 mOsm/L) 
(Nutricia, Zoetermeer, The Netherlands) or Collate First Life Puppy Colos­
trum (composition: suppl. Table 1 )  (Nettex, Kent, U K) using a 1 ml syringe 
with a disposable feeding needle attached to it. Groups of 4-5 pups were 
placed in glass petri dishes filled with nesting material. The petri dishes were 
placed on a heating pad and temperature inside the petri dishes was kept 
around 30 °C. After 1 4  hours of hand-feeding, the pups were terminated by 
decapitation and livers and blood were collected. 
To investigate the influence of receiving T0901 31 7  during fetal develop­
ment on coping with a high fat/high cholesterol diet, pregnant C57BL/6J 
females received chow only or chow supplemented with 0.0 1 5% w/w 
T090 1 31 7  from day 1 0 of gestation until day 1 after delivery. All dams re­
ceived chow till the pups were weaned. Offspring received chow until 6 
weeks of age and received either chow or a semi-synthetic Western-type 
diet (HFHC) containing 1 5% (w/w) cacao butter and 0.25% (w/w) choles­
terol (Diet W; Special Diet Services, Witham, U K) for two weeks. Offspring 
was terminated at 8 weeks of age. 
Analytical Procedures 
Liver homogenates were made by homogenization of the complete fe­
tal liver (approximately 20-80 mg, depending on age) in 200 µ L ice-cold 
water. Hepatic lipids were extracted using the Bligh and Dyer method (7). 
Commercially available kits were used for the determination of total cho­
lesterol (Roche, Mannheim, Germany) in liver lipid extracts as well as in 
plasma. Pooled plasma samples from all animals of one group were used 
for lipoprotein separation by fast protein liquid chromatography (FPLC) as 
described previously (28). 
RNA isolation and PCR procedures 
Total RNA was extracted from frozen tissues with TriReagent (Sigma, St. 
Louis, MO, USA), and quantified using a NanoDrop N DlO00 spectrophotom­
eter (NanoDrop Technologies Inc., Wilmington, DE, USA). cDNA synthesis 
and real-time quantitative PCR were performed as described by Plosch 
et al ( 1 5). PCR results of liver and intestine were normalised to 1 8S mRNA 
levels, which were analysed in separate runs. Primer and probe sequences 
for AbcgS, Abcg8, Abca 1 ,  Hmgcr as well as 18S are published elsewhere 
( 1 5). The following primers/probes were used: For Lxra, sense 5'-TGCCT­
GATGTTTCTCCTGATTCT-3' ; antisense 5'-CCTCCCTGGTCTCCTGCAT-3' ; and 
probe 5'- TTGAGGTTCTGTCTTCCACAACTCCGTTG-3' (accession number 
N M_01 3839). For Lxrb, sense 5'-AAGGACTTCACCTACAGCAAGGA-3'; anti­
sense 5'-GAACTCGAAGATGGGATTGATGA-3'; and probe 5 ' -CTTCCACCGT­
GCAGGCTTGCAG-3' (accession number NM_009473). 
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Statistics 
All data are presented as mean ± SD with a p-value smaller than 0.05 
considered significant. Statistical analyses were performed using SPSS 14.0 
for Windows (SPSS Inc., Chicago, USA) . All data was analyzed using a Krus­
kal Wallis test followed by Mann-Whitney-Li -test. 
Results 
10901317 administration influences cholesterol levels in pregnant mice 
and their offspring 
Dams receiving T0901317 from 10.5 dpc to 19.5 dpc had slightly lower 
body weights on day 19.5 of gestation compared to control dams (Table 
l ) .  Liver weights of the treated animals, expressed as a percentage of total 
body weight, were increased by -50% during the entire treatment period 
(Table 1) . T0901317 treatment had no influence on the number of offspring 
per dam (Table 1) . 






weight dams lg) 
control T09 
29.8 ± 2. 1 3 1 .9 ± 2.0 
30.6 ± 3. 1 27.8 ± 1 .7 
33.3 ± 2.0 3 1 .5 ± 4.4 
35.7 ± 1 .5 32.2 ± 1.2· 
25.8 ± 1 .5 24.8± 1 .6 
liver weight dams 
to body weight 1%1 
control T09 
5.71 ± 0.57 8.23 ± 0.50· 
4.72 ± 0.66 8.09 ± 1 . 1 7" 
5.21 ± 0.40 8.27 ± 0.96" 
4.08 ± 0.43 7.36 ± 0.39" 
5.42 + 0.40 10.0 ± 0.60° 
average number of 
fetuses per dam 
control T09 
7.0 ± 1 .9 8.3 ± 2.9 
7.2 ± 2.2 7.0 ± 1 .4 
6.0 ± 1 .8 6.2 ± 1 .8 
6.3 ± 1 .0 7.3 ± 1 .5 
5.3 ± 1 .0 6.6 + 0.9 
weight fetuses lg) 
control T09 
0.23 ± 0.09 0.31 :!: 0.07 
0.38 ± 0.07 0.39 ± 0.05 
0.98 ± 0.23 0.91 ± 0.22 
1 .22 ± 0. 1 4  1 .04 ± 0. 1 4" 
1 .38 ± 0. 13  1.26 ± 0. 19  
length fetuses Imm) 
control T09 
1 1 .9 ± 1 .4 1 2. 1  ± 0.9 
1 3.8 :!: 0.7 1 4.0 ± 1 .0 
20.2 ± 2.2 20.0 ± 2.0 
2 1 .6 ± 1 .5 19.5 :!: 0.8° 
25.3 ± 0.9 25.5 ± 1 . 1  
Parameters of C57BL/ 6J OlaHsd dams and fetuses on several days of gestation receiving chow or 0.01 5% w /w 
T0901 3 1 7  in the diet. Data are mean ± SD. N=6 dams per group; •, p<0.05 T090 1 3 1 7  vs chow 
T0901317 administration significantly reduced hepatic cholesterol levels 
to 75% of control values after 3 days of treatment, and to 70% and 67% of 
0 A. f10 
B.  
.§, 1 0  
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days post coitum post partum days post coitum 
Figure 1. (A) Hepatic and (B) plasma cholesterol levels in pregnant mice. Black bars, control mice; open bars, 
mice receiving 0.01 5% T090 13 1 7 in the diet from day 10 pc on. Values represent the mean ± SD. n=6; •, p < 0.05 
for treated vs control. 
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control levels, respectively, after 9 and 1 1  days of treatment (Figure la). 
Plasma cholesterol concentrations were increased by -50% in treated 
dams compared to controls from 5 days of treatment onwards (Figure lb). 
FPLC analysis revealed that the increase in cholesterol reflected elevated 
HDL levels (data not shown) . 
..!21 A. � 
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Figure 2. (A) Hepatic and (B) plasma cholesterol levels in offspring of mice treated with a control diet (black bars) 
or a diet containing 0.01 5% T090 1 3 1 7  (open bars) from day 1 0.5 of gestation. Values represent the mean ± SD. 
n=6: •, p < 0.05 for treated vs control. 
Fetuses of treated dams weighed 1 5% less and were l 0% shorter in 
length at l 9.5dpc, while at the other days of gestation no differences in 
weight or length between the groups were observed (Table 1 ). Fetal he­
patic cholesterol levels were decreased at day 1 3.5 and day 1 7.5 of gesta­
tion compared to controls, while no differences were seen at other days of 
gestation (Figure 2a). HE staining of fetal livers showed no morphological 
differences between control and treated fetuses (data not shown). Plasma 
cholesterol in the offspring was measured at day 1 9.5 of gestation and at 
day one after delivery only and found to be doubled in the treated fe­
tuses/newborns (Figure 2b). FPLC analysis showed a profi le typical for fetal 
murine plasma and revealed that the increase in cholesterol on day 1 9  of 
gestation reflects elevated IDL/LDL levels (Figure 3). 
0.4 




1 0  15  20 25 30 35 
Fraction 
VLDL IDU LDL HDL 
Figure 3. FPLC analysis of pooled plasma (n= l O  per group) of 1 9  dpc control fetuses (black squares) or 1 9  dpc 
fetuses from dams receiving T090 1 3 1 7  (open squares). Analysis was performed as described in Materials and 
Methods. 
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Administration of 10901 31 7 to dams induces Lxr target genes in fetal tissue. 
Feta l hepatic Lxra expression levels were a round half the va lues of adu lt 
expression leve ls throughout gestation and rose to approximate ly adu lt lev­
els at day one after del ivery ( Figure 4a) . Surpris ing ly, fetal hepatic expres­
sion levels of Lxrb were 2-3 times higher on all days of gestation compared 
to adu lt hepatic expression levels and remained at this level at day l after 
del ivery ( Figure 4b) . Admin istration of T09 1 31 7  to the d iet of the dam did not 
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Figure 4. Changes in relative hepatic gene expression in C57BL/6 fetuses on several days of gestation upon treat­
ment of the dam with T090 1 3  l 7. Hepatic expression levels of (A) Lxra, (B) Lxrb, (C) Abcg5, (D) Abcg8, (E) Abca 1 
and (F) Hmgcr, are displayed. Results were normalized to 1 8s mRNA levels. Adult expression levels are arbitrarily 
defined as l .  Black bars, control fetuses: open bars, fetuses from dams receiving 0.0 1 5% T090 1 3 1 7. Values repre­
sent the mean ± SD. n=6; •, p < 0.05 for treated vs control. 
I n  feta l contro l  l iver, cholesterol transporters and LXR target genes 
Abcg5/g8, encoding the canal icu lar cholesterol  transporter, were ex­
pressed a l 00 times lower than adult  levels at day 1 3.5 and remained very 
low during the gestation .  At day one after del ivery, Abcg5/g8 expression 
levels acutely increased and were comparable to adu lt expression levels 
(F igure 4c and 4d) . Hepatic Abcg5/g8 expression was induced 20- and 
5-fold respective ly at day 1 3.5 dpc in  fetuses from T0901 31 7-receiving dams 
compared to contro l  fetuses. The induction was most p ronounced on day 
Lxr activation during fetal development 
1 7.5 of the gestation, when hepatic expression levels of Abcg5 in treated 
fetuses were 50 times higher and Abcg8 levels were 25 times higher than 
in control fetuses. On day one after delivery, Abcg5 expression levels were 
induced 4 times and Abcg8 levels were induced 2.5 times in livers of mice 
exposed to T0901 3 1 7  before birth. 
Expression levels of the cholesterol transporter Abca 1 were similar to 
adult levels at day 1 3.5 and day 1 5.5 of gestation in the fetal liver and were 
2-3 times higher than adult levels at day 1 7.5 and 1 9.5 of gestation and at 
day 1 after delivery (Figure 4e}. Administration of T0901 3 17  to the diet of 
the dam induced fetal hepatic expression levels of Abca l significantly at 
day 1 5.5 and day 1 9.5 of gestation to 2-fold and 1 .3-fold of control levels, 
respectively. Fetal hepatic expression levels of the rate-controlling enzyme 
in of the cholesterol synthesis pathway Hmgcr were around adult levels 
throughout the gestation and did not change upon treatment of the dam 
with T0901 3 17  ( Figure 4f). 
In the fetal intestine, Abcg5/g8 expression levels were very low before 
day 1 7.5 of gestation and rose to around adult levels on day 1 after delivery 
(Figure 5a and b}. Administration of T0901 3 1 7  to the diet of the dam led to 
a significant increase of Abcg5 expression levels on day 1 9.5 of gestation in 
fetal intestine. On all other days examined the increase seen in Abcg5 and 
AbcgB expression levels upon T0901 31 7 administration was not significantly 
different from controls. Abca l expression levels in fetal intestine ranged be­
tween 0.5 times adult expression to around adult expression levels through­
out gestation. Addition of T0901 3 17  to the diet of dams led to 3-5 times 



















1 5.5  
C. 
* 
days post coitum 
* 











o o o 
1 5.5  
days post coitum 
Figure 5. Changes in relative intestinal gene expression in C57BL/6 fetuses on several days of gestation upon 
treatment of the dam with T090 1 3 1 7. Expression levels of intestinal (A) Abcg5, (B) Abcg8 and (C) Abca l are 
displayed. Results were normalized to 1 8s mRNA levels. Adult expression levels are arbitrarily defined as 1 .  Black 
bars, control fetuses; open bars, fetuses from dams receiving 0.01 5% T090 1 3 1 7. Values represent the mean ± SD. 
n=6; •, p < 0.05 for treated vs control. 
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Gene expression levels in pups on day one after delivery are indepen­
dent of dietary cholesterol 
Since we found fetal hepatic Abcg5/g8 levels to be extremely low during 
gestation and suddenly increased to adult levels after delivery, we inves­
tigated whether this increase was caused by the change from a low-cho­
lesterol environment in the uterus to a high-cholesterol diet after delivery. 
C57BL6/6J pups were taken away from the dam immediately after delivery, 
not allowing them to suckle, and were hand-fed for fourteen hours. The 
pups received either an oral rehydration salts solution or puppy colostrum, 
to mimic mother 's  milk. No differences in intestinal (Figure 60) or hepatic 
(Figure 6b) Abcg5/g8 expression levels between the two groups were seen. 















AbcgB Abcg5 AbcgB 
Figure 6. Relative Abcg5/g8 expression in hand-fed C57BL/6 pups on day one after delivery. Hepatic (A) and 
intestinal (Bl Abcg5 and Abcg8 expression levels are displayed. Results were normalized to 1 8s mRNA levels. Black 
bars, control pups fed a colostrum replacer; open bars, pups fed oral rehydration solution (see materials and 
methods for contents). Values represent the mean ± SD; n=5. 
1090131 7  directly induces Lxr in the fetus 
To investigate to what extent T0901317-induced effects were directly me­
diated by fetal Lxra, Lxra+t- females were crossed with Lxra+t- males. In this 
way, fetuses of all Lxra genotypes were obtained, i .e. ,  Lxra+t+, Lxra+1-, and 
Lxra+ . Only results of Lxra+t+ (wild type) and Lxra-1- (knockout) are shown, 
since Lxra+t- responded similar to wild type pups. Lxra gene expression was, 
as expected, not detectable in knockout fetuses ( Figure 7a). Hepatic ex­
pression levels of Abca 1  were not different in knockout fetuses from T0901317 
treated dams compared to wild-type fetuses from T0901317 treated dams 
(Figure 7b). Expression of Abcg5/g8 in Lxra+t+ fetuses from dams receiving 
T0901317 was increased about 15 times compared to Lxra+t+ fetuses from 
control dams while T0901317 treatment in Lxra+ fetuses led to a 2.5 increase 
of Abcg5/g8 compared to untreated knockout fetuses, but relative expres­
sion levels in the T0901317 treated knockout fetuses was still very low with 
an average of 0. 18, compared to an average of 0.08 in untreated knock­
out fetuses for Abcg5 (Figure 7c and 7d). T0901317 administration did not 
change hepatic cholesterol levels in wild type or knockout fetuses (data 
not shown). 
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Figure 7. Changes in relative hepatic gene expression in wild type (Lxr'•) and Lxr-knockout (Lxr'·) fetuses on day 
1 9.5 of gestation upon treatment of the heterozygote dam with T0901 3 1 7. Results were normalized to 1 8s mRNA 
levels. Hepatic expression levels of fetal (A) Lxra, (B) Abcg5, (C) Abcg8 and (D) Abca l are displayed. Black bars, 
control fetuses; open bars. fetuses from dams receiving 0.01 5% T090 1 3 1 7. Values represent the mean ± SD. n=6; *, 
p < 0.05 for treated vs control, # ,  p < 0.05 for knockout vs wild type. 
Perinatal Lxr activation does not influence adult cholesterol metabolism 
Offspring of T090131 7 and chow-fed mice were fed either a high-fat/ 
high cholesterol diet {HFHC) or standard low-cholesterol chow from 6 u ntil 
8 weeks of age, after which the animals were sacrificed. There were no dif­
ferences in body weight or body weight to liver weight ratio between the 
four treatment groups within one gender {Table 2). 
Table 2. Parameters of adult offspring 
liver weight to body hepatic total plasma 
weight offspring fgl weight (%) cholesterol (umol/gl cholesterol (mM) 
control T09 control T09 control T09 control T09 
M CON 22.9 ± 1 .2 20.7 ± 4.6 5.7 ± 0.5 5.5 ± 0.6 1 .6 ± 0.2 1 .8 ± 0.4 2.4 ± 0. 1  2.2 ± 0.4 
M HFHC 22.7 ± 0.8 23.8 ± 0.9 5.2 ± 0.7 5.4 ± 0.4 3.4 ± 0.7* 3.8 ± 0.4* 3.7 ± 0.7 3.6 ± 0.8 
F CON 1 7.6 ± 0.8 1 9.6 ± 1 .2 4.5 ± 0.6 4.0 ± 1 .5 3.2 ± 0.5 2.6 ± 0.4 1 .8 ± 0.4 1 .8 ± 0.4 
F HFHC 1 7.2 ± 1 .9 18.5 + 1 .2 5 . 1  ± 0.5 4.3 ± 0.3 9.3 + 1 .9* 7.5 ± a.a• 2.4 ± 0.5 2.9 ± 0.2 
Parameters of C57BL/ 6J offspring of dams that received either chow or chow with T090 1 3 1 7. The offspring received 
either chow or a high fat/high cholesterol diet from 6 till 8 weeks of age. Data are mean ± SD. N=6; •, p<0.05 HFHC 
vs CON 
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Hepatic gene expression levels  of the representative LXR target genes 
Abcg8 and Abca l were higher in a l l  offspring fed H FH C  (Figure Ba and 
b) ,  regard less of receiving T090 1 31 7 during gestation.  H epatic and plasma 
cho lesterol levels were induced i n  al l  offspring that received H FHC com­
pared to contro l s  (Tab le 2) . Hepatic cho lestero l level s  were 2 t imes higher 
in the contro l  females than in the control males ,  and females showed a 3 
times increase of hepatic cho lestero l  leve ls upon receiving H FHC, whi le the 
H FHC-fed ma les showed a 2 times increase compared to chow-fed males .  
I n  a l l  offspring,  increases in hepatic cholestero l upon the H FHC diet were 
independent from the treatment in utero. 
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Figure 8. Changes in relative hepatic gene expression in offspring of mice fed chow containing 0.0 1 5% T090 1 3 1 7  
o r  control chow during gestation. The offspring received either chow o r  a high fat/high cholesterol diet from 6 till 
8 weeks of age. (A) Gene expression in male offspring, (B) gene expression in female offspring. Open bars: con­
trol offspring of control mice, light shaded bars: high fat/high cholesterol offspring of control mice; dark shaded 
bars: control offspring of T090 1 3 1 7-fed mice; black bars: high fat/high cholesterol offspring of T090 1 3  l 7-fed mice. 
Values represent mean ± SD. n=6; •, p < 0.05 for control chow vs control high fat, #, p < 0.05 for T0901 3 1 7  chow vs 
T090 1 3 1 7  high fat. 
Discussion 
The Liver X Receptors are of great significance in regu lating cholesterol 
metabol ism in the adu lt. Safar, the influence of LXR on cho lesterol metabo­
l ism during fetal development is u nknown. I n  this study  we show for the fi rst 
time that cholesterol  metabolism in the feta l mouse can be activated by 
addition of the LXR agonist T090 1 31 7  to the diet of the dam. The LXR-spe­
cific effects on cholesterol metabol ism in  the fetus a re comparab le to the 
effects seen in adu lt mice (21 ) ( 1 5) .  
Annicotte et al. i nvestigated expression patterns o f  Lxr in various fe­
ta l mouse tissues using in situ hybridization experiments (2) , and showed 
that both Lxra and Lxrb are expressed in feta l l iver from day l 0.5 post 
coitum (dpc) onwards .  They suggest that Lxr is i m portant but not es­
sential for norma l  feta l development, as is evident from the phenotypes 
of the various Lxr-nu l l  m ice ( l ;  1 4; 25) . Balasubramaniyan et al. reported 
low RNA expression levels of Lxra and Rxra during feta l rat development 
(5) , comparab le to our resu l ts, and Sakamoto et al. showed that Lxra is 
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mainly expressed in fetal rat macrophages from gestational day 12 on­
wards, while expression in the hepatocyte is only present from gestational 
day 18 onwards (20). Safar, however, metabolic functions of Lxr in the fe­
tus have not been determined. In the current study, we focused on the 
regulatory functions of Lxr in fetal cholesterol metabolism in the mouse. 
The synthetic Lxr agonist T0901317 has frequently been used to de­
lineate functions of Lxr in the adult mouse (8; 15; 21). We show that overall 
effects of this agonist in the developing fetus are in concordance with find­
ings in adult mice. Activation of Lxr led to higher fetal plasma cholesterol 
concentrations. Fetal murine lipid profiles are distinctly different from adult 
lipid profiles, with only one predominant lipoprotein present in fetal plasma 
in the last stages of gestation (3; 10). In treated fetuses on day 19.5 of gesta­
tion the increase in plasma cholesterol represents an increase in all lipopro­
tein fractions, putatively attributable to induction of hepatic and intestinal 
Abca 1 which is crucial for lipoprotein formation. Contrarily, hepatic cho­
lesterol concentrations were lowered . Since absence of effects on hepatic 
Hmgcr expression suggests unaffected cholesterol biosynthesis, this latter 
effect is assumed to be caused by induction of Abca 1 and the heterodi­
meric cholesterol transporter Abcg5/Abcg8 (8). Abcg5/g8 in hepatocytes 
are crucially involved in transporting cholesterol into the bile. It has been 
shown that bile formation is an ontogenetically regulated process and that 
bile excretory function is still immature at birth in rodents (4; 9). Our results 
indicate that the rapid increase in hepatic Abcg5/g8 expression levels on 
day one after delivery is apparently not directly caused by the onset of 
dietary cholesterol intake of the pup. Molecular mechanisms behind this 
increase in hepatic cholesterol transporters remain undefined. Based on 
our data, it is tempting to speculate that both excretory pathways to HDL 
and to bile are already functional in the fetal mouse liver under conditions 
of Lxr activation. 
Gene expression levels of Abcg5/g8 were very low in the fetal liver and 
increased 10-fold at day one after delivery compared to expression levels 
during gestation. In the fetal intestine, gene expression levels of Abcg5/g8 
were also very low before day 17.5 of gestation, but increased gradually 
over the following gestational days to reach 80%-100% of adult levels at 
day 1 after delivery. Abcg5/g8 is thought to transfer cholesterol and other 
sterols from the enterocytes back into the intestinal lumen, hence reducing 
cholesterol absorption efficiency ( 16). As stated previously, Abcg5/g8 are 
target genes of Lxr, which in turn is activated by oxysterols. We postulated 
that the increase in hepatic gene expression levels on day one after de­
livery were caused by the sudden change from exposure to low levels of 
cholesterol or oxysterols in the uterus to receiving high amounts of dietary 
cholesterol (derivatives) from mother' s  milk after delivery. To test this hy­
pothesis, we hand-fed newborn pups that had not yet received mother's  
milk for fourteen hours with either a colostrum replacer or with oral rehydra­
tion solution which does not contain any lipids. Hepatic and intestinal gene 
expression levels of Abcg5/g8 did not differ between the two groups and 
were comparable to gene expression levels of control pups on day one 
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after delivery in our previous experiments. 
Since administration of T0901317 to the diet of the dam led to induction 
of LXR target genes in fetal liver and intestine, we assume that T0901317 is 
transported across the placenta and directly activates fetal Lxr. However, 
there is a possibility that effects observed in the fetus were caused by high­
er plasma (chole) sterol levels in the treated dam. To determine whether 
induction of L xr target genes in the fetuses were caused by direct actions 
of T0901317 or by the changed lipid profile of the dam, we crossed Lxra-het­
erozygous mice and provided T0901317 to the pregnant mice. In this way, 
the fetal environment was similar for all fetuses but potential direct effects 
of T0901317 in fetuses of the same dam were dependent on the different 
genotype of the fetuses. In Lxra+ fetuses exposed to T0901317 via the dam, 
hepatic expression of the Lxr target genes AbcgS and Abcg8 was about 15 
times lower than in wild type and heterozygote fetuses of the same dam. 
Our data indicate that T0901317 is indeed directly effective in fetuses, main­
ly via the activation of Lxr alpha. However, there was a small but significant 
two-fold increase in hepatic AbcgS/gB expression levels even in the ab­
sence of Lxr alpha. This could be due to activation of Lxr beta in these fe­
tuses. Fetal hepatic expression of Lxrb was about 3 times higher compared 
to adult expression levels, as was seen in the WT-experiments, and could 
compensate the loss of Lxra activity in the knockout mice. 
To determine whether pharmacological activation of the Lxr system dur­
ing fetal development, i.e. severe distortion of fetal lipid homeostasis, has 
detrimental or beneficial long-term effects, we fed a hig fat/ high choles­
terol (HFHC) diet to 6-week old offspring obtained from control or T0901317-
treated wild type dams. As expected, based on previous studies (23; 27) ,  
plasma cholesterol levels, hepatic cholesterol levels and hepatic gene 
expression of cholesterol transporters rose upon receiving the HFHC diet. 
T0901317 administration before birth, however, had no influence on any of 
the parameters. We can therefore assume that, although administration 
of T0901317 in utero has considerable direct and strong effects on the fe­
tal cholesterol metabolism, these metabolic adaptations are diminished 
during (young) adulthood and do not influence general responses to a 
HFHC diet provided for a relatively short period of time. Obviously, this does 
not exclude the occurrence of (subtle) concequences on other aspects of 
cholesterol metabolism that have not been addressed in this work. 
I n  conclusion, we present for the first time evidence that Lxr is function­
ally active in fetal liver when stimulated with the synthetic agonist T0901317. 
Moreover, the pathways controlled by Lxr in adult mouse liver related to 
maintenance of cholesterol homeostasis can be influenced by providing 
this synthetic agonist via the diet of the dam. Yet, effects appeared to be 
transient and activation of Lxr in utero did not evidently affects coping with 
a high fat/high cholesterol diet in adulthood. 
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Abstract 
There is increasing evidence that the metabolic state of the mother dur­
ing pregnancy affects long-term glucose and lipid metabolism of the off­
spring. The Liver X Receptors (LXR) a and fl are key regulators of cholesterol, 
fatty acid and glucose metabolism. LXRs are activated by oxysterols and 
expressed in fetal mouse liver from day l 0 of gestation onwards. In the pres­
ent study, we aimed to elucidate whether in utero pharmacological acti­
vation of LXR would influence fetal fatty acid and glucose metabolism and 
whether this would affect lipid homeostasis at adult age. Exposure of preg­
nant mice to the synthetic LXR agonist T0901 31 7 increased hepatic mRNA 
expression levels of Lxr target genes and hepatic and plasma triglyceride 
levels in fetuses and dams. T0901 31 7 treatment increased absolute de nova 
synthesis and chain elongation of hepatic oleic acid in dams and fetuses. 
T0901 31 7 exposure in utero influenced lipid metabolism in adulthood in a 
gender specific manner: hepatic triglyceride content was increased (+45%) 
in male offspring and decreased in female offspring (-42%) when fed a 
regular chow diet, compared with untreated gender controls. Plasma and 
hepatic lipid contents and hepatic gene expression patterns in adult male 
or female mice fed a high fat diet were not affected by T0901 31 7 pretreat­
ment. We conclude that LXR treatment of pregnant mice induces immedi­
ate effects on lipid metabolism in dams and fetuses. Despite the profound 
changes during fetal life, long-term effects appeared to be rather mild and 
gender selective without modulating the lipid response to a high-fat diet. 
LXR induces lipogenesis in utero 
Introduction 
In humans, the nutritional condition during pregnancy has been shown to 
have a persistent effect on aspects of lipid and carbohydrate metabolism 
of the developing fetus. Maternal overnutrition leads to a higher incidence 
of insulin resistance, obesity, hypertension and cardiovascular diseases in 
adult offspring (6) . Effects of a high-fat maternal diet during pregnancy on 
long-term health status of the offspring are relatively well-studied in animal 
models (3) . However, relatively little is known about long-term consequenc­
es of targeted alterations in fetal lipid metabolism in utero. 
The Liver X Receptors have been identified as key players in the regula­
tion of cholesterol, fatty acid and carbohydrate metabolism in adult mam­
mal s. Liver X Receptors LXRa (NRl H3) and LXRl3 (NRl H2) are members of the 
nuclear receptor superfamily of ligand-activated receptors. Both LXR iso­
forms are activated by oxidized cholesterol metabolites (oxysterols) with no 
LXRa/13 specificity documented (20) .  Expression of LXRa is mainly restricted 
to liver, intestine, adipose tissue and macrophages, while LXRl3 is broadly 
expressed (23). Activated LXRs heterodimerize with ligand-activated Reti­
noid X receptor (RXR) at LXR response elements present in the promotors 
of target genes to induce their transcription. Activation of LXRs induces 
expression of the sterol regulatory element binding protein l e  (SREBPl c) 
that subsequently activates the lipogenic genes acetyl-CoA carboxylase 
(ACC) , fatty acid synthase (FASN) and stearoyl-Coenzyme A desaturase 
1 (SCDl ) (29) . It has been postulated that activation of LXR could induce 
carbohydrate response element-binding protein (ChREBP) and in this way 
indirectly influence glycolysis via influencing expression of liver-specific py­
ruvate kinase (PKLR) (7) .  
Expression of Lxra and Lxrb has been demonstrated in mouse fetuses 
from day 11.5 post coitum onwards (2) , however, the functional role of LXRs 
during fetal development and in the newborn has not been defined. LXR 
does not appear to be essentia l for normal fetal development as mice with 
targeted inactivation of Lxra-, Lxrb-, or Lxra/b (1, 17, 21) show normal fetal 
development. 
Mechanisms by which feta l and early postnatal environment influence 
lipid and glucose homeostasis in adult life are poorly defined. We previ­
ously showed that treatment of pregnant mice with the widely used LXR 
agonist T0901317 affects cholesterol metabolism in the fetus. T0901317 treat­
ment of pregnant mice activated LXR in the fetuses, resulting in induction of 
genes involved in fetal cholesterol metabolism. Interestingly, the treatment 
did not profoundly influence cholesterol metabolism at adult age (27, 27) .  
To delineate the functional importance of LXRs in control of fetal fatty acid 
and carbohydrate metabolism, we supplemented the diet of pregnant 
mice with T0901 317. In the present study we aimed 1 .  to determine whether 
pharmacological activation of Lxr in fetuses through maternal treatment 
with T0901317 activated Lxra or Lxrb in the fetal liver and influenced fetal 
fatty acid and glucose metabolism; and 2. to assess whether Lxr activa­
tion during fetal development changed lipid homeostasis into adulthood, 
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when weaned onto standard chow or on a high-fat diet. Our results indi­
cate that maternal T0901317 treatment activates Lxrs and strongly affects 
lipid metabolism in the fetus. The prenatal treatment only had relatively 
minor, gender-selective effects on lipid homeostasis in (young) adulthood 
and did not influence the response to a short-term high-fat diet. 
Materials and Methods 
Animals 
Animals were housed in temperature-controlled rooms (23 °C) with 1 2  
hours light cycling and received standard RMH-B mouse chow (Arie Blok 
BV, Woerden , The Netherlands) and water ad libitum. Pregnant C57BL/6J 
mice were obtained from Harlan (Horst, The Netherlands) at 2 days post 
coitum (dpc). Lxra+t- female mice (25) on a C57BL/6J background were 
crossed with Lxra+t- male mice on the same background in our laboratory 
to obtain offspring with Lxra+t+ , Lxra+t- and Lxra-1- genotypes as previously 
described (27) . All experimental procedures were approved by the local 
Ethical Committee for Animal Experiments of the University of Groningen . 
Experimental procedures 
From day 10 post coitum until day one after delivery, C57BL/6J wild-type 
females received standard chow only or chow supplemented with 0.01 5% 
w/w T0901317 (Cayman Chemicals, Ann Arbor, Michigan) , as described in 
(26) . At days 1 3.5, 15.5, 1 7.5  and 19.5 post coitum pregnant C57BL/6J mice 
were anaesthetized with isoflurane and terminated by heart puncture. 
Lxra+t- females received the T09013 l 7 diet from day 10 pc till day 19.5 pc and 
were terminated at day 19.5 pc. Blood was collected in EDTA containing 
tubes. Liver samples of the dams were snap-frozen in liquid n itrogen . Fetus­
es were removed from uteri, their weight and length were measured, and 
they were terminated by decapitation and dissected. Pups were sacrificed 
at day 1 post partum. Blood samples were taken by exsanguisation . Livers 
and intestines of fetuses and pups were collected, immediately snap-fro­
zen in liquid nitrogen and stored at -80 °C until mRNA isolation or biochemi­
cal analysis. Samples for microscopic evaluation were snap-frozen in liquid 
n itrogen for Oil-Red-O staining. Pups were genotyped by PCR using allele­
specific primers (wild-type: sense 5'-CACCCATTCTCCCGTGCTTCTCTT G-3' ;  
knockout: sense, 5'-GGGCCAGCTCATTCCTCCCACTCAT-3'; antisense for 
both, 5 '-GTTTCTCTCCCCTATCTAGGGAGAC-3' ) .  
To investigate lipogenesis and chain elongation of several fatty acids in 
the liver, a separate group of pregnant females on chow or on chow with 
T0901317 received these diets with 10 mg/g [ l -13C] acetate ( lsotec, Miam­
isburg, OH, USA) added from day 17.5 of gestation till day 19.5 pc and were 
terminated at 19.5 pc. 
To investigate the influence of receiving T0901317 during fetal develop­
ment on coping with a high fat/high cholesterol diet at adult age, preg-
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nant C57BL/6J females received chow only or chow supplemented with 
0.015% w/w T0901317 from day 10 of gestation until day 1 after delivery. All 
dams received chow till the pups were weaned. Offspring received chow 
until 6 weeks of age and received either chow or a semi-synthetic Western­
type diet (HFHC} containing 15% (w/w) cacao butter and 0.25% (w/w) cho­
lesterol (Diet W; Special Diet Services, Witham, UK)  for two weeks. Offspring 
was terminated at 8 weeks of age. 
Analytical Procedures 
Liver homogenates were made by homogenization of the complete 
fetal liver or (approximately 20-80 mg, depending on age) in 200 µL ice­
cold water. Hepatic lipids were extracted using the Bligh and Dyer method 
(4). Pooled plasma samples from all animals of one group were used for 
lipoprotein separation by fast protein liquid chromatography (FPLC} as 
described previously (28) . Commercially available kits were used for the 
determination of triglycerides in liver extracts, plasma samples and FPLC 
fractions (Roche, Mannheim, Germany) . 
Determination of fatty acid synthesis using MIDA 
MIDA allows quantitation of the biosynthesis of polymers in vivo and is 
described in detail elsewhere (13) . Hepatic lipids from mothers and their 
fetuses receiving [ 1-13C] acetate were extracted and hydrolyzed by add­
ing 0.5 ml 0.5M HCI in acetonitril and heating for 45 minutes at 100° C. As 
an internal standard, 100 ul or 5 ul of C17:0 (0.5 mg/ ml) in chloroform was 
added to the mother and fetal liver extracts, respectively. Fatty acids were 
extracted by adding 1,5 ml hexane, 5 minutes shaking and centrifugation 
for 5 minutes at 2500 rpm. The organic phase was transferred to a clean 
tube, and samples were dried down at 40° C under N2. Samples were de­
rivatized for 15 minutes at RT using 50 ul of 1: 2: 6 pentafluorobenzyl: trietha­
nolamine: acetonitril solution. 0.5 ml 0. 1 M HCI was added and the deriva­
tives were extracted using 1 ml hexane, 5 minutes shaking and 5 minutes 
centrifugation at 2500 rpm after which the organic phase was transferred 
to a GC-MS vial. Enrichments of the PFB-derivatives of hepatic fatty acids 
were measured by gas chromatography-mass spectrometry. Derivatives 
were separated on a Zebron ZB-1 30 m x 0.25 mm ID (0.25 µm film thick­
ness) capillary column (Phenomenex, Torrance, USA) . The oven tempera­
ture started at 100° C for 1 min, increased to 200° C at a rate of 50° C/min, 
then increased to 270° C at a rate of 5° C/min, and finally increased to 
300° C at a rate of 50° C/min, and remained at 300° C for 4 minutes. Mass 
spectrometry analysis was performed by electron capture negative ioniza­
tion (ECNI ) with methane as a moderating gas. The ion monitored were 
m/z 255-259 corresponding to the m0-m4 mass isotopomers for C16:0, m/z 
269-273 for C17:0, m/z 283-287 for C18:0 and m/z 281-285 for C18: l eu9. Calcu­
lations on the newly synthesized polymers, the isotope enrichments of their 
monomer precursor (acetyl-CoA) , and synthesis and chain-elongation of 
stearic acid and oleic acid are described elsewhere (19, 22) . 
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RNA isolation and PCR procedures 
Total RNA was extracted from frozen tissues with TriReagent (Sigma, St. 
Louis, MO, USA) and quantified using a NanoDrop ND1000 spectrophotom­
eter (NanoDrop Technologies Inc., Wilmington, DE, USA) . cDNA synthesis 
and real-time quantitative PCR were performed as described by Plosch 
et al (21). Primer and probe sequences for 18S, Srebpl c, Accl , Fasn, Gk, 
G6p, Pckl , Pk (12) , Scdl (25) , Fxr, Ppara (15) , Lxra, Lxrb (27) ,  have been pub­
lished, with the exception of Rxra, sense 5'-GGCAAACATGGGGCTGAAC 
-3 '; antisense 5' - GCTTGTCTGCTGCTTGACAGAT -3' ;  and probe 5'- CCAGCT­
CACCAAATGACCCTGTTACCAAC -3' (accession number NM_Ol 1305) , lnsr, 
sense 5'- TGAGTCAGCCAGTCTTCGAGAA -3' ; antisense 5' -ACTACCAG­
CATTGGCTGTCCTT- 3 ' ;  and probe 5'- CTGCCATCATGTGGTCCGCCTTCT 
-3' (accession number NM_0l 0568) . Expression levels were normalized to 
those of l 8S ribosomal RNA. 18S rRNA was analyzed in separate runs and 
not found significantly different between the experimental groups. 
Histology 
Liver histology was examined on frozen liver sections after Oil-Red-O 
staining for neutral lipids by standard procedures. 
Statistics 
Statistical analyses were performed using SPSS 14.0 for Windows (SPSS Inc., 
Chicago, USA) . Differences between the groups were analyzed by Kruskal 
Wallis test followed by Mann-Whitney-Li-test. Data presented are means ± 
SD. A p-value smaller than 0.05 was considered to be statistically significant. 
Results 
T0901 31 7 treatment to dams strongly induces genes involved in lipogenesis 
in dams and fetuses and acts mainly via Lxra 
As described previously, dams receiving T0901317 from 10.5 dpc to 19.5 
dAs described previously, dams receiving T0901317 from 10.5 dpc to 19.5 
dpc had slightly lower body weights on day 19.5 of gestation compared 
to control dams (26). Liver weights of the treated dams, expressed as a 
percentage of total body weight, were increased by -50% during the en­
tire treatment period. Body weight of the fetuses on day 13.5, 15.5, and 
17.5 pc was not influenced by T0901317 administration; only on day 19.5  it 
was slightly reduced in the treated animals (26) . T0901317 treatment had 
no influence on the number of offspring per dam or on their body weights 
(1.26 ± 0.19 vs. 1.38 ± 0.13 g in treated and untreated animals, respectively, 
at day 1 after birth) (26) . 
Our first aim was to establish whether T0901317 treatment of the wild­
type dams affects gene expression levels of lipogenic Lxr target genes in 
dams and fetuses. In dams (Suppl. Figure 1 a to c) and in fetuses (Figure 1 a 
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to d) , administration of T0901317 strongly increased hepatic mRNA levels of 
Srebpl c. Fasn and Scdl compared to controls. Accl induction in the fetus 
was less pronounced by T090131 7  treatment. Administration of T0901317 to 
pregnant mice did not significantly affect expression levels of nuclear re­
ceptors Rxra, Ppara or Fxr in the fetal liver (Suppl. Figure 2a to c) . 
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Figure 1. Changes in relative hepatic gene expression of fetuses on several days of gestation upon treatment of 
the dam with T090 1 3 1 7. Expression of fetal (A) Srebp l c, (B) Accl ,  (C) Fasn, and (D) Scd l .  Results were normalized 
to 1 8s mRNA levels. Adult expression levels are arbitrarily defined as l .  Black bars, control fetuses; open bars, 
fetuses from dams receiving 0.01 5% T090l 3 l 7. Values represent the mean ± SD. n=6 dams per group; •, p < 0.05 
for treated vs control. 
To ascertain to what extent T0901317-induced effects on lipid metabolism 
were Lxra or -13 mediated, Lxra+t- females were crossed with Lxra+t- males. 
T0901317 treatment to the heterozygous dams resulted in significantly lower 
expression levels of lipogenic LXR target genes (Srepb 1 c, Fasn) in the liver 
of Lxra knockout fetuses than in wild-type fetuses (Figure 2a and 2b) , indi­
cating that the observed effects are, at least partly, mediated via an Lxr 
alpha-specific effect. 
T0901 31 7 administration induces transient hepatic steatosis in pregnant 
mice and their fetuses 
T0901 317 treatment increased hepatic triglyceride content - 4-fold in 
pregnant females after three days of treatment (Figure 3a) . This effect 
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Figure 2. Changes in relative hepatic gene expression in wild type and Lxra-knockout fetuses at day 1 9  .5 of ges­
tation upon treatment of the heterozygote dam with T090 1 3 1 7. Hepatic expression levels of fetal (A) Srebpl c and 
(B) Fasn are displayed. Results were normalized to 1 8s mRNA levels. Adult expression levels are arbitrarily defined 
as l .  Values represent the mean ± SD. n=6 dams per group, with an average of 5 fetuses per dam; #, p < 0.05 for 
treated vs control, •, p < 0.05 for knockout vs wild type. 
del ivery. T090 1 31 7  treatment decreased plasma trig lyceride concentra­
tions in dams, but on ly during the pregnancy ( Figure 3b) . FPLC ana lysis of 
materna l  plasma at day 1 9  of gestation revea led that the reduction in tri­
g lycerides in the T0901 31 7-treated dams was main ly  in VLDL-sized fractions 
( Figure 3c) . 





VLDL IDULDL HDL 
Figure 3. (A) Hepatic and (B) plasma triglyceride levels on several days of the gestation of dams, and (C) 
triglyceride levels in FPLC samples of pooled plasma (n=6 per group) of dams at day 19 of gestation. Black bars 
or black line, control mice; open bars or dotted line. mice receiving 0.0 1 5% T090 1 3 1 7  in the diet. Values represent 
the mean ± SD. n=6 dams per group; •, p < 0.05 for treated vs control. 
Materna l  T0901 31 7  treatment increased hepatic trig lyceride concen­
trations in  the fetuses ( Figure 4a) . At day one after del ivery, however, tri­
g lyceride concentrations in l ivers of T09 1 31 7-exposed pups remained at 
( induced) feta l level, whereas concentrations in control pups surged. Feta l 
p lasma trig lyceride concentrations, measurab le  at 1 9.5  dpc and at day 1 
after del ivery, were significantly e levated upon LXR activation ( Figure 4b) . 
Both in the contro l and in the T090 1 3 1 7-exposed pups,  plasma l ipid levels 
strongly increased after de l ivery. FPLC ana lysis showed a profi le typical  for 
feta l murine plasma and revea led that the increase in  plasma TG reflects 
e levated IDL/LDL levels ( Figure 4c) . Consistent with gene expression data, 
in Lxra knockout fetuses T090 1 31 7  administration  increased hepatic tri­
g lyceride concentrations to a lower extent compared to wild type fetuses 
LXR induces lipogenesis in utero 
A. B. 
E 4o 
� g .s 4 
1
30 U) 
U) � 3 
� 20 [ 
j
10 
* f 2 ., 




Days post coitum 
C. 
0.15 ]" 15  
D. 
� §. 
.§.0.10 - 10 
1 ! 
� 0 05 [ 
f 
u 
0.00 1 0 _10_ ....22... _lQ..  40 Lxra +/+ L.xra -1-
VLDL IDLJLDL HDL 
Figure 4. (A) Hepatic and (B) plasma and triglyceride levels on several days of the gestation of fetuses. (C) 
Triglyceride levels in FPLC samples of pooled plasma (n=20 per group) of 19 dpc fetuses. (D) Hepatic triglyceride 
concentrations in wild type and Lxr knockout fetuses on day 1 9  of gestation upon treatment of the heterozygote 
mother with T090 1 3 1 7. Black bars or black line, control mice; open bars or dotted line, mice receiving 0.0 1 5% 
T090 1 3 1 7  in the diet. Values represent the mean ± SD. n=6 dams per group; •. p < 0.05 for treated vs control. 
(-70% vs. - 1 50%, respectively; each p <0.01 ; Figure 4d). Oil-Red-O staining 
for neutral lipids confirmed lipid accumulation in treated wild-type pups at 
day 1 3.5, 1 5.5, 1 7.5 and 1 9.5 of gestation and at day one after delivery. Liv­
ers of control and T0901 31 7-treated wild-type fetuses on day 1 7.5 and day 
one after delivery are shown in Figure Sa to d) . 
Figure 5. Oil-Red-O (ORO) staining for neutral fat in developing fetal liver on several days of gestation upon treat­
ment of the mother with T0901 3 1 7. No staining was observed in liver sections from fetuses from dams receiving 
the control diet (A. 1 7.Sdpc and C. 1 dpp, respectively). Oil-red-O staining was found in liver sections from fetuses 
from dams treated with T0901 3 1 7  (B, 1 7.5 dpc and D, l day post partum, respectively). Original magnification 20x. 
mean ± SD. n=6 dams per group; •, p < 0.05 for treated vs control. 
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1090 131 7 treatment increases absolute synthesis and total pool of oleate in 
pregnant dams and fetuses at El 9.5 
Using a 1 3C-acetate method, we quantified to what extent T0901 31 7 
treatment affected the de nova hepatic synthesis of palmitate, stearate 
and oleate and the hepatic pool size of these fatty acids in dams and 
fetuses. T0901 31 7 treatment increased total de nova synthesis and chain 
elongation of oleate (C 1 8: 1 ) in dams and fetuses at day 1 9.5 of gestation 
(Figure 6a and b), but did not significantly altered palmitate (C1 6:0) or stea­
rate (C l 8:0) synthesis. Chain elongation of stearate was reduced in treated 
fetuses. In dams, T0901 31 7 administration increased the total hepatic pool 
of oleate and it increased both the oleate and the palmitate pool in fe­
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Figure 6. Absolute de novo lipogenesis and chain elongation, and total pool size of several fatty acids in livers of 
dams and fetuses at day 1 9  of gestation. (A) Absolute synthesis in dams; (B) absolute synthesis in fetuses; (C) total 
pool of fatty acids in dams; (D) total pool of fatty acids in fetuses. C 1 6:0 (palmitate), C 1 8:0 (stearate) and C 1 8: 1  
(oleate) fractions were analyzed and calculated a s  described i n  the Materials and Methods section. Black bars: 
de novo lipogenesis in control animals; Open bars: de nova lipogenesis in T090 1 3 1 7  treated animals; dark grey 
bars: chain elongation in control animals; light grey bars: chain elongation in T090 1 3 1 7-treated animals. Values 
represent the mean ± SD. n=4 fetuses from 3 dams in the T090 1 3 1 7-treated group; n=4 fetuses from 8 dams in 
the control group; #, p < 0.05 for total new synthesis (A and B) or total pool (C and D) in treated animals versus 
controls; •, p < 0.05 for de novo lipogenesis in treated animals versus controls; $, p < 0.05 for chain elongation in 
treated animals versus controls. 
In utero Lxr activation does not influence basal insulin signaling 
To test the hypothesis that Lxr activation influences carbohydrate me­
tabolism in the wild-type mouse, via induction of gene expression of Sreb­
pl c and Chrebp and their subsequent target genes, we measured hepatic 
expression levels of several genes involved in carbohydrate metabolism in 
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fetuses from untreated and treated wild-type dams. Treatment of dams 
with T0901317 had no influence on hepatic gene expression levels of G6pc, 
Pckl , Gck, Chrebp, Pklr or lnsr in the fetuses (Suppl. Fig 3a to f) . Since gene 
expression levels do not necessarily reflect physiological changes, we 
examined whether T0901317 treatment influenced insulin signaling in off­
spring. We performed an adapted insulin tolerance test in 1-day old pups 
of treated and untreated dams. lntraperitoneal injection of 1-day old pups 
with 0.75U/kg insulin lowered blood glucose levels by 50% compared to 
pups injected with saline. Prenatal T0901317 treatment of the dams did not 
influence this insulin response, compared with controls. 
Long-term effects of prenatal Lxr activation in offspring into adulthood 
We determined whether T0901317 treatment of the dam had long-last­
ing effects in the fetuses, i.e., into adulthood. Previous studies have indicat­
ed that a perinatal programming phenotype may only become apparent 
in adulthood upon exposure to a metabolic challenge. We administered 
T0901317 from day 10 of gestation until day l after delivery to C57BL/6J 
females via the diet (0.015% w/w in chow) . Nest sizes were comparable in 
the two treatment groups, with an average of 6 pups per nest. After wean­
ing, offspring received chow until 6 weeks of age; subsequently, offspring 
received either chow or a semi-synthetic Western-type diet (HFHC) con­
taining 15% (w/w) cacao butter and 0.25% (w/w) cholesterol for two weeks. 
Body weight, liver weight and liver weight to body weight was previously 
described (27) and was similar in al l male and in al l female offspring. In 
chow-fed offspring, gene expression levels of Srebpl c, Fasn and Scdl were 
not different between pretreated and untreated male offspring on con­
trol diet (Figure 7a) . Control-fed females from T0901317-treated dams how­
ever, showed lower Fasn expression levels (-30%) compared to untreated 
females (Figure 7b) . Male offspring on control diet from treated dams had 
-42% higher hepatic triglyceride levels than male offspring on control diet 
from untreated dams, while female offspring on control diet from treated 
dams had -42% lower hepatic triglyceride levels than female offspring on 
control diet from untreated dams (Table l ) . 
Table 1 .  Parameters of offspring 
hepatic triglycerides (umol/g) plasma triglycerides (mM) 
control T09 control T09 
Male control 2.4 ± 0.6 3.4 ± 1 .0 # 0.43 ± 0.08 0.34 ± 0. 1 7  
Male high fat 6.6 ± 1 .2 * 6.7 ± 2.1 * 0.35 ± 0. 1 5  0.33 ± 0. 1 3  
Female control 1 1 . 1  ± 2.3 6.4 ± 2.9 # 0.21 ± 0.05 0.25 ± 0.08 
Female high fat 1 1 .6 +  4.5 9.5 + 2.0 0.26 + 0.1 1 0. 1 9  + 0.05 
Parameters of C57BL/6J offspring of mothers that received either chow or chow supplemented with 0.0 1 5% 
T090 1 3 1 7. The offspring received either chow or a high fat/high cholesterol diet from 6 till 8 weeks of age. Data 
are mean ± SD. N=6; *, p<0.05 HF/HC vs CON #,  p<0.05 T09 vs CON 
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Plasma triglycerides in male and females were not influenced by T0901317 
pretreatment (Table 1), although FPLC analysis showed that control male 
offspring receiving CON diet had slightly higher VLDL  levels than other 
male offspring groups (Figure 7c). No change in triglyceride FPLC profiles 
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Figure 7. Changes in relative hepatic gene expression in offspring of mice fed chow containing 0.0 1 5% T090 1 3 1 7  
or control chow during gestation, and FPLC profiles o f  this offspring. The offspring received either chow or a high 
fat/high cholesterol diet from 6 till 8 weeks of age. (A) Gene expression in male offspring, (B) gene expression in 
female offspring. (C) FPLC profile of male offspring, (D) FPLC profile of female offspring. Open bars and black 
lines: control offspring of control mice, light shaded bars and black dotted line: high fat/high cholesterol offspring 
of control mice; dark shaded bars and grey lines: control offspring of T090 13 1 7-fed mice; black bars and grey 
dotted lines: high fat/high cholesterol offspring of T090 1 3 1 7-fed mice. Values represent the mean ± SD. n=6; • p < 
0.05 for high fat vs control, # ,  p < 0.05 for T090 1 3 1 7  vs control during gestation. 
The high-fat diet increased hepatic gene expression levels of the lip­
ogenic LXR target genes Srebplc and Scdl in all male and female off­
spring, regardless of exposure to T0901317 during gestation (Figure 7a and 
b). Interestingly, a gender specificity was observed concerning Fasn ex­
pression. Fasn expression levels were significantly higher in high-fat male 
offspring from untreated dams compared to control-fed male offspring 
from untreated dams (+200%, p=0.017), while Fasn expression levels were 
not upregulated by the high fat diet in pretreated male offspring com­
pared to pretreated control males (p=0.247). Similarly, females pretreated 
with T0901 317 showed no upregulation of Fasn upon receiving the high fat 
diet. In all male offspring, hepatic triglyceride levels were increased in ani­
mals that received the high fat diet, independent from pretreatment with 
T0901 317 (Table 1). The high fat diet did not lead to higher hepatic triglyc­
eride levels in female offspring. Feeding the high fat diet did not signifi-
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cantly change plasma triglyceride levels or FPLC profiles in either males or 
females from chow-fed or T0901317-fed dams (Table 1, Figure 7b and c). 
Discussion 
We previously showed that targeted treatment of pregnant mice with 
the synthetic LXR agonist T0901317 activates Lxr in the fetuses. In the present 
paper, we investigated whether in utero Lxr activation by T0901317 chang­
es fatty acid and glucose metabolism in the fetus and in adult offspring. 
Our data show that this treatment results in acute effects on lipid homeo­
stasis in dams and fetuses, but not on glucose homeostasis in fetuses, and 
in relatively minor but persistent consequences on fatty acid metabolism 
during adulthood. 
Supplementation of the diet of the dam with T0901317 induced LXR tar­
get genes Srebpl c, Accl , Fasn, and Scdl in the fetal liver, suggesting that 
T0901317 is transported across the placenta activates Lxr. We previously 
showed that maternal T0901317 administration did not influence fetal he­
patic gene expression levels of Lxra or b (27). Our present results in Lxra 
knockout fetuses show that hepatic Lxr effects are mainly caused by Lxra 
and that Lxrb compensates about 50% of Lxr action in the absence of Lxra. 
Lxr-specific effects on lipid metabolism in the mother and in the fetus 
are comparable to the effects seen in non-pregnant adult mice (21, 24). 
T0901317 administration increased hepatic triglyceride levels in dams, 
which was similar to studies in adult male mice (12) (14). Hepatic triglycer­
ide accumulation decreased during gestation in treated dams, possibly 
by increased transport from the liver, either to other tissues or to the rapidly 
growing fetus. The hepatic lipid concentrations in one-day old pups varied 
considerably within one group. Possibly, this is caused by the variation in 
feeding time of the pups. Prolonged fasting leads to hepatic lipid accumu­
lation (26). Because we could not control the breast feeding times by the 
mother, some pups could have been fasted for a longer time than other 
pups, leading to higher liver triglyceride concentrations compared to pups 
that were fed prior to termination. 
Grefhorst et al. found no difference in plasma triglycerides in wild-type 
male mice treated with T0901317 compared to controls (11). T0901317 treat­
ed dams showed a lowering of plasma triglycerides compared to controls, 
representing a decrease in VLDL levels. Since plasma triglycerides in fe­
tuses and pups from treated dams were increased, this seems to imply that 
treated dams transfer more lipid to the fetus compared to controls. Further 
studies have to elucidate how LXR activation influences lipid transport to 
the fetus. 
Treated dams and fetuses showed an increase in absolute hepatic syn­
thesis of oleic acid. Based on the 13C-acetate method used and the ab­
sence of increased palmitate and stearate synthesis, we interprete that this 
observation is due to increased palmitate elongation and subsequent de­
saturation by stearoyl-coenzyme A desaturase 1 (Scdl ). Scdl catalyzes the 
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synthesis of monounsaturated fatty acids from saturated fatty acids ( 1 0) .  
Scd l i s  a target gene o f  Lxr, a n d  its expression was increased i n  maternal  
and feta l l iver upon T090 131 7 exposure. 
Apart fro m  the wel l-characterized ro le of Lxr in cholesterol metabol ism, 
a potentia l ro le control l ing g lucose homeostasis via activation of Srebpl c 
and Chrebp has been suggested [9, 1 6) ,  a lthough this role remains contro­
vers ia l  (8, 1 8) .  Us ing an adapted insu l in to lera nce test in 1 -day old pups, 
no effect of the T0901 31 7  pre-treatment was found on g lucose leve ls. Our  
resu l ts show that  Lxr  activation did not quantitatively infl uence the hepatic 
expression of any of the tested genes related to g lucose metabolism in the 
fetus.  
We next investigated whether Lxr activation by T0901 31 7, which induced 
profound changes in  l ipid metabol ism in  perinatal l ife, a lso had long­
lasting effects in l ip id homeostasis, i .e.  into adu lthood. Female chow-fed 
offspring fro m  T090 1 3 1 7-treated dams showed lower  Fasn expression levels 
and lower hepatic trig lyceride levels compared to untreated chow-fed fe­
male offspring .  Striking ly, a lthough no changes were seen on gene expres­
sion levels, in the male chow-fed offspring hepatic trig lyceride levels were 
higher than in untreated chow-fed male offspring .  Apparently, treatment 
with T0901 31 7  in utero reduces hepatic storage of trig lycerides in female 
offspring whi le it induces hepatic storage of trig lycerides in male offspring .  
The subt le changes in adu lt l ipid metabol ism caused by in utero Lxr  ac­
tivation could be en larged by receiving a h igh-fat diet at adu lt age. As 
expected (5) , short term (two weeks) high fat feeding  led to higher expres­
sion levels  of l ipogenic genes in a l l  offspring and higher hepatic trig lycer­
ide leve ls in male offspring . However, these effects were regard less of in 
utero treatment with T0901 31 7. Apparently, receiving a high-fat diet for two 
weeks on ly e l iminates rather than increases the gender-specific effects 
caused by in utero Lxr activation.  Based on this observation it is tempting 
to s pecu late that long-term high-fat feeding would possibly override the 
relatively sma l l  effects of the prenata l treatment. 
We conclude that Lxr activation by T090 1 31 7  treatment of p regnant 
mice induces immediate effects on l ipid metabolism in dams and fetuses, 
inc luding increases in fatty acid synthesis and trig lyceride levels .  Lxr activa­
tion did not s ignificantly influence expression of carbohydrate metabolism 
related genes,  nor  the glucose response to insu l in administration.  Despite 
profound changes in l ipid metabol ism during feta l l ife, long-term effects 
on l ipid metabol ism appear to be rather mi ld ,  and not related to the l ipid 
response to a h igh-fat diet. 
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Supplemental Figure 1. Changes in relative hepatic gene expression in genes encoding proteins involved in de 
novo lipogenesis in C57BL/6 dams on several days of gestation upon treatment of the dam with T090 1 3 1 7. Expres­
sion of maternal hepatic (A) Srebp 1 c, (BJ Fasn, and (CJ Scd 1 .  Results were normalized to 1 8s mRNA levels. Black 
bars, control dams; open bars, dams receiving 0.015% T090 1 31 7. Values represent the mean ± SD. n=6; *, p < 0.05 
for treated vs control. 
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Supplemental Figure 2. Changes in relative hepatic gene expression in C57BL/6 fetuses on several days of gesta­
tion upon treatment of the dam with T090 1 3 1 7. Hepatic expression levels of fetal (A) Rxra, (BJ PPARa and (CJ Fxr 
are displayed. Results were normalized to 1 8s mRNA levels. Adult expression levels are arbitrarily defined as 1 .  
Black bars, control fetuses: open bars, fetuses from dams receiving 0.01 5% T090 1 3 1 7. Values represent the mean ± 
SD. n=6; *, p < 0.05 for treated vs control. 
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Supplemental Figure 3. Hepatic gene expression of proteins involved in glucose metabolism in C57BL/6 fetuses on 
several days of gestation upon treatment of the dam with T0901 3 1 7. Hepatic expression levels of fetal (A) G6pc, 
(B) Pckl , (CJ Gck, (DJ Chrebp, (El Pklr and (Fl lnsr are displayed. Adult expression levels are arbitrarily defined 
as 1 .  Black bars, control fetuses; open bars, fetuses from dams receiving 0.0 1 5% T090 1 3 1 7. Values represent the 
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Abstract 
Prenatal nutrition as influenced by nutritional status of the mother has been 
identified as a determinant of adult disease. Feeding low-protein diets 
during pregnancy in rodents is a well-established model to induce "pro­
gramming" events in offspring. We hypothesized that protein restriction 
would influence fetal lipid metabolism by inducing epigenetic adaptations. 
Pregnant C57BL/6J mice were exposed to a protein restriction protocol 
(9% vs. 1 8% casein). Shortly before birth, dams and fetuses were sacrificed. 
To identify putative epigenetic changes, CpG island methylation microar­
rays were performed on DNA isolated from fetal livers. 204 gene promoter 
regions were found to be differentially methylated upon protein restriction. 
The liver X-receptor (Lxr) alpha promoter was hypermethylated in protein­
restricted pups. Lxr alpha is a nuclear receptor critically involved in control 
of cholesterol and fatty acid metabolism. The mRNA level of Lxra was 
reduced by 32% in fetal liver upon maternal protein restriction, whereas 
expression of the Lxr target genes Abcg5/ Abcg8 was reduced by 56% and 
5 1 %, respectively. In parallel, expression of lipogenic genes was reduced 
in the low protein group. In vitro methylation of a mouse Lxra-promoter/ 
luciferase expression cassette resulted in a 24-fold transcriptional repression. 
Our study demonstrates that, in mice, protein restriction during pregnancy 
interferes with DNA methylation in fetal liver. Lxra is a target of differential 
methylation and Lxra transcription is dependent on DNA methylation. It is 
tempting to speculate that perinatal nutrition may influence adult lipid me­
tabolism by DNA methylation which may contribute to the epidemiological 
relation between perinatal/neonatal nutrition and adult disease. 
LXR regulation by DNA methylation 
Introduction 
An overwhelming body of evidence links fetal {mal)nutrition to the de­
velopment of chronic diseases at adult age {DOHaD hypothesis, Develop­
mental Origins of Health and Disease {4; 5)). Epidemiological data show 
that children small for gestational age {SGA), that were undernourished 
during intrauterine development, have a higher risk to develop cardio­
vascular diseases or the metabolic syndrome in adulthood (3). In humans, 
fetal malnutrition is related to external factors (starvation, malnutrition, 
drug consumption of the mother) or to internal factors such as placental 
dysfunction leading to reduced routing of nutrients to the fetus {32). 
Knowledge of underlying mechanisms of "metabolic programming" 
may help to design strategies to halt the current epidemic in metabolic 
diseases. For this purpose, several animal models have been developed 
{34). Maternal dietary protein restriction is a well-characterized protocol 
to mimic fetal malnutrition in laboratory animals, from rodents to sheep 
{34). Moderate protein restriction (i.e., from 1 8-20% to 8-10%) in an isocaloric 
diet has been shown to increase the susceptibility to develop hyperten­
sion, insulin resistance, obesity or dyslipidemia in rodents, especially when 
"second hit" strategies, such as feeding high fat or high salt diet, at adult 
age are superexposed. 
Several explanations for the various observed facets of the long-term 
consequences of fetal malnutrition have been proposed. For some as­
pects, morphological changes during early development may play a role, 
such as reduced nephron numbers as a pre-determinant of adult hyper­
tension (13). In recent papers, epigenetic mechanisms like DNA methyla­
tion have been proposed to be involved in metabolic programming. In a 
series of elegant experiments Lillycrop and colleagues (7; 12; 22-24) have 
demonstrated that dietary protein restriction can modify the promoter 
methylation pattern of selected genes involved in metabolic processes 
and ultimately change gene expression. These authors proposed changes 
in cellular methyl group metabolism as the underlying mechanism for dif­
ferential DNA methylation, as the process could be prevented by addition 
of folate to the protein restricted diet (22). A genome-wide approach has 
not been published so far. 
CpG islands, CG-dinucleotide-rich regions in the promoter of a gene, 
have been shown to be of crucial importance for the transcriptional ac­
tivity of particular promoters (28). In general, transcription of a gene is 
blocked when the CpG island is methylated. This phenomenon has been 
extensively studied in tumor biology as methylation of tumorsupressor gene 
promoters or demethylation of protooncogen-promoters may be involved 
in oncogenesis (25). A useful approach to assess epigenetic changes in tis­
sues involves the application of differential methylation hybridization (DMH) 
(14). For this, DNA isolated from tissues of interest and adequate controls is 
treated with methylation-sensitive restriction enzymes. Hypermethylated 
DNA is protected from enzymatic digestion and is therefore overrepresent­
ed in the DNA sample. This difference in abundance can be detected by 
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microarray technology in a genome-wide manner {36) . 
A detai led characterization of the effects of maternal  dietary protein 
restriction on the developing mouse fetus is a pre-requisite for our under­
sta nding of metabol ic programming .  I n  the current study, we a pplied DMH 
tec hnology to identify genes involved in  metabolic programming by feta l 
ma lnutrition.  C57BL/6J mice were fed control ( 1 8% protein) or protein re­
stric ted d iet {9%) throughout pregnancy. Shortly before birth , the animals  
were terminated and fetal l iver DNA was ana lyzed us ing a 4.6k mouse 
CpG is land microarray (36) . Overa l l ,  1 37 genomic regions were identified 
to be hypermethylated and 1 45 to be hypomethylated upon dietary pro­
tein  restriction . We characterized one of the meta bol ica l ly most interest­
ing hypermethylated genes, i .e. ,  the l iver-X-receptor ( Lxr) a lpha,  in deta i l .  
Lx r  a lpha (or  N rl h3) i s  a nuc lear receptor crucia l ly i nvolved in cel l u lar  l ipid 
homeostasis (35) . Lxr alpha is activated by oxysterols ,  binds to its heterodi­
meric partner, the retinoid X-receptor {RXR) and then activates a broad 
variety of target genes ( 1 5) .  Activation of the LXR target gene Srebpl c re­
su lts in increased l ipogenesis required for formation of cholesteryl ester { 1 7) .  
F ina l ly, expression o f  the adenosine triphosphate-binding cassette {ABC) 
transporters Abcal , Abcg5 and Abcg8 is regulated by LXR, leading to in­
creased removal of stero ls  out of the cel l  (27 ) .  Therefore, Lxr a lpha is a key 
reg u lator of l ipid homeostasis . 
Our  DMH/DNA microarray experiment identified the Lxra promoter as 
a target of DNA hypermethylation i n  a protein restriction model. Conse­
quently, purpose of this study was to characterize the effects of Lxra pro­
moter hypermethylation on the expression of Lxra and its target genes in the 
mouse fetus and to l ink it to feta l l ip id metabol ism . Moreover, we performed 
extensive in vitro studies both with endogenous Lxr a nd Lxr-promoter/ lucif­
erase constructs to pinpoint the re lation between DNA methylation and 
gene expression on the  molecular leve l .  
Material and Methods 
Animals 
C57BL/6J Sv1 29/Ola Hsd mice were obtained from Harlan (Horst, The 
Nether lands) . Animals were housed in temperature-control led rooms (23 
0C) with 12 hours l ight cyc l ing and free access to standard pel let d iet and 
water ad l ibitum.  To exclude gender-specific effects, on ly male fetuses 
were used for al l of the ana lyses described . Gender of the fetuses was de­
termined by PCR as previously described (20; 33) . Experimenta l  procedures 
were approved by the local ethical  committee for an ima l  experiments of 
the U niversity of Groningen.  
Experimental procedures 
Al l  females received the control d iet { 1 80 g casein/kg ,  Arie B lok BV, Wo­
erden,  The Netherlands) two weeks prior to mating .  Virgin females were 
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time mated .  After confi rmation of mating by the appearance of a vag ina l  
p lug  the  females were a l located to  be fed either the  contro l diet or a low 
protein diet (90g casein/kg ) .  The diets are described in detai l  elsewhere 
(21 ) .  At day 1 9.5 of gestation females were anaesthetized with isofl uran e  
a n d  ki l led by cardiac puncture. B lood was col lected in EDTA conta in ing 
tubes. Organs were snap-frozen in l iqu id nitrogen and stored at -80°C .  
Fetuses were removed from uteri, weight a n d  length were measured a n d  
fetuses were sacrificed a n d  dissected. The feta l tissues were randomly as­
signed to the different fol low-up procedures to avoid bias by feta l size or  
position in the uterus. One ma le fetus per  dam was used for DNA and R N A  
iso lation, o n e  for R N A  only, a n d  the remaining ones were used for stero l 
ana lysis .  B lood samples were taken by exsanguisation .  Organs of fetuses 
were col lected, immediately snap-frozen in l iquid nitrogen and stored at 
-80°C.  
CpG island microarray 
DNA was isolated from feta l l iver samples using the QuiAmp DNA min ikit 
(Qiagen, Hi lden, Germany) fol lowing the manufacturer's instructions. The 
CpG is land microarray was performed fol lowing the procedures described 
by Yan and col leagues (36) . Briefly, feta l DNA ( 1 -2 µg) from 5 fetuses per 
experimenta l group was restricted with Mse l (New England Bio labs, Fran k­
furt am Main,  Germany) to fragments of 200 base pairs on average. The 
number of  samples (n=5) was calcu lated according to Al l ison (2) . The DNA 
fragments were l igated to universal  l inker primers (H- 1 2, 5'-TAATCCCTC­
GGA-3 ' and H-24, AGGCAACTGTGCTATCCGAGGGAT-3 ' )  and cut with the 
methylation-sensitive restriction enzymes BstU I and Hpa l l  (New Eng land 
Biolabs) . Fragments contain ing methylated sites are protected against 
restriction and wi l l  hence be relatively enriched by this procedure. The 
products were then PCR-ampl ified using the H-24 primer. As demonstrated 
by Yan and col leagues (36) , this wi l l  result in  proportiona l  ampl ification of 
the undigested fragments . After purification the PCR product was coupled 
to Aminoal lyl-dUTP and labeled with Alexa dye 647 (protein  restriction  
diet) or Alexa dye 555  (contro l diet) , respectively. The samples were puri­
fied and hybridized overnight to a mouse CpG is land microarray conta in­
ing 4, 642 clones (obtained from the Sanger Institute) (36) . After Scann ing 
(Axon 4000A) , s l ide norma l ization was performed using a sub-grid intensity 
based method (GeneTraffic,  lobion ) .  The generated tiff images were used 
to quantify the spot intensities . The latter steps were done at the Ontario 
University Health Network Microarray Centre (Toronto, Canada) . Data 
were ana lyzed by the SAM software package (31 ) as described below. To 
restrict the resu lts to CpG is lands in the proximity of gene promoters, we 
l imited the results to clones within 4000 bp distance to a transcription start 
site. F inal ly, the resu lts were annotated and sorted by the GO term Biolog i­
cal  Process, level 4 (BP4) using DAV ID  software ( 1 0) .  I nformation regard ing 
the clones represented on the CpG i s land microarray can be obtained 
from the Ontario U niversity Health Network Microarray Centre: http://data .  
microarrays .ca/cpgmouse/. The CpG is land microarray data d iscussed i n  
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this publication have been deposited in the Gene Expression Omnibus, 
accession number 00000 [reviewer link :  http://www.ncbi.nlm.nih.gov/geo/ 
query/acc.cgi?token=vlsrpgyoguogihk&acc=GSE15280] . 
Gene expression analysis 
TriReagent (Sigma, St. Louis, MO} was used to isolate total RNA from fe­
tal livers and intestines according to the manufacturer's instructions. RNA 
was quantified using a NanoDrop N DlO00 spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, DE} .  cDNA synthesis was performed as de­
scribed ( (26)} . Real time quantitative PCR was performed using an Applied 
Biosystems 7700 sequence detector according to the manufacturer's in­
structions. Primers and probes were obtained from lnvitrogen (Breda, The 
Netherlands). Primers and probes were described previously (http://www. 
labpediatricsrug.nl), with the exception of DNA methyltransferase 1 (Dnmtl; 
accession number N M_0l 0066.3; sense TGGTGCTGAAGCTCACACTG, anti­
sense CCATACTGTCCAGCCTGGAG, probe CTGCCTGGTCCGCATGGGC­
TAC), Dnmt3a (accession number NM_007872.4, isoform 1 and 2; sense CG­
GCAGAATAGCCAAGTTCA, antisense CTGGTCTTTGCCCTGCTTTA, probe 
CAAAGTGAGGACCATTACCACCAGGT CAAAC) and Dnmt3b (accession 
number NM_00100361 , isoforms 1 to 4; sense CCAGTCTTGGAGGCAATCTG, 
antisense CTGGAGACCTCCCTCTTAGACAG, probe CACCAGAGAC­
CAGAGGCCGCAG). Expression levels were normalized to those of 18S 
ribosomal RNA which was analyzed in separate runs. 
Inhibition of DNA methylation by zebularine 
The mouse hepatoma cell line Hepal .6 was grown in Dulbecco's modi­
fied Eagle medium (Gibco, B reda, the Netherlands} , 10% fetal bovine 
serum (Gibco), under standard cell culture conditions. One day before 
treatment, 1 million cells/10 mm dish were seeded. Cells were incubated 
for 72 hours with 0 µM,  20 µM, 50 µM, 100 µ M or 200 µ M  of the DNA methyla­
tion inhibitor zebularine {l- {�-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one; 
Sigma). Genomic DNA and RNA were isolated with TriReagent (Sigma) as 
described by the manufacturer. 
Bisulfite sequencing of the Lxra promoter 
To characterize the methylation pattern of the Lxra promoter, bi­
sulfite sequencing was performed (11 ): DNA was treated with bisulfite 
using the EZ DNA methylation kit (Zymo Research, Orange, CA) accord­
ing to the manufacturer's instructions. The Lxra promoter was amplified 
using the primers 5 '-AGGGAGGTTGGGAATATAGGTT-3' and 5'-CTAC­
CAAAAAATCCTTCCTACTAA-3'. PCR products were cloned into the pCR2.1  
topo vector (lnvitrogen} and several randomly picked clones from inde­
pendent biological samples were sequenced. The sequences obtained 
were analyzed with the QUMA software package (19) using standard set­
ting (upper limit of unconverted CpHs: S; lower limit of percent converted 
CpHs: 95; upper limit of alignment mismatches: 1 0; lower limit of percent 
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identity: 90) . The difference of overall-methylation between groups was 
calculated by Mann-Whitney-Li -test. 
Functional LXR promoter analysis 
A region of the LXRa promoter from -926 to +413 was amplified by PCR 
using the primers 5' -GGCAAAACTATCATCATCGTCGTC-3' and 5' -TTGCT­
GGGAGAAGAGGGTGTTGC-3', and cloned into the promoterless, CG-free 
luciferase vector pCpGl-basic (18) . This construct was methylated by Sssl 
methylase (New England Biolabs) . The CG-free CMV-luciferase vector 
pCMV-CpGI was used as control as described before (18) . The CpG vec­
tors were kindly provided by Maja Klug and Dr. Michael Rehli, University 
Hospital Regensburg, Germany. 
COS7 (African Green Monkey kidney fibroblast cell line) and HepG2 (hu­
man hepatocellular carcinoma cell line) cells were grown at 0. 1% gelatine 
(Sigma) in Dulbecco's modified Eagle medium supplemented with l 0% fetal 
bovine serum (Gibco) under standard cell culture conditions. All constructs 
were transfected using Fugene (Roche, Mannheim, Germany) according 
to manufacturer' s instructions. 48 hours after transfection, cells were lysed 
with Luciferase Cell Culture Lysis Reagent (Promega, Leiden, the Nether­
lands) as described by the manufacturer and the luciferase activity was 
determined using 1% Triton X-100 (Sigma) , 25 mM Glycyl-Glycin (Sigma) , 15 
mM MgSO4 (Merck, Amsterdam, the Netherlands) 5 mM ATP (Roche) 6.25 
uM D-Luciferin (Sigma) in a Berthold Microplate Luminometer (Berthold, 
Pforzheim, Germany). Luciferase was normalized to B-galactosidase activ­
ity to correct for transfection efficacy. 
Sterol analysis 
Liver specimens were dried and the weight was noted before extracting 
sterols and oxysterols with chloroform/methanol. Briefly, sterols and oxyster­
ols were extracted by cyclohexane after alkaline hydrolysis of the corre­
sponding esters. After evaporation, the hydroxyl groups of the sterols were 
silylated and transferred into the GC vials. Cholesterol was determined by 
gas chromatography, cholesterol precursors, plant sterols and oxysterols 
by gas chromatography-mass spectrometry as previously described (30) . 
Statistics 
Statistical analyses were performed using SPSS 14.0 for Windows (SPSS 
Inc., Chicago, USA). Differences between the groups were analyzed by 
Mann-Whitney-Li-test and corrected for multiple testing (False-Discovery 
Rate (FDR) < 10%). A p-value smaller than 0.05 was considered statistically 
significant. Data presented are means ± SD. 
For the analysis of the CpG island microarray data, a modified T-test 
using Statistical Analysis of Microarrays (SAM) was used. SAM is a variant 
of permutation analysis developed for microarray analysis and extensively 
described by lusher et al. (31). The input to SAM is the normalized signal ra­
tio for each clone from a set of microarrays and a response variable (diet) 
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from each experiment. SAM tests whether  the mean c lone s ignal  d iffers 
from zero. SAM a lso computes the FDR va lue in this experiment. FDR was 
set to 1% by adjusting the delta va lue (cut-off) . SAM computes a statistic D 
va lue (D-score) for each c lone, measuring the strength of the relationship 
between clones and the diet variable.  A l ist of sig nificant a l tered clones 
(FDR<l %) was generated.  
Results 
Maternal protein restriction has l imited effects on fetal biometric param­
eters 
We applied a mi ld ,  wel l -characterized protein restriction protocol (9% vs. 
1 8% casein) to pregnant C57BL6/J mice. P rotein restriction did not lead to 
differences in body weight, l iver size, or plasma tota l cho lestero l concen­
trations in the dams (Ta b le 1 ) .  Litter sizes were identica l  in both treatment 
groups (Tab le 1 ) .  No d ifferences in  feta l body weight, feta l body length, 
feta l l iver weight or p lacenta l  weights were noted (Tab le 1 ) .  
Table 1 .  Basic parameters of dams and fetuses on day 1 9  .5 of pregnancy 
dams 
body weight [g] 
liver weight [g] 
ratio liver weight/body weight [%] 
plasma cholesterol [mmol/I] 
number of fetuses 
male fetuses 
placental weight [g] 
fetal weight [g] 
fetal length [w/o tail ,  m m] 
liver weight [mg] 
ratio liver weight/body weight [%] 
control diet 
36.5 ± 2. 1 
1 .6 ± 0. 1 
4.3 ± 0.3 
1 .58 ± 0.63 
6.2 ± 2.6 
0. 1 1 0  ± 0.025 
1 . 1 0  ± 0. 1 5  
20.7 ± 1 .7 
45 ± 7 
4. 1 ± 0.5 
low protein 
35.2 ± 1 .3 
1 .4 ± 0. 1 
4.0 ± 0.4 
1 . 1 7  ± 0.28 
6.5 ± 1 .7 
0. 1 03 ± 0.0 1 6 
1 .20 ± 0.27 
2 1 .2 ± 2.0 
56 ± 1 1  
4 .4 ± 0.78 
Dams were terminated at day 1 9  .5 (n=5) . The number of fetuses includes male and female fetuses. All fetal char­
acteristics are given for male fetuses only. Fetal length was measured from the forehead to - but not including 
- the tail. No significant differences were noted. 
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CpG island microarray identifies 204 differentially methylated gene 
promoters 
To identify CpG-island which are differentially methylated upon dietary 
protein restriction and, hence, may be involved in metabolic programming, 
a 4.6K mouse CpG island microarray was performed on fetal liver DNA. 
Briefly, unmethylated sequences are digested by methylation-sensitive re­
striction enzymes which leads to a relative enrichment of methylated DNA 
(36}. To limit variation, only DNA from male fetuses was used; consequently, 
only male fetuses were used for all biochemical analyses throughout the 
entire study. 
SAM analysis of the CpG island microarray data revealed 137 clones 
to be hypermethylated upon protein restriction and 145 were found to be 
hypomethylated when compared to controls. As the assay identified all 
differentially methylated DNA regions regardless of their position in the 
proximity of genes, we restricted the analysis to all regions situated closer 
than 4000 nucleotides from a transcription start site of known genes. These 
areas were considered to represent or to contain gene promoters. This 
restriction yielded l 01 regions which were hypo methylated upon dietary 
protein restriction and 106 regions which were hypermethylated. 
After removal of 3 repetitive sequences the data were analyzed by the 
DAVID software package and sorted by biological functions (BP level 4) . 183 
gene regions could be annotated (see Supplemental Table l for details} , 
88 were used for the BP 4 categorization. A total of 36 promoters of genes 
involved in nucleobase/nucleic acid metabolism was identified. Promoters 
of genes involved in protein metabolism (33} , transport (32} , regulation of 
cellular metabolism (27} and biopolymer metabolism (27} were also identi­
fied. Ten differentially methylated regions were linked to precursor/energy 
metabolism, intracellular transport, establishment of cellular function, or 
cellular organization, respectively. Finally, 4 genes involved in heart devel­
opment were found. Obviously, some genes are involved in more than one 
pathway. 
Interestingly, the liver-x-receptor alpha (Lxr alpha, Nrl h3} was identi­
fied with the CpG island microarray. Lxr alpha is a nuclear receptor that 
is involved in four of the gene clusters mentioned. The Lxr alpha promoter 
is contained on clone UHNmmcpg0009844 (http://data.microarrays.ca/ 
cpgmouse/} which was found to be hypermethylated upon dietary pro­
tein restriction. As Lxr alpha is crucial for the regulation of both cholesterol 
homeostasis and lipogenesis and may therefore be involved in metabolic 
programming, we have chosen to characterize the effects of Lxra promot­
er methylation in more detail. 
The Lxra promoter is hypermethylated upon dietary protein restriction 
Computer analyses revealed the presence of two short, CG-rich stretch­
es in the promoter of murine Lxra (Figure lA} which are considered as a 
single CpG island. The first region, with 7 CG dinucleotides, ranges from -60 
to +6 and hence includes the transcription start site. 
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It contains one putative Spl- and two putative MAZ binding sites as postu­
lated by Alberti et al. (1). The second region spans from +117 to +231 and 
contains the alternative splicing site 1 B. In this region, 1 0  CG dinucleotides 
can be found. 
To characterize the methylation pattern identified in the CpG island mi­
croarray on the molecular level, we performed bisulfite sequencing of the 
Lxra promoter CpG island (Figure 1 B and Supplemental Table 2). In fetuses 
from dams fed control diet, the CpG island was only marginally methylat­
ed. The overall-methylation in the protein-restricted group was significantly 
higher than in the control group (10% upon protein restriction vs. 1% in the 
control group; p=0.00002). Interestingly, methylation of some CpG position 
was not effected while other positions were methylated up to 39% (Figure 
1B). 
A. 
- 1 8 1  t g t c t t caccc t t ggag t t c t ac t ggct t gg c t cag t cc t ggggc t ag t ggggagag c t t 
- 1 2 1  gg�c t t cccagaggcaggggaggagggaggc t gggaacacaggc t gggg c t t gg t g t@] 
MAZ 
- 6 1 lm,aa t t c@gcjcg]tgqcgggacc t t tgc tclqi"c'gjaggtgt c t t tgggaggaggggggag 
Sp1 MAZ MAZ 
�� tgac t c t ggaggc t g c t ggga t t aggg t ggggg t ga c t gagaagcag t cc t t c  
1' transcription start site Sp1 
6 1  t g t cagag caaagagc c t ccaggg t gaggagaggaaggagagaga t ggaa c t agac�Q.!. 
1' splicing site 1 A  
1 2 1 c tgjc'ghggaa�cagt t t tgg t agagggt aggggacagggtgm§hc t aagag 
1' splicing site 1 B 
1 8 1 gg t ggc@Mcjcooggaggag t t ag t c t gg t ggggaag c t ac c tic9jtgggpg]9gggcc t aa 
241 t gaag c t aagag t c t t ggg t�ccag t aggaaggacccc t t ggcag t ccct cccc t tggc 
B .  
control diet 
1 2 3 4  5 6 
protein restriction 
7 8 9 1 0 1 1 1 2 1 3  1 4 1 5 1 6 1 7  1 8  
Figure 1 .  Methylation pattern o f  the Lxra CpG island. (A) Structure o f  the murine Lxra promoter. The postulated 
CpG islands are underlined. Bold: Transcription factor binding sites according to Alberti et al. ( 1 ) .  MAZ. MYC-asso­
ciated zinc finger protein; SP 1 ,  specificity factor 1 .  (B) Bisulfite sequencing of the Lxra promoter. Circles represent 
the CpG positions identified in the Lxra promoter. The black inlay represents the level of methylation of each CpG 
position. Above. control group ( 1 5  clones analyzed) ;  below. protein restriction group ( 18 clones analyzed) . 
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Lxra is regulated by methylation of its CpG island 
To assess whether the Lxra promoter CpG island indeed regulates ex­
pression of the Lxra gene, the mouse hepatoma cell line Hepal .6 was 
treated with the DNA methylation inhibitor zebularine. Bisulfite sequencing 
of DNA obtained from control cells and cells treated with 200 µM zebu­
larine (the highest dose tested} confirmed that zebularine blocked meth­
ylation of the Lxra promoter CpG island: The average CpG methylation 
level was reduced from 69% in untreated cells to 17% in cells treated with 
200 µM zebularine (Supplemental Figure l } . In parallel, inhibition of DNA 
methylation by zebularine led to an increase of Lxra mRNA expression in a 
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Figure 2. Lxra gene expression in mouse Hepa 1 .6 cells treated with the methylation inhibitor zebularine. Hepa 1 .6 
cells were incubated for 72 hours with 0 µM, 20 µM, 50 µM, 1 00 µM or 200 µM of the DNA methylation inhibitor 
zebularine as described in Material and Methods. Lxra gene expression was determined by Taqman real-time 
PCR. •, p < 0.05 (Mann-Whitney-U-test) treated vs. untreated control. 
Zebularine treatment does not specifically act on the Lxra CpG island 
but interferes with DNA methylation in general. To specifically determine 
the function of the Lxra CpG island in vitro, a luciferase reporter assay 
was performed. For this purpose, the Lxra CpG island was cloned into a 
CpG-free luciferase vector (pCpGL, (18) ) and methylated by Sss methylase 
in vitro. When transfected in the kidney cell line COS7, the activity of the 
unmethylated Lxra promoter construct was 24-fold higher than that of the 
Sss-methylated vector (Figure 3A}. As a control, a CpG-free CMV-luciferase 
construct (pCpG-CMV, (18) ) was treated in the same way and did not show 
differences in activity (Figure 3B} . The experiment was repeated in HepG2 
cells and yielded comparable results, a reduction of activity by 97% upon 
SSS methylation of the Lxra promoter (data not shown} . 
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Figure 3. Effects of promoter methylotion on reporter gene expression. (A) A region of the LXRo promoter from 
-926 to +4 1 3  was amplified by PCR and cloned into the promoterless, CG-free luciferase vector pCpGl-basic ( 1 8) .  
The vector was methylated and transfected in  HepG2 cells as  described in  Material and Methods. 48 hours after 
transfection luciferase activity was determined. Luciferase was normalized to B-galactosidase activity. •, p<0.05 
(Mann-Whitney-LI-test). (B) The CG-free CMV-luciferase vector pCMV-CpGI was used as control as described 
before ( 1 8) .  
LXR target genes are down-regulated in the fetal liver upon maternal pro­
tein restriction 
To study the influence of Lxra promoter methylation in vivo, gene expres­
sion of Lxra and selected LXR target genes were measured in fetal liver 
at day 19.5 (n=S-10). As shown in Table 2, expression of Lxra in the protein 
restricted group was reduced by 32% when compared to the control group 
(p=0.03). Expression of Lxrb was identical in both groups (1.00 ± 0.22 vs. 0.9 1  
± 0.15 in the control and the protein restricted group, respectively). 
In parallel with the reduced expression levels of Lxra itself, its target 
genes showed markedly decreased expression levels in the protein re­
stricted group compared to controls: expression of the sterol half-trans­
porters Abcg5 and Abcg8 was reduced to 44 and 49% of control values, 
respectively, upon protein restriction (p=0.001 and p=0.016 for Abcg5 and 
Abcg8, respectively). Expression of Abcal was reduced by 18% (p=0.027). 
Moreover, expression of genes involved in de nova lipogenesis was strongly 
reduced by protein restriction: Accl expression was suppressed by 28% 
(p=0.001), Acc2 by 5 1 %  (p=0.004), and Scdl by 40% (p=0.001). The gene 
encoding fatty acid synthase (Fasn) was expressed at 76% of control lev­
els which did not reach statistical significance (p=0.360). Expression of the 
genes encoding the sterol regulatory element-binding proteins (Srebpl a, 
Srebpl c and Srebp2) was differentially affected: While the expression levels 
of Srebpla and Srebp2 were reduced in the protein-restricted group (by 21 
and 24%, respectively), no difference was found for Srebpl c. Similarly, no 
influence of dietary protein restriction on the expression of Ppara, Pparg or 
Chrebp was found. 
To exclude a compensatory overexpression of genes responsible for DNA 
methylation, the m RNA expression of  the genes encoding the three DNA 
methyltransferase 1, 3a and 3b was measured and found to be identically 
expressed in the protein restricted group (92%, l 02% and 98% for Dnmtl, 
Dnmt3a and Dnmt3b, respectively) when compared to the control group. 
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Table 2. Hepatic gene expression in male fetuses from dams fed control or protein restricted diet 
control diet low protein 
Lxra 1 .00 ± 0.21 0.68 ± 0. 1 9  * 
Lxrb 1 .00 ± 0.22 0.9 1  ± 0. 1 5  
Srebp la  1 .00 ± 0. 1 8  0.79 ± 0. 1 9  * 
Srebp lc 1 .00 ± 0.38 0.96 ± 0. 1 2  
Srebp2 1 .00 ± 0. 1 1 0.76 ± 0.23 * 
Chrebp 1 .00 ± 0.57 1 .03 ± 0.41 
Ppara 1 .00 ± 0. 1 8  0.79 ± 0.22 
Pparg 1 .00 ± 0.46 0.77 ± 0. 1 9  
AbcgS 1 .00 ± 0.34 0.44 ± 0. 1 4  * 
AbcgB 1 .00 ± 0.56 0.49 ± 0. 1 8  * 
Abca l 1 .00 ± 0 . 1 6 0.82 ± 0. 1 2  * 
Ace ! 1 .00 ± 0. 1 2  0.72 ± 0. 1 8  * 
Acc2 1 .00 ± 0.33 0.49 ± 0.3 1 * 
Fasn 1 .00 ± 0.47 0.76 ± 0.20 
Scd l 1 .00 ± 0.43 0.60 ± 0. 1 4  * 
Acadm 1 .00 ± 0.26 0.97 ± 0.30 
Dnmt l  1 .00 ± 0.28 1 .08 ± 0.09 
Dnmt3a 1 .00 ± 0.20 0.87 ± 0. 1 9  
Dnmt3b 1 .00 ± 0. 1 2  0.93 ± 0.30 
Apobec l 1 .00 ± 0.21 0.76 ± 0. 1 9  * 
Hepatic RNA was isolated from male fetuses at day 1 9.5 pc. Gene expression was studied by Taqman Real-time 
PCR as described in Material and Methods. n = 8-1 0. Values represent the mean ± SD. •, p < 0.05 (Mann-Whitney­
U-test) . 
Expression of the RNA deaminase Apobecl was reduced by 24% (p=0.021) 
in the protein-restricted group, in accordance with the hypermethylation 
of its promoter region as identified in the CpG island microarray (Supple­
mental Table 1) . 
LXR target genes are downregulated in the fetal intestine upon materna l  
protein restriction 
Lxra is mainly expressed in the liver, the intestine and in macrophages in 
adult mice. Therefore, we questioned whether the consequences of ma­
ternal protein restriction observed in the fetal liver, i.e., downregulation of 
Lxr target genes, would also be present in the fetal intestine. 
Chapter 6 
� 
We measured expression of Lxra, Lxrb and several wel l-known intestinal 
target genes of LXR {Table 3). The mRNA expression of both Lxra and Lxrb 
was significantly reduced upon maternal dietary protein restriction {by 16% 
and 34%, respectively). In parallel , the expression of the LXR target genes 
Abcg5 and Abcal was significantly reduced {by 28% and 39%, respec­
tively). The expression levels of Abcg8 were very variable between the 
samples, therefore we could not detect a statistically significant effect of 
maternal protein restriction on Abcg8 mRNA expression. 
Ultimately, the mRNA levels of the DNA methyltransferases Dnmtl and 
Dnmt3b were not significantly affected by maternal protein restriction, 
whereas that of Dnmt3a was slightly but significantly reduced {-21%) upon 
maternal protein restriction (Table 3). 
Table 3. Intestinal gene expression in male fetuses from dams fed control or protein restricted diet 
control diet low protein 
Lxra 1 .00 ± 0 . 1 6  0.84 ± 0. 1 3  * 
Lxrb 1 .00 ± 0.20 0.66 ± 0. 1 5  * 
AbcgS 1 .00 ± 0.24 0.72 ± 0.26 * 
Abcg8 1 .00 ± 0.25 0.79 ± 0.3 1 
Abca l 1 .00 ± 0 . 1 3  0.6 1 ± 0. 1 5  * 
Dnmt l 1 .00 ± 0 . 1 9  0.84 ± 0. 1 7 
Dnmt3a 1 .00 ± 0 .20 0.79 ± 0. 1 4  * 
Dnmt3b 1 .00 ± 0 .25 0.80 ± 0. 1 4  
Intestinal RNA was isolated from male fetuses at day 1 9.5 pc. Gene expression was studied by Taqman Real-time 
PCR as described in Material and Methods. n = 9- 1 0. Values represent the mean ± SD. •, p < 0.05 (Mann-Whitney­
U-test) . 
Maternal protein restriction interferes with fetal l ipid metabolism 
Lxr plays a major role in the regulation of hepatic lipid metabolism via 
regulation of cellular cholesterol homeostasis and de nova lipogenesis. 
Table 4 shows plasma and liver concentrations of cholesterol, cholestanol, 
lathosterol and the two major plant sterols campesterol and sitosterol. In 
adult animals, cholestanol and plant sterols are used as surrogate mark­
ers for cholesterol absorption, whereas lathosterol levels reflect cholesterol 
synthesis. In fetal plasma, concentrations of cholestanol and campes­
terol were significantly reduced upon protein restriction {by 24 and 36%, 
respectively), whereas total cholesterol ,  sitosterol and lathosterol were 
unchanged. In the fetal liver, cholesterol ,  and cholestanol concentrations 
were significantly reduced {by 11 and 27%, respectively) in the protein 
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restricted fetuses compared to control-fed animals. No differences were 
found with regards to lathosterol, campesterol or sitosterol concentrations. 
Moreover, we could not detect differences in the hepatic concentrations 
of the common oxysterols 7a-hydroxycholesterol, 24-hydroxycholesterol 
and 27-hydroxycholesterol (data not shown). 














1 .64 ± 0. 1 4  
6.95 ± 0.72 
3. 1 8  ± 0.98 
23.49 ± 5.69 
1 2.78 ± 3.02 
25.3 ± 0.96 
73.6 ± 8.92 
1 07 ± 7.36 
1 84 ± 3 1 .8 
66.2 ± 1 4.9 
low protein 
1 .39 ± 0.27 
5.28 ± 0.96 * 
3.40 ± 0.77 
1 5 . 1 0  ± 4.25 * 
1 0.53 ± 2.23 
22.5 ± 0.9 1 * 
54.0 ± 5.98 * 
1 22 ± 2 1 .2 
1 39 ± 20.9 
54.9 ± 9 .36 
Sterols were isolated from male fetuses at day 19 .5 pc and analyzed by GC-MS as described in Material and 
Methods. Values represent the mean ± SD of 5 dams per groups and 5 averaged fetal values per group.•. p < 
0.05 (Mann-Whitney-U-test) . 
Discussion 
Dietary protein restriction during pregnancy is a widely accepted model 
to mimic fetal undernutrition. It has been shown that dietary protein re­
striction during fetal development has long-term consequences on many 
physiological parameters in rodents, an effect commonly referred to as 
metabolic programming. To explain metabolic programming, morpho­
logical changes as well as epigenetic effects, i.e., DNA methylation and 
histone modifications are currently discussed. 
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Using fetal hepatic DNA, Lillycrop and colleagues have shown that 
dietary protein restriction leads to hypomethylation of CpG islands in the 
promoter regions of selected genes (22; 23). They therefore proposed that 
a shortage of methyl group donors, together with adaptations in DNA 
methyltransferase 1 (Dnmtl) activity, could lead to global DNA hypometh­
ylation, which would be one possible explanation of metabolic program­
ming. Consequently, restriction of vitamin B12, folate, and methionine lead 
to global DNA hypomethylation in fetal sheep as identified by restriction 
landmark genome scanning (29). 
Despite the fact that dietary protein restriction is a commonly applied 
model, genome-wide data on its impact on fetal DNA methylation are not 
available.  We therefore applied a 4. 6K mouse CpG island microarray to 
study differential methylation in a genome-wide way. The genes previously 
identified to be hypomethylated upon protein restriction, i.e., GR and the 
PPARs (22; 23), were not represented with suitable clones on these microar­
rays. We show here that mild protein restriction of the dam, i.e., in the ab­
sence of growth retardation of the pups, leads to hypomethylation of 1 01 
gene-related CpG islands in the fetal liver. Interestingly, 1 06 regions were 
hypermethylated. Based on the hypothesis that the previously reported 
hypomethylation of selected promoters upon protein restriction is a con­
sequence of limited methyl group availability, one would anticipate that 
hypomethylation would be the major consequence. We could not observe 
any compensatory up-regulation of the DNA methyltransferases Dnmtl, 
Dnmt3a or 3b. Our results indicate that the differences in DNA methylation 
as a consequence to maternal protein restriction may be more a reloca­
tion of resources than a passive process caused by substrate shortage. It 
can hence be hypothesized that maternal protein restriction could, at the 
molecular level, be mechanistically different from maternal methyl-group 
limitation as used by Sinclair et al. in sheep (29). 
The CpG islands identified as differentially methylated belong to genes 
which can be assigned to a variety of biological functions when analyzed 
by the DAVID software package (10). We focused on Lxra (Nrlh3) which 
encodes for a key regulator of cellular lipid homeostasis. In general, Lxra 
is highly expressed in the liver, intestine, and macrophages ( (35)). When 
activated by oxysterols, Lxr alpha binds to its heterodimer partner Rxr. The 
Lxr/Rxr complex then trans-activates expression of genes responsible for 
removal of cholesterol from the cell (16). This includes genes involved in 
cholesterol excretion (Abcal, Abcg5/g8) as well in de novo lipogenesis 
(Srebp's). Thereby, cholesterol is either directly excreted from the cell or 
can be esterified with newly synthesized fatty acids. 
To characterize the influence of CpG island methylation on the expres­
sion of Lxra, we treated mouse hepatoma cells (Hepal .6) with the meth­
ylation inhibitor zebularine in different concentrations (8). The expression 
of Lxra mRNA increased in a dose-dependent manner. It is tempting to 
speculate that the de-methylation of the Lxra CpG island is responsible 
for its enhanced transcription. However, as zebularine has promiscuous 
effects on other genes which may explain this observation, we used a re-
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porter assay to specifically demonstrate the functionality of the Lxra CpG 
island. When cloned in front of a luciferase reporter construct (18) and 
methylated in vitro by Sss methylase, the Lxra promoter - including the CpG 
island - almost completely lost its transcriptional function. These findings 
together demonstrate that the CpG island identified in this paper is able to 
significantly modify the expression of Lxra at least in vitro. 
The murine Lxra promoter contains several transcription factor binding 
sites, as already described by Alberti et al. (1) , namely of the MYC-asso­
ciated zinc finger protein (MAZ) and Specificity Factor 1 (SPl ) .  Most inter­
estingly, the first SPl site (-54 to -49) contains one CG dinocleotide and is 
surrounded by two others. It has been suggested that cytosine methylation 
at or close to SPl motifs is involved in the regulation of SPl binding to DNA 
(9) . Consequently, SPl methylation has been shown to occur in a variety of 
gene promoters, both in normal tissue differentiation and in tumorigenesis. 
U sing bisulfite sequencing we here demonstrate that the Lxra promoter 
CpG island is indeed selectively hypermethylated upon protein restriction 
at some positions, while others are not affected. The aforementioned SPl 
site belongs to the positions hypermethylated upon protein restriction. It 
can be hypothesized that methylation of this particular SPl site, putatively 
combined with binding of regulatory proteins, is involved in the observed 
transcriptional silencing of Lxra by DNA methylation. 
CpG island methylation is generally considered to repress transcription. 
Consequently, we could observe a small but significant reduction of Lxra 
gene expression in the fetal liver in our protein restriction model. Lxra mRNA 
expression was 68% ± 19% of control values (p=0.003; n=B-10) . Downstream, 
we could observe a major reduction in the expression of a number of well­
characterized Lxr target genes, e.g. , Abcg5, Abcg8 and Abcal . Abcg5 
and Abcg8 together facilitate the transfer of cholesterol and several other 
sterols from the liver into the bile ((6) ) .  Unfortunately, we were not able to 
collect bile from the fetuses. Abcal is involved in transfer of cellular choles­
terol to HDL. Sterol composition of fetal plasma and liver was inconclusive 
and does not allow an interpretation of the physiological relevance of the 
observed changes in Abcg5/g8 expression. This is partially because it is not 
yet known whether sterol transport mechanisms in adults and fetuses are 
comparable. Therefore, more work is needed to explore the differences 
in sterol metabolism observed in our study. On the other hand, LXR has 
been shown to be involved in the regulation of de novo lipogenesis by 
regulating the expression of several key genes (17) .  Consequently, many 
genes involved in fatty acid metabolism (Accl , Acc2, Fasn, Scdl ) were 
markedly lower expressed in the protein-restricted fetuses. This may have 
consequences for fatty acid metabolism on the long term. 
Besides in the liver, Lxra is expressed at high levels also in the intestine 
and in macrophages. We did not collect fetal macrophages but were able 
to confirm our finding in the fetal intestine: Similar to the liver, the mRNA 
expression of the LXR target gene Abcal was reduced. Interestingly, mRNA 
expression of Abcg5 and Abcg8 was only mildly (Abcg5) or not significantly 
(Abcg8) reduced. 
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Thus, in the liver Abcg5/Abcg8 are more severely affected than Abcal 
while in the intestine it is the reverse order. In a recent paper we have com­
pared the activation of LXR target genes by pharmacological agonists in 
the fetal liver and the fetal intestine (33). In that study we found a similar 
pattern for the upregulation of those transporters, with Abcg5/Abcg8 be­
ing more affected in the liver and Abcal in the intestine. This may point to 
additional factors being involved in the regulation of these genes in the 
liver and the intestine. 
Perspectives and Significance 
To the best of our knowledge, we are the first to publish genome-wide 
methylation data in a model of dietary protein restriction. Our data show 
that differential methylation of CpG islands may be an important epigen­
etic regulator of gene expression and hence provide a plausible link be­
tween maternal-fetal nutrition and fetal physiology. Despite the fact that 
we could only detect minor changes in physiological readout parameters 
in the fetuses, such as sterol concentrations in liver and plasma, it is tempt­
ing to speculate that the observed changes in CpG methylation may have 
long-term consequences on metabolic regulation. This may even be more 
pronounced when metabolic challenges as high fat or high cholesterol 
loads require regulatory pathways to come in action. 
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Supplemental Figure 1. Inhibition of Lxra promoter methylation by zebularine. 
The mouse hepatoma cell line Hepa 1 .6 was grown in Dulbecco' s modified Eagle medium, 1 0% fetal bovine 
serum (Gibco), under standard cell culture conditions. One day before treatment, 1 million cells/ 1 0  mm dish were 
seeded. Cells were incubated for 72 hours with O µM or 200 µM of the DNA methylation inhibitor zebularine, re­
spectively. DNA methylation was studied using bisulfite sequencing as described in Material and Methods. Open 
bars show the percentage of methylated CGs in control cells. closed bars in cells treated with zebularine. CpG 
positions are numbered according to Figure 1 . 
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Supplemental Table 1 .  Differentially methylated promoter sites in the male fetal mouse liver 
GOTERM BP 4: nucleobase, nucleoside, nucleotide and nucleic acid UHN score 
metabolism mmcpg 
Med28 mediator of RNA polymerase I I  transcription, subunit 28 0006966 -8.3 
homolog (yeast) 
Tcfap2b transcription factor AP-2 beta 0008668 -6.4 
Mib2 mindbomb homolog 2 (Drosophila) 0006460 -6.3 
Polr2d polymerase (RNA) I I  (DNA directed) polypeptide d 0007883 -6. 1 
Ebfl  early B-cell factor 1 00 1 4 1 3 1  -5.4 
Hist2h2bb similar to histone h2b-6 1 6  00081 1 6  -5.4 
Ebf4 early B-cell factor 4 0006826 -5. 1  
Pitxl paired-like homeodomain transcription factor 1 000 1 573 -4.9 
Pop7 processing of precursor 7 ,  ribonuclease P family 0005721 -4.8 
Sytl l synaptotagmin-like 1 0000775 -4.7 
Otp orthopedia homolog (Drosophila) 000801 1 -4.6 
Notch3 notch gene homolog 3 (Drosophila) 0002330 -4.4 
Narg i NMDA receptor-regulated gene 1 000 1 097 -4.3 
Dlx4 distal-less homeobox 4 0006582 -4.2 
lrxl l 1 iroquois homeobox protein-like 0000807 -4. 1 
Sox2 1 SRY-box containing gene 21  000 1 1 70 -4. 1  
Pitx2 paired-like homeodomain transcription factor 2 0006604 -3.7 
Nr l h3 nuclear receptor subfamily 1 ,  group h, member 3 0009844 3.7 
Esx l extraembryonic, spermatogenesis, homeobox 1 0000555 3.7 
Thoc3 tho complex 3 00 1 2926 3.7 
Gata4 GATA binding protein 4 0000388 3.7 
Pcaf p300/cbp-associated factor 000665 1 3.8 
H nrpc heterogeneous nuclear ribonucleoprotein c 0005 1 60 3.9 
Ziprol zinc finger proliferation 1 0000331 3.9 
Rln3 relaxin 3 0007265 4 
Al591 476 expressed sequence ai59 1 47 6 000 1 596 4 
24 1 001 8C20Rik riken cDNA 24 1 00 1 8c20 gene 0008401 4 
Zfp l 1 0  zinc finger protein 1 1 0 0000 1 20 4 
Sfrs5 splicing factor, arginine/serine-rich 5 (srp40, hrs) 0005236 4 
Thoc l tho complex 1 0000 1 72 4.8 
Tigd4 tigger transposable element derived 4 00001 76 4.8 
Mta2 metastasis-associated gene family, member 2 0000255 4.9 
Aars alanyl-tRNA synthetase 0007541 5 . 1  
Casp8ap2 caspase 8 associated protein 2 0007521 5.4 
Hod homeobox only domain 00002 1 9  8.2 
Apobec l apolipoprotein b editing complex 1 00 1 1 490 8.9 
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GOTERM BP 4: transport UHN score 
mmcpg 
Mmp23 matrix metallopeptidase 23 0006460 -6.3 
Jak2 janus kinase 2 00 1 0339 -5.5 
l 200009B 1 8Rik riken cDNA 1 200009b 18 gene 0008 1 1 9  -5.3 
Cacna l d  calcium channel, voltage-dependent, I type, alpha 0006644 -5.3 
l d  subunit 
Sytl l synaptotagmin-like 1 0000775 -4.7 
Dab2 disabled homolog 2 (Drosophila) 00 1 0 1 62 -4.6 
Trpc4ap transient receptor potential cation channel, subfamily 0000323 -4.4 
c, member 4 associated protein 
06 1 0009B22Rik riken cDNA 06 1 0009b22 gene 00 1 0573 -4.3 
Slc 1 7a5 solute carrier family 1 7  (anion/sugar transporter) , 0008041 -4.2 
member s 
Accn l amiloride-sensitive cation channel 1 ,  neuronal 00 1 380 1 -4 
(degenerin) 
Ndufs l nadh dehydrogenase (ubiquinone) fe-s protein 1 0000003 -4 
Cyp5 1 cytochrome P450, family 5 1  000885 1 -4 
Mtrr 5-methyltetrahydrofolate-homocysteine 0000544 -3.9 
methyltransferase reductase 
Aqp6 aquaporin 6 0003 1 27 -3.9 
Nrl h3 nuclear receptor subfamily 1 ,  group h, member 3 0009844 3.7 
Thoc3 tho complex 3 00 1 2926 3.7 
Lcn2 lipocalin 2 000 1 429 3.7 
Slc30a3 solute carrier family 30 (zinc transporter), member 3 00 1 1 486 3.8 
Abcf2 ATP-binding cassette, sub-family f (gcn20) , member 2 00 1 34 1 8  4 
Slc34a l solute carrier family 34 (sodium phosphate) ,  member 1 0004858 4 
Osbpl3 oxysterol binding protein-like 3 000895 1 4 
Cyp5 1 cytochrome P450, family 5 1  00 1 1 447 4 
Kirrel2 kin of irre like 2 (Drosophila) 0004278 4.5 
Ralb v-ral simian leukemia viral oncogene homolog B (RAS 0008352 4.8 
related) 
Thoc l tho complex 1 00001 72 4.8 
Tigd4 tigger transposable element derived 4 0000 1 76 4.8 
Mta2 metastasis-associated gene family, member 2 0000255 4.9 
Chmp4b chromatin modifying protein 4b 0009 1 20 5 
Kcnip l kv channel-interacting protein 1 0007488 5 . 1  
Utx ubiquitously transcribed tetratricopeptide repeat 0009539 5.5 
gene, x chromosome 
Attp signaling molecule A TTP 00 1 3683 6.2 
Mrc2 mannose receptor, c type 2 0007556 6.8 
Ntsr2 neurotensin receptor 2 0003794 7.6 
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GOTERM BP 4: regulation of cellular metabolism UHN score 
mmcpg 
Med28 mediator of RNA polymerase I I  transcription, subunit 28 0006966 -8.3 
homolog (yeast) 
Tcfap2b transcription factor ap-2 beta 0008668 -6.4 
Mib2 mindbomb homolog 2 (Drosophila) 0006460 -6.3 
Ebf l early B-cell factor l 00 1 4 1 3 1  -5.4 
Ebf4 early B-cell factor 4 0006826 -5. l 
Pitx l paired-like homeodomain transcription factor l 000 1 573 -4.9 
Otp orthopedia homolog (Drosophila) 000801 l -4.6 
Notch3 notch gene homolog 3 (Drosophila) 0002330 -4.4 
Narg i NMDA receptor-regulated gene l 000 1 097 -4.3 
Dlx4 distal-less homeobox 4 0006582 -4.2 
lrxl l iroquois homeobox protein-like l 0000807 -4. l 
Sox2l SRY-box containing gene 2 1  000 1 1 70 -4. 1 
Pitx2 paired-like homeodomain transcription factor 2 0006604 -3.7 
Nrl h3 nuclear receptor subfamily l ,  group h,  member 3 0009844 3.7 
Esxl extraembryonic, spermatogenesis, homeobox 1 0000555 3.7 
Gata4 goto binding protein 4 0000388 3.7 
Pcaf p300/cbp-associated factor 000665 1 3.8 
Zipro l zinc finger proliferation 1 0000331 3.9 
Rln3 relaxin 3 0007265 4 
Al59 1 476 expressed sequence ai59 1 47 6 000 1 596 4 
24 1 00 1 8C20Rik riken cDNA 24 1 00 l 8c20 gene 0008401 4 
Zfp l 1 0  zinc finger protein 1 1 0 0000 1 20 4 
Sfrs5 splicing factor, arginine/serine-rich 5 (srp40, hrs) 0005236 4 
Tigd4 tigger transposable element derived 4 0000 1 76 4.8 
Mta2 metastasis-associated gene family, member 2 0000255 4.9 
Casp8ap2 caspase 8 associated protein 2 0007521 5.4 
Hod homeobox only domain 00002 1 9  8.2 
GOTERM BP 4: protein metabolism UHN score 
mmcpg 
Mib2 mindbomb homolog 2 (Drosophila) 0006460 -6.3 
Jak2 janus kinase 2 00 1 0339 -5.5 
Hist2h2bb similar to histone h2b-6 1 6 00080 1 6  -5.4 
Grpel2 grpe-like 2, mitochondrial 00 1 0438 -4.9 
Map3k66 mitogen-activated protein kinase kinase kinase 0000775 -4.7 
Trpc4ap transient receptor potential cation channel. subfamily 0000323 -4.4 
c,  member 4 associated protein 
Traf2 tnf receptor-associated factor 2 0008336 -4.4 
Eef l b2 eukaryotic translation elongation factor 1 beta 2 0000003 -4 
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Nrl h3 nuclear receptor subfamily 1 .  group h,  member 3 0009844 3.7 
Cyp5 1 cytochrome P450, family 5 1  001 1 447 4 
Mta2 metastasis-associated gene family, member 2 0000255 4.9 
Attp signaling molecule ATTP 00 1 3683 6.2 
Mrc2 mannose receptor, c type 2 0007556 6.8 
Ntsr2 neurotensin receptor 2 0003794 7.6 
GOTERM BP 4: intracellular transport UHN score 
mmcpg 
Jak2 janus kinase 2 001 0339 -5.5 
1 200009B 1 8Rik riken cDNA 1 200009b 1 8  gene 0008 1 1 9  -5.3 
Sytl l synaptotagmin-like 1 0000775 -4.7 
Trpc4ap transient receptor potential cation channel. subfamily 0000323 -4.4 
c,  member 4 associated protein 
06 1 0009B22Rik riken cDNA 06 1 0009b22 gene 00 1 0573 -4.3 
Thoc3 THO complex 3 00 1 2926 3.7 
Kirrel2 kin of irre like 2 (Drosophila) 0004278 4.5 
Ralb v-ral simian leukemia viral oncogene homolog b (ras 0008352 4.8 
related) 
Thoc l tho complex 1 0000 1 72 4.8 
Utx ubiquitously transcribed tetratricopeptide repeat 0009539 5.5 
gene, x chromosome 
GOTERM BP 4: establishment of cellular localization UHN score 
mmcpg 
Jak2 janus kinase 2 00 1 0339 -5.5 
1 200009B 1 8Rik riken cDNA 1 200009b 1 8  gene 00081 1 9  -5.3 
Sytl l synaptotagmin-like 1 0000775 -4.7 
Trpc4ap transient receptor potential cation channel, subfamily 0000323 -4.4 
c, member 4 associated protein 
06 1 0009B22Rik riken cDNA 06 1 0009b22 gene 00 1 0573 -4.3 
Thoc3 tho complex 3 00 1 2926 3.7 
Kirrel2 kin of irre like 2 (Drosophila) 0004278 4.5 
Ralb v-ral simian leukemia viral oncogene homolog b (ras 0008352 4.8 
related) 
Thoc l tho complex 1 00001 72 4.8 
Utx ubiquitously transcribed tetratricopeptide repeat 0009539 5.5 
gene, x chromosome 
GOTERM BP 4: blopolymer metabolism UHN score 
mmcpg 
Jak2 janus kinase 2 001 0339 -5.5 
Hist2h2bb similar to histone h2b-6 l 6 00080 1 6  -5.4 
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Pop7 processing of precursor 7, ribonuclease P family, (s. 0005721 -4.8 
cerevisiae) 
Map3k6 mitogen-activated protein kinase kinase kinase 6 0000775 -4.7 
Traf2 tnf receptor-associated factor 2 0008336 -4.4 
Fbxo 1 7  f-box protein 1 7  00 1 0796 -3.9 
Prmt5 protein arginine n-methyltransferase 5 0005873 -3.7 
Thoc3 tho complex 3 00 1 2926 3.7 
Pcaf p300/cbp-associated factor 000665 1 3.8 
Hnrpc heterogeneous nuclear ribonucleoprotein c 0005 1 60 3.9 
Zdhhc l zinc finger, dhhc domain containing l 0009586 3.9 
Sfrs5 splicing factor, arginine/serine-rich 5 (srp40, hrs) 0005236 4 
Cul3 cullin 3 0004928 4. 1 
Dtxl deltex l homolog (Drosophila) 00 1 2898 4.2 
Ripk l receptor (tnfrsf) -interacting serine-threonine kinase l 000 1 664 4.3 
Trim2 tripartite motif protein 2 0009679 4.3 
Usp25 ubiquitin specific peptidase 25 001 0332 4.4 
Amy2 amylase 2, pancreatic 0009373 4.7 
Thoc l tho complex l 0000 1 72 4.8 
Mta2 metastasis-associated gene family, member 2 0000255 4.9 
Aars alanyl-tRNA synthetase 0007541 5 . 1  
Dusp6 dual specificity phosphatase 6 0000008 5.7 
Arl6 ADP-ribosylation factor-like 6 0007394 5.7 
Attp signaling molecule ATTP 00 1 3683 6.2 
Mib2 mindbomb homolog 2 (Drosophila) 0006460 6.3 
Apobec l apolipoprotein b editing complex l 001 1 490 8.9 
Usp38 ubiquitin specific peptidase 38 0002296 9.3 
GOTERM BP 4: cellular localization UHN score 
mmcpg 
Jak2 janus kinase 2 00 1 0339 -5.5 
l 200009B l 8Rik riken cDNA 1 200009b 1 8  gene 0008 1 1 9  -5.3 
Sytl l synaptotagmin-like l 0000775 -4.7 
Trpc4ap transient receptor potential cation channel, subfamily 0000323 -4.4 
c, member 4 associated protein 
06 l 0009B22Rik riken cDNA 06 l 0009b22 gene 00 1 0573 -4.3 
Thoc3 tho complex 3 001 2926 3.7 
Kirrel2 kin of irre like 2 (Drosophila) 0004278 4.5 
Ralb v-ral simian leukemia viral oncogene homolog b (ras 0008352 4.8 
related) 
Thoc l tho complex l 0000 1 72 4.8 
Utx ubiquitously transcribed tetratricopeptide repeat 0009539 5 .5 
gene, x chromosome 
Hepatic DNA from male dpc 19 .5 fetuses was used for a 4.6k CpG island microarray as described by Yan et 
al. [ 1 5] to identify differentially methylated clones. n=5 per group. Data were analyzed by the SAM software 
package [24]. The results were restricted to clones within 4000 base pair distance to a transcription start site and 
annotated and sorted by the GO term Biological Process, level 4 (BP4) using DAVID software [24]. A positive score 
indicates hypermethylation in fetuses from dams on protein restricted diet. UHNmmcpg: clone number, http:// 
data.microarrays.ca/cpgmouse/. 
LXR regulation by DNA methylation 
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6 . 1 7E-07 
Based on fetal liver DNA. the Lxra promoter CpG island was bisulfite-sequenced as described in the Materials and 
Methods section. 1 5  Clones from the control diet group and 18 from the protein restriction group were studied. 
CpG number refers to the relative number of the CpG island (as shown in Figure l B. whereas CpG position refers 
to the position in the promoter (Figure l A) . Number of methylated CpGs gives the number of methylated clones 
compared to the total number of clones studied, and the ratio presents the same data as percentage. The P­
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Abstract 
Intrauterine malnutrition is associated with increased susceptibility to 
chronic diseases in adulthood. Growth-restricted infants display a less fa­
vorable lipid profile already shortly postnatal. Maternal low protein diet 
(LPD) during gestation is a well-defined model of fetal programming in ro­
dents and affects lipid metabolism of the offspring. Effects of LPD through­
out gestation on physiological relevant parameters of lipid metabolism are 
unclear. We aimed to determine effects of LPD on maternal-fetal choles­
terol fluxes and fetal lipid synthesis in mice. Pregnant mice (dams) were fed 
a control (18% casein) or a low protein diet (9% casein) from E0.5 onwards. 
We quantified maternal-fetal cholesterol transport and maternal choles­
terol absorption at E19.5 using stable isotopes. We determined fetal lipid 
biosynthesis at E19.5, after administration of [1-13C] -acetate from E17.5 on­
wards. LPD did not change fetal and maternal plasma and hepatic con­
centrations of cholesterol and triglycerides. LPD affected neither the mag­
nitudes of maternal-fetal cholesterol flux, maternal cholesterol absorption, 
nor fetal synthesis of cholesterol and palmitate (both groups, -14% and 
-13%, respectively) . We conclude that LPD throughout gestation in m ice 
does not affect maternal-fetal cholesterol transport, fetal cholesterol or 
fatty acid synthesis, indicating that programming effects of LPD are not 
mediated by short-term changes in maternal-fetal lipid metabolism.  
Gestational low protein and lipid fluxes 
Introduction 
Epidemiological studies indicate that inadequate intrauterine nutrition 
is associated with increased susceptibility to develop chronic diseases 
in adulthood (e.g. diabetes, hypertension and cardiovascular disease; 
'metabolic programming') (28) . Comparably, associations between small 
body size at birth and a less favourable lipid profile in adult life have been 
described (2, 9, 15) . Already in the first postnatal days, growth restricted 
human infants display a more atherogenic lipid profile (increased plasma 
concentrations of triglycerides, total cholesterol and LDL-cholesterol) com­
pared to infants with a birth weight appropriate for gestational age (34) . 
Elevated plasma cholesterol is an established risk factor for the develop­
ment of cardiovascular diseases later in life, while on the other hand insuf­
ficient cholesterol supply to the fetus impairs its development (14). It was 
demonstrated that the fetus is capable of synthesizing a large fraction of 
the required cholesterol de novo (3, 12, 35) . As an independent source of 
cholesterol, maternal cholesterol can be transported to the fetal circula­
tion (37) .  Recently it was shown that maternal-fetal cholesterol transport 
is influenced by maternal plasma cholesterol levels (7) .  Interestingly, high 
maternal cholesterol levels increase the development of fetal aortic fatty 
streaks, as shown in human and animal studies (24, 25) . Hence, the meta­
bolic condition of the mother during pregnancy can affect lipid metabo­
lism in the offspring. 
Maternal dietary protein restriction during gestation is an established 
model to mimic fetal undernutrition and study metabolic consequences 
hereof in the offspring (1). Studies in rats have indicated that maternal 
protein restriction during gestation leads to features of the metabolic syn­
drome in adulthood, e.g. , increased blood pressure (20) , decreased insulin 
sensitivity and alterations in lipid profile (8, 23) .  In mice, maternal protein 
restriction during pregnancy impaired glucose clearance in the adult off­
spring (30) . Furthermore, experiments in mice showed that a low protein 
diet affected the renin-angiotensin system (important in the regulation of 
blood pressure) in the fetus already. (11) . 
Recently, we demonstrated in mice that maternal gestational protein 
reduced the expression of genes involved in lipid synthesis and cholesterol 
metabolism in the fetal liver (29) . Since the liver is a key player in regulat­
ing cholesterol and fatty acid homeostasis, we hypothesized that changes 
in fetal hepatic gene expression could translate into short term ("acute" ) 
effects on cholesterol and fatty acid metabolism (such as maternal-fetal 
cholesterol flux and/or fetal cholesterol and lipid synthesis) . I f  true, short­
term effects on fetal lipid metabolism could be involved in the mechanism 
by which metabolic programming takes place. We aimed to determine 
the acute effects of maternal protein restriction during gestation on ma­
ternal-fetal cholesterol flux and on de novo fetal cholesterol synthesis and 
fatty acid synthesis in mice. 
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Materials and Methods 
Animals 
C57BL/6J mice (age 20±1 weeks) were obtained from Harlan (Horst, The 
Netherlands) . Animals were housed in temperature-controlled rooms (23 
0C} with 12 hours light cycling, and free access to standard RMH -B mouse 
chow prior to the experiments (Arie Blok BV, Woerden , The Netherlands) 
and water ad libitum. Experimental procedures were approved by the lo­
cal Ethical Committee for Animal Experiments of the University of Gronin­
gen. 
Experimental procedures 
All females received the control diet containing 180 g casein/kg (puri­
fied diet, 4400. 1 8, Arie Blok BV, Woerden , The Netherlands) two weeks prior 
to mating. Virgin females were time mated using vaginal smears to assess 
their stage of estrous before introducing the male. After confi rmation of 
mating by detection of a vaginal plug, the females were allocated to either 
the control diet or the isocaloric low protein diet (90g casein/kg, purified 
diet 4400.17, Arie Blok BV, Woerden , The Netherlands) during the gestation­
al period. The experimental diets are identical to the diets used by Langley­
Evans (18) and are described in detail in Supplemental Table 1. Animals 
were weighed every two days. On embryonic day 14.5 (E l 4.5) pregnant 
mice received an intravenous dose of 0.52 mg (1.265 µmol) cholesterol-D7 
dissolved in lntralipid ® (20%, Fresenius Kabi, Den Bosch, The Netherlands) 
and an oral dose of 0.97 mg (2.30 µmol) cholesterol-D5 dissolved in medi­
um-chain triglyceride oil. Weights of the dams ranged from 27.3 to 33. 1 g 
at E 14.5 of gestation and were not significantly different between the two 
dietary groups. From E 17.5 onwards both diets were supplemented with 10 
mg/g [ 1 -13C] acetate (lsotec, Miamisburg, OH , USA} . Blood spots were col­
lected from the tail on filter paper before admin istration of labeled choles­
terol and acetate and daily from E14.5 onwards until E19.5 of gestation. At 
E l  9.5 females were anaesthetized with isoflurane and terminated by cardi­
ac puncture. Figure 1 shows a schematic overview of the experimental set­
up. Blood was collected in EDTA tubes. Liver and brain were snap-frozen in 
liquid n itrogen. Fetuses were removed from uteri, weight and length were 
measured and fetuses were sacrificed and dissected. Blood samples were 
taken by exsanguination. Liver and brain of fetuses were collected, imme­
diately snap-frozen in liquid nitrogen and stored at -80 °C. Sex of the fetuses 
was determined by PCR as previously described (16, 33) 
Analytical procedures 
Cholesterol was extracted from blood spots and plasma according to 
Neese et al (26). Hepatic and brain lipids from mothers and pups and lip­
ids from whole (complete) pups were extracted according to Bligh and 
Dyer (5) . Unesterified cholesterol from blood spots, plasma and tissues were 
analyzed by gas chromatography quadrupole mass spectrometry (32, 32). 
Gestational low protein and lipid fluxes 
Commercially available kits were used for the determination of total cho­
lesterol in brain, liver and plasma samples (Roche, Mannheim, Germany). 
Hepatic fatty acids from livers of mothers and their fetuses were analyzed 
by gas chromatography quadrupole mass spectrometry (27). 
Fractional cholesterol absorption measurement 
Fractional cholesterol absorption was measured using an adapted plas­
ma dual isotope ratio method (31) using blood spots obtained at 120 hours 
after intravenous and oral administration of stable-isotopically-labeled 
cholesterol. For calculation of the fractional cholesterol absorption, the ra­
tio of OS-cholesterol and D7-cholesterol in blood spots was divided by the 
ratio of OS-cholesterol and D7-cholesterol in the administered dose. The 
resulting value represents the fractional cholesterol absorption (32). 
Mass isotopomer distribution analysis (MIDA) 
To determine de nova cholesterol and palmitate synthesis, the MIDA ap­
proach was used (13, 26, 26). MIDA allows determination of the enrichment 
of the pool of acetyl-CoA precursor units that has entered newly synthe­
sized cholesterol or palmitate molecules during the course of [13C]-ace­
tate administration. Analysis of the isotopomer pattern of these molecules 
allows for determination of the fraction (f) of newly synthesized cholesterol 
or palmitate, respectively in plasma or tissue. All normalized mass isoto­
pomer distributions measured by GC-MS (mO- mOx) were corrected for 
the natural abundance of 13C by multiple linear regression as described 
by Lee (22) et al. to obtain the excess fractional distribution of mass isoto­
pomers (mO- mOx) due to incorporation of the infused [1-13C] acetate as 
described in (27, 27). For determination of the absolute amount of newly 
synthesized hepatic palmitate, we multiplied f by the total amount of he­
patic palmitate at the end of the experiment. 
Statistics 
We regarded the whole litter as one experimental unit, according to 
Festing (10). All data are presented as means ± SD. Statistical analyses were 
performed using SPSS 1 4.0 for Windows software (SPSS Inc., Chicago). All 
data were analyzed using the Mann-Whitney-U-test with a p-value smaller 
than 0.05 considered significant. 
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Figure 1. Experimental set-up. 
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Results 
Low protein diet affects body weight in dams but not in fetuses 
At E0.5 there was no difference in body weight of dams between both 
groups. At E 1 9.5, dams on a low protein diet had lower body weights than 
control dams (Table 1 ). Food intake during gestation was not different until 
E 1 7.5 (data not shown), but was lower in dams on a low protein diet be­
tween E 1 7.5 and E 1 9.5. There was no significant difference in the other pa­
rameters analyzed, including liver weight to body weight ratio of dams, 
litter size, body weight, body length or liver weight to body weight ratio in 
fetuses (Table 1 ). 
Table 1. Parameters of dams and fetuses at E l  9.5 of gestation 
Control diet Low protein diet 
weight dam (g) 35.6 ± 2.0 32. 1  ± 1 .0* 
food intake dam (g/day) 6.3 ± 1 .2 4.2 ± 0.7* 
liver weight 4.5 ± 0.4 5.0 ± 0.2 to body weight dam (%) 
litter size (n) 7.3 ± 1 .7 6.2 ± 2. 1 
weight fetus (g) 1 .07 ± 0. 1 l 0.99 ± 0. 1 5  
length fetus (mm) 20.4 ± 1 .4 20.5 ± 1 .5 
liver weight 2.8 ± 0.8 2.9 ± 1 . 1 to body weight fetus (%) 
Parameters of C57BL/6J dams and fetuses at El 9.5 of gestation receiving control diet or low protein diet during 
gestation. Data are mean ± SD. N= 5 (low protein) and 10 (control) dams per group; •, p<0.05 Low protein diet vs 
control diet 
Low protein diet does not affect total cholesterol concentrations in tissues 
To investigate if receiving a low protein diet during gestation influenced 
total cholesterol concentrations in dams and fetuses, we measured total 
cholesterol in tissues on El 9.5. Figure 2a shows that total cholesterol levels in 
liver or brain in dams did not significantly differ between the two groups. In 
fetuses, protein restriction did not significantly affect total cholesterol levels 
in liver, brain, or whole body (the complete fetus) (Figure 2b). 
Low protein diet does not affect maternal fractional absorption of choles­
terol. 
We investigated whether the low protein diet quantitatively affected 
cholesterol absorption in the dam and cholesterol transport to the fetus 
during the last stage of gestation. Cholesterol absorption in dams was 
found to be 64 ± 8% in control dams and 67 ± 8 in low protein (NS). 
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Figure 2. Total cholesterol levels in tissues of (A) dams and (B) fetuses. Whole body cholesterol in fetuses repre­
sents the amount of total cholesterol in the complete fetal body. Open bars, control mice; closed bars, mice 
receiving a low protein diet during gestation. Values represent the mean ± SD. n = 5 for low-protein dams and 1 0  
for control dams. 
Low protein diet does not quantitatively affect maternal-fetal cholesterol 
transport 
Maternal-fetal transport of cholesterol was determined by measure­
ment of the fraction of labeled cholesterol in several tissues of dams and 
fetuses at E1 9.5. To determine whether the administration route to the dam 
had any influence on cholesterol transport to the fetus, fractions of both D5 
and D7-labeled cholesterol in tissue and plasma were calculated. The rate 
of elimination of D5 and D7 cholesterol was measured every 24 hours after 
administration (E14.5) until termination (E19.5) and did not significantly dif­
fer between dams on low protein diet or on control diet (data not shown) .  
The fraction of orally administered D5 cholesterol constituted about 0.5% 
of total cholesterol in livers and plasma of both groups. The fraction of oral­
ly administered D5 cholesterol in brain was near detection level in dams of 
both groups (Figure 3a) . In fetuses at E19.5, the fraction of D5 cholesterol 
was measurable in liver, plasma, brain and whole body, albeit very low in 
both groups (Figure 3b) . 
The fraction of IV-administered D7 cholesterol in dams was 2.2 ± 0.2% in 
liver of control dams and 2.8 ± 0.2% in liver of low protein dams, 0.16 ± 0.04% 
in plasma of control dams an 0.36 ± 0.06% in plasma of low protein dams 
and below detection in brain at E19.5 of gestation for both groups (com­
parisons all NS, Figure 3c) .  In fetuses at E19.5, the fraction of D7 cholesterol 
was 1.0 ± 0.05% in liver of control fetuses and 
1.1 ± 0.06% in liver of low protein fetuses. Fractions of D7 cholesterol in 
plasma brain and whole body of fetuses were detectable, but below 0.5% 
in both groups (Figure 3d) . No significant differences were found in the frac­
tional enrichments of D5 or D7 cholesterol between control or low-protein 
dams or fetuses. 
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Figure 3. Fractional enrichments of orally administrated OS-cholesterol in tissues of {A) dams and {B) fetuses and 
of iv-administrated D7-cholesterol in tissues of (C) dams and {D) fetuses at day 1 9.5 of gestation. Open bars, 
control mice; closed bars, mice receiving a low protein diet during gestation. Values represent the mean ± SD. n 
= 5 for low-protein dams and l O for control dams. 
Low protein diet does not quantitatively affect maternal or fetal lipid syn­
thesis 
All dams received 1 3C-labeled acetate in the diet from E 1 7.5 onwards to 
investigate if receiving a low protein diet during gestation would influence 
cholesterol or palmitate synthesis in dams and fetuses in the last stage of 
gestation. Precursor pool enrichments were -9% for control dams and low 
protein dams at 24 and 48h (Figure 4a), indicating steady-state and com­
parable levels of precursor pool enrichment in both groups. Fractional con­
tribution of newly synthesized cholesterol was 1 1 .9 ± 0.4% for control dams 
and 9.2 ± 2.7% for low protein dams at 24h (NS) and 1 7.0 ± 0.6% for control 
dams and 1 4.9 ± 3.2% for low protein dams at 48h (NS, Figure 4b). 
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Figure 4. Fractional precursor pool enrichment {A) and fractional contribution of newly synthesized cholesterol {B) 
in dams on a control diet (open circles) or a low protein diet (closed squares) during gestation. Fractions were 
measured making use of blood spots collected on filter paper {n = 5 for low-protein dams and 1 0  for control 
dams) .  Dams received l 3C-labeled acetate in the diet from day 1 7.5 of gestation onwards. Blood spots ob­
tained 24 and 48 hours after administration were used for the calculations of the precursor pool enrichment and 
fractional contribution of newly synthesized cholesterol. Values represent the mean ± SD. 
Gestational low protein and lipid fluxes 
We determined the incorporation of newly synthesized cholesterol in 
the fetus by calculating fractional newly synthesized cholesterol at E1 9.5  in 
different tissues of dams and fetuses receiving the control diet or the low 
protein diet using MIDA. Fractional synthesis in dams was 1 7.4 ± 0.6% in liver 
for control dams and 1 5.0 ± 3.0% in livers of low protein dams, 1 6.7 ± 1 .5% in 
plasma of control dams and 1 4.4 ± 6.9% in plasma of low protein dams, 1 .4 
± 0.4% in brain of control dams and 1 .5 ± 0.4% in brain of low protein dams 
(all NS, Figure Sa) .  
Fractional synthesis in fetuses was 1 2.6  ± 0.5% in liver of control fetuses 
and 1 4.8 ± 2. 1 %  in liver of low protein fetuses, 1 3. 1  ± 2. 1 %  in plasma of con­
trols and 1 5.4 ± 5.3% in plasma of low protein fetuses, 3.3 ± 0.02% in brain 
of control fetuses and 4.0 ± 0.4% in brain of low protein fetuses, 9.7 ± 1 .4% in 
whole body of control fetuses and 1 0.7 ± 1 .2% in whole body of low protein 
fetuses (all NS, Figure Sb) . 
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Figure 5. De novo fractional cholesterol synthesis in tissues of {A) dams and (8) fetuses. Open bars. control mice; 
closed bars, mice receiving a low protein diet during gestation. 1 3C-acetate was administrated in the diet 
and fractional synthesis was calculated using MIDA. n = 5 for low-protein dams and 1 0  for control dams. Values 
represent the mean ± SD. 
No significant differences were found in fractional cholesterol synthesis 
between dams and fetuses on a control diet compared with dams and 
fetuses on a low protein diet. 
Fractional and absolute de novo synthesis of pa Imitate (Cl 6:0) in livers 
of dams and fetuses was calculated using MIDA. Fractional de novo syn­
thesized palmitate was 23 ± 2% in control dams and 23 ± 5% in low protein 
dams. Fractional de nova synthesized palmitate was 1 2.3 ± 0.4% in control 
fetuses and 1 4.8 ± 1 .0% in low protein fetuses (Figure 60) .  Absolute de nova 
synthesis of palmitate was 7.3 ± 1 .4 µmol/gram liver in control dams and 4.7 
± 0.9 µmol/gram liver in low protein dams (p 0.2) . Absolute de nova synthesis 
of palmitate was 1 8.7 ± 1 .4 µmol/gram liver in control fetuses and 25.0 ± 2.8 
µmol/gram liver in low protein fetuses (Figure 6b) .  No significant differences 
considering fractional or absolute de nova synthesis of palmitate between 
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Figure 6. De novo (A) fractional and (BJ absolute pa Imitate (C 1 6:0) synthesis in livers of dams and fetuses. Open 
bars, control mice; closed bars, mice receiving a low protein diet during gestation. l 3C-acetate was adminis­
trated in the diet and fractional and absolute synthesis were calculated using MIDA. n = 5 for low-protein dams 
and l O for control dams. Values represent the mean ± SD. 
Discussion 
A maternal low protein diet during the gestational period is a widely 
used animal model for intrauterine malnutrition to study the mechanisms 
underlying 'metabolic programming'. The purpose of using this diet during 
gestation is to mimic intrauterine malnutrition and its possible metabolic 
consequences. Most frequently, the low protein diet has been applied in 
rats in which gestational protein restriction resulted in impaired nephro­
genesis and hypertension (21), disturbed glucose tolerance, obesity and 
alterations in lipid metabolism (8) in the adult offspring. Several studies in 
mice demonstrate that maternal low protein during gestation leads to fea­
tures of the metabolic syndrome in offspring. Male offspring from protein­
restricted dams developed increased adiposity and glucose intolerance 
at adult age (4). When fed a high-fat diet, male offspring from protein re­
stricted dams show a higher increase in body weight, relative fat mass, 
hyperglycemia, hypercholesterolemia and hyperleptinemia, compared 
to high-fed diet offspring from control dams (6). Studying the metabolic 
effects of protein restriction during gestation in mice allows for extrapola­
tion to studies on programming effects in different knock out mice. In the 
ApoE*3-Leiden mouse, a model for development of atherosclerosis, mater­
nal protein restriction "aggrevated" the dyslipidaemia and induced more 
severe atherosclerotic lesions in female adult offspring fed an atherogenic 
diet (36). 
Some human and animal studies showed that metabolic programming 
has differential effects in adult male and female offspring, albeit inconsis­
tent. In the present study, no differences between male and female pups 
in the studied parameters were observed. 
We used a unique stable isotope method to determine maternal-fetal 
cholesterol fluxes and fetal lipid synthesis in mice. Administration of D5 and 
D7-labeled cholesterol to the dam enabled us to distinguish between cho-
Gestational low protein and lipid fluxes 
lesterol of different maternal sources transported from dam to fetus. The 
simultaneous administration of l 3C-acetate to the dam allows determina­
tion of cholesterol and fatty acid synthesis in maternal and fetal organs. 
In the present study, the low protein diet slightly decreased maternal 
food intake and maternal weight, when compared to control diet. Yet, no 
differences in fetal weight or length were seen in protein restricted fetuses 
compared to controls. The observation on fetal weight corresponds with 
several other studies using the same diet in rats {17, 19, 19). 
In previous experiments in mice, we showed that protein restriction dur­
ing gestation decreased mRNA expression of genes important in choles­
terol transport and fatty acid synthesis in fetal livers {29, 29). These data 
supported the hypothesis that acute effects on lipid homeostasis could be 
related to the induction of programming. The present study unequivocally 
demonstrates that maternal protein restriction during gestation does not 
induce acute, major quantitative changes in maternal-fetal cholesterol 
transport, cholesterol biosynthesis or fatty acid biosynthesis in the last stage 
of pregnancy in mice. This finding underscores the notion that changes in 
mRNA expression levels do not always translate into changes in physiologi­
cal relevant parameters. 
We do realize that a theoretical limitation of the present study is the rap­
idly changing metabolism of dam and fetus during gestation, which consti­
tutes metabolically a "non-steady state" condition per definition. We feel, 
however, that this limitation most likely applies equally for both the control 
and the low protein group, and does not invalidate our main conclusions. 
Another realization involves the timing of our experiment to the late stage 
of gestation. Theoretically, the protein restriction diet could have influ­
enced cholesterol flux to the fetus in the first stage of gestation. We do not 
have indications for this possibility as we did not find any differences in total 
cholesterol content in fetal organs in the last stage of gestation. Based on 
the results, it seems reasonable to assume that the effects of the maternal 
diet on cholesterol fluxes and/or on fetal hepatic lipid synthesis during the 
first stage of gestation are negligible. The presently used model does allow 
determination of effects of the maternal environment on maternal-fetal 
transport and on fetal cholesterol and fatty acid synthesis. The method 
could be applicable to studies investigating the influence of various mater­
nal conditions such as maternal overnutrition or maternal diabetes on fetal 
lipid metabolism. In conclusion, programming effects of maternal protein 
restriction during gestation are not accompanied by immediate changes 
in fetal-maternal cholesterol transport or lipid synthesis in mice. Apparently, 
programming effects of maternal LPD on lipid metabolism are more medi­
ated by more complex pathways than these acute effects. 
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Chapter 7 
Supplemental Data 
Component Control Diet Low Protein Diet 
(g per 1 00g diet) ( 1 8% casein) (9% casein) 
Casein 1 8.00 9.00 
Sucrose 2 1 .30 24.30 
Corn Starch 42.5 48.50 
Cellulose Fibre 5.00 5.00 
Vitamin mix AIN-76 0. 1 2  0. 1 2  
Mineral mix AIN-76 0. 1 2  0. 1 2  
Corn oil 1 0.00 1 0.00 
Choline choride 0.20 0.20 
Methionine 0.50 0.50 
Supplemental Table 1 .  Composition of the diets provided 
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Abstract 
Nutritional conditions during human fetal life can influence the risk to 
develop cardiovascular diseases and the metabolic syndrome in adult 
life ( 'metabolic programming' ). Dysregulated fatty acid metabolism and 
impaired glucose tolerance are hallmarks of the metabolic syndrome. We 
aimed to establish a mouse model of metabolic programming focusing on 
the effects of a maternal low protein diet during gestation on glucose and 
lipid metabolism in the adult offspring. Pregnant mice received a control 
or a low protein diet (18% vs. 9% casein) throughout gestation. Offspring 
received a low fat diet or a high fat diet from 6-22 weeks of age. Mater­
nal low-protein-diet did not affect glucose metabolism in male offspring. 
In male offspring, the high-fat diet led to insulin insensitivity, regardless of 
the diet of the dam. Female offspring from normal-protein fed dams was 
relatively resistant to diet-induced metabolic dysregulation.  Maternal low­
protein-diet during gestation led to deteriorated insulin sensitivity upon 
high-fat feeding in female offspring, as determined by biochemical and 
microarray analyses. We conclude that in mice maternal protein restriction 
during gestation does not change the glucose response to a high fat diet in 
male offspring. However, gestational protein restriction changes fatty acid 
and glucose metabolism in female offspring in such a way that it resembles 
male metabolism. Our findings show that while fetal malnutrition has lim­
ited impact in male mouse offspring, it programs an adapted response to 
high-fat diet in females. 
Long term effects of prenatal protein restriction 
Introduction 
A substantial number of studies in humans and animals show that malnu­
trition during fetal life increases the susceptibility to develop cardiovascular 
diseases and metabolic syndrome at adult age {3, 4, 27, 35). 
The inverse relationship between fetal nutrition and adult health has led 
to the formulation of the 'metabolic programming' hypothesis, stating that 
'early adaptations to a nutritional stress/stimulus can permanently change 
the physiology and metabolism of the organism and continue to be ex­
pressed even in the absence of the stimulus/stress that initiated them' {23). 
Major experimental support for this hypothesis comes from animal studies 
showing that prenatal nutrition is critically linked to the development of 
metabolic disease at adult age. In these studies, mostly performed in rats, 
maternal protein restriction {9% casein versus 1 8% casein in standard diet) 
leads to features of the metabolic syndrome at adult age in the offspring, 
e.g., obesity, increased blood pressure and decreased insulin sensitivity {12, 
17, 34). The underlying molecular mechanisms of metabolic programming 
have not yet been defined {36). One of the proposed mechanisms for met­
abolic programming refers to DNA methylation in the fetus {19-21 ). Animal 
studies indicate that the DNA methylation status of the promoter region 
of specific genes is associated with susceptibility to nutritional influences 
during fetal development, leading to life-long changes in metabolism {37 ). 
Previous studies in our laboratory have shown that in mice, maternal pro­
tein restriction causes a shift in global DNA methylation in the fetal liver, 
accompanied by acute gene expression changes in several metabolic 
pathways (Chapter 6). 
The long-term physiological consequences of maternal protein restric­
tion and of the shift in DNA methylation status in mice have not yet been 
extensively explored. Animal studies in this area have frequently applied 
rat models {7-9, 11). We aimed to transfer this nutritional model to mice, 
which would in future provide us with the opportunity to use genetically 
modified mouse models for mechanistic studies. We hypothesized that, 
in accordance to rats, protein restricted mouse offspring would display a 
higher susceptibility to develop features of the metabolic syndrome espe­
cially when challenged with a high-fat diet. 
We focused on several features of the metabolic syndrome, thereby ob­
taining a broad characterization of our model, including gender-selective 
programming effects. We examined whether maternal protein restriction 
affects glucose and lipid metabolism, and whether coping with a high-fat 
diet differs between genders. 
Our results indicate that in male mouse offspring, prenatal protein restric­
tion does not influence the response to a high-fat diet. In female offspring, 
however, prenatal protein restriction leads to a 'male type' of metabolism. 
Our study suggests that gender-specific factors are critically involved in 
metabolic programming. This finding may have implications for future 
treatment strategies of the metabolic syndrome. 
Chapter 8 
Materials and Methods 
Animals 
C57BL/6J mice were obtained from Harlan (Horst, The Netherlands). Ani­
mals were housed in temperature-controlled rooms (23 °C) with 12 hours 
light cycling and free access to standard pellet diet and water ad libitum. 
Experimental procedures were approved by the local Ethical Committee 
for Animal Experiments of the University of Groningen. 
Experimental procedures 
All females received the control diet (semisynthetic diet, 180 g casein/ 
kg, Arie Blok BV, Woerden, The Netherlands) two weeks prior to mating. 
Virgin females were time mated. After confirmation of mating by the ap­
pearance of a vaginal plug the females were allocated to be fed either 
the control diet or a low protein diet (semisynthetic diet, 90 g casein/kg) 
during the gestational period. Control and low protein diets are described 
in detail elsewhere (17). From postnatal day one on, all mothers received 
the control diet. Pups were weaned at postnatal day 21 and received the 
control diet until the age of 6 weeks. From this age on, the offspring re­
ceived either the control or a high fat diet (40% of calories from bovine 
lard, Arie Blok BV, Woerden, The Netherlands) for 14 weeks. At the age of 20 
weeks, mice were anesthetized and a microtip pressure transducer (Millar 
Instr. Inc. , Houston, TX, USA) was inserted into the aortic arch. After a 5-min 
period of stabilization arterial systolic/diastolic blood pressures (SBP, DBP) 
were recorded. Subsequently the catheter was inserted into the LV cavity 
via the right carotid artery. After another 5-min period of stabilization, heart 
rate (HR) was measured, after which the catheter was retracted. After these 
measurements, the mice were terminated by cardiac puncture. Blood was 
collected in EDTA containing tubes, and organs were snap-frozen in liquid 
nitrogen and stored at -80 °C until analysis. Samples for microscopic evalu­
ation were fixed in paraformaldehyde for Hematoxylin/Eosin staining. 
Insulin sensitivity 
One week before performing blood pressure measurements, a whole 
body glucose test was carried out in the offspring (n=4 per group), to de­
termine insulin sensitivity. Animals were fasted overnight for 9 hours before 
performing an intraperitoneal glucose tolerance test. Blood glucose be­
fore and after fasting was measured using a Lifescan EuroFlash glucose 
meter (Lifescan Benelux, Beerse, Belgium), and a blood spot after fasting 
and before T=0 was taken via the tail on filter paper. At T=0, 95mg/kg (or 
556 µmol/kg) of [6,6-2H] -glucose (20 mg/ml) was injected intraperitone­
ally. Blood glucose was measured and a blood spot was taken every 10 
minutes for 60 minutes, and subsequently every 15 minutes until 90 min­
utes had passed, after which one capillary of blood was drawn via orbita 
punction. Analysis of glucose was performed via extraction of 6.5mm discs 
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from blood spots in ethanol and extractions were analyzed using GCMS 
as described (30}. Plasma insulin concentrations were determined using 
a commercially available ELISA kit (Mercodia ultrasensitive mouse insulin 
Elisa, Orange Medical, Tilburg, the Netherlands} . Calculations on the glu­
cose fractions were performed as described in (31}. 
RNA isolation and micro-array 
Total RNA was extracted from frozen tissues with TriReagent (Sigma, St. 
Louis, MO, USA} . The quality and concentration of the RNA were deter­
mined using the 2100 Bioanalyser (Agilent, Amstelveen, The Netherlands} 
using the Agilent RNA 6000 Nano Kit. For amplification and labeling of the 
RNA with the lllumina TotalPrep RNA Amplification Kit (Applied Biosystems, 
Nieuwerkerk ad IJssel, The Netherlands} 200 ng of RNA from each sample 
was used. The Mouse Ref-8 vl . 1  (male} and Mouse Ref-8 v2.0 (female} ex­
pression arrays (lllumina, San Diego, USA} were processed according to 
the manufacturers' protocol. Slides were scanned immediately. First line 
quality check, background correction and quantile normalization of the 
data was done with Beadstudio Expression module v 3.2.7. Statistics and 
genelists were generated using Genespring GX 9 (Agilent} . Comparison 
was between changes in expression patterns from low-protein offspring on 
a high fat diet and normal-protein offspring on a high-fat diet. Since differ­
ent arrays were used for males and females, gene sets between genders 
could not be compared. Gene set enrichment analysis (GSEA, version 2.0} 
(28} was used to explore the global gene expression pattern. Gene sets 
passing the criteria FDR<0.05 and nominal p-value <0.01 were added to 
our lists. The a priori defined gene sets were obtained from the molecular 
signatures database where the c2 curated gene sets and additional lipid 
metabolism related (metabolic} sets (26} were used. 
Statistics 
All data are presented as mean ± SD with a p-value smaller than 0.05 
considered significant. Differences between the groups were analyzed by 
Univariate testing with a General Linear Model (3 way ANOVA} with diet 
during gestation, sex and diet after delivery as independent variables. 
Statistical analyses were performed using SPSS 14.0 for Windows (SPSS Inc., 
Chicago, USA} . 
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Results 
In utero protein restriction influences insulin sensitivity at adult age in fe­
males 
Prenata l diet did not influence body weight, liver weight to body weight 
ratio, fat pad weight to body weight ratio {Table l )  or body weight gain 
(Supplemental Figure l ). 
Table 1 .  Parameters of offspring at time of section 
Perinatal Postnatal liver weight Fat pad weight Average food intake 
Diet Gender Diet Weight ta body weight (%) ta body weight (%) during 12 weeks (g/week) 
Male LF 29. 1  ± 3.4 # 3.3 ± 0.8 4.5 ± 1 .5 20.6 ± 2.2 
1 8% HF 36.2 ± 5.4 .# 4.1 ± 0.7 6.6 ± 0.8 20.1 ± 1 .3 
Female LF 20.5 ± 1 .2 3.4 ± 0.7 1 .6 ± 0.9 1 7. 1  ± 1 .5 
HF 27.9 + 4.6 • 3.8 + 0.5 5.3 ± 2 . 1  20.4 + 2 . 1  
Male LF 28.5 ± 3.8 # 3.5 ± 0.8 4.8 ± 1 .8 20.3 ± 0.9 
9% HF 35.5 ± 5.0 "# 4. 1  ± 1 .0 6'2 ± 1 .3 1 9. 1  ± I . I  
Female LF 20.4 ± 1 .6 3.7 ± 0.4 1 .6 ± 0.9 1 6.7 ± 0.9 
HF 28.2 ± 5.0 • 3.9 + 0.5 6.8 ± 2.7 18.6 + 1 .8 
Parameters of C57BL/6J OlaHsd offspring at 20 weeks of age on low fat (LF) or high fat (HF) diet from dams 
receiving a normal-protein diet ( 1 8% casein) or a low protein diet (9% casein) during gestation. Values are mean 
± SD. N=6 per group. Significant differences of main effects are indicated by: •: p< 0.05 for high fat vs control; # 
: p<0.05 for male vs female. GLM analysis disclosed significant interactions between gender and postnatal diet 
concerning fat pad weight to body weight (p<0.05) and food intake (p <0.00 1 )  and between perinatal diet and 
postnatal diet concerning food intake (p<0.05). 
Serum fasting glucose concentrations were increased by -30% {p<0.001 ) 
in all high-fat fed offspring compared to low fat-fed offspring (Figure l a). 
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Figure 1 .  Plasma (A) glucose and (B) insulin concentrations and (C) insulin sensitivity in C57BL/6J offspring at 20 
weeks of age. The offspring received a low fat or a high fat diet from 6 to 20 weeks of age. Results from male 
(M) and female (F) offspring from normal protein-fed dams ( 1 8%) or low protein-fed dams (9%) are shown. Black 
bars, low fat-fed offspring; open bars, high fat-fed offspring. Values are mean ± SD. N=6 per group. Significant 
differences of main effects are indicated in the figures. • :  p< 0.05 for high fat vs low fat. GLM analysis disclosed a 
significant three-way interaction between prenatal diet, gender and postnatal diet concerning insulin concen­
trations (p=0.004) and a significant two-way interaction between prenatal and postnatal diet concerning insulin 
sensitivity (p=0.0 1 8) .  
Long term effects of prenatal protein restriction 
A three-way interaction between gender, prenatal and postnatal diet 
was found for plasma insulin concentrations (p=0.004). Insulin levels were 
increased by -200% on average in all high-fat fed offspring, except in high 
fat-fed female offspring from normal protein dams, who had unchanged 
insulin levels compared to low-fat female offspring (Figure 1 b). Considering 
insulin sensitivity, a two-way interaction between prenatal and postnatal 
diet was found (p=0.00). Insulin sensitivity was decreased by -40% in all 
offspring on a high fat diet compared to low fat offspring, except in high 
fat-fed female offspring from normal protein dams, that did not show 
changes in insulin sensitivity compared to low fat-fed females from normal 
protein dams (Figure le). Metabolic Clearance Rate (MCR) and Rate of 
Appearance (Ra) describe how fast glucose is cleared from the plasma 
and how fast glucose appears in the plasma, respectively. Combined, 
these parameters are a reflection of insulin resistance. Males on high fat 
diet had lower MCR compared to low fat-fed males (-18%). Females, how­
ever, showed unchanged MCR upon receiving a high-fat diet (Figure 2a) 
(two-way interaction between gender and postnatal diet, p<0.001). Ra was 
unchanged in male offspring receiving a high fat diet compared to low fat­
fed male offspring. In females, Ra was increased in high-fat fed offspring 
compared to low fat-fed females (+43%). (two-way interaction between 
gender and postnatal diet, p<0.001). Furthermore, a two-way interaction 
was found between gender and prenatal diet (low protein versus normal 
protein) considering MCR and Ra (p=0.04 and p=0.02, respectively). Both 
parameters were increased in low protein female offspring compared to 
offspring from normal protein dams (+15% for MCR and +20% for Ra), whi le 
no effect of maternal low protein on MCR or Ra was seen in male offspring 
(Figure 2a and b). 
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Figure 2. (A) Metabolic clearance rate and (B) rate of appearance of glucose in C578L/6J offspring at 20 weeks 
of age. The offspring received a low fat or a high fat diet from 6 to 20 weeks of age. Results from male (M) and 
female (F) offspring from normal protein-fed dams ( 1 8%) or low protein-fed dams (9%) are shown. Black bars, low 
fat-fed offspring; open bars, high fat-fed offspring. Values are mean ± SD. N=6 per group. GLM analysis disclosed 
significant two-way interactions between gender and postnatal diet concerning metabolic clearance rate 
(p<0.00 1 )  and rate of appearance (p<0.001 ) and between prenatal diet and gender concerning metabolic 
clearance rate (p=0.04) and rate of appearance (p=0.02). 
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Diastolic blood pressure is higher in offspring exposed to low protein in 
utero 
As increased blood pressure is one of the documented ha l lmarks of 
prenata l protein restriction in rats, we invasively measured blood pressure 
levels in a l l  offspring at 20 weeks of age.  Aortic diastol ic b lood pressure was 
higher in low protein offspring compared to offspring from normal protein 
dams (+ 1 2%, p=0.02, Table 2) . Aortic systo lic blood pressure was not influ­
enced by the prenata l  diet, but was s ignificantly h igher  in  male and female 
offspring exposed to the h igh-fat d iet compared to controls (+7%, p=0.04, 
Table 2) . Furthermore, an  interaction between prenata l  diet and postnata l 
diet was found considering heart rate (p=0.002} (Table 2) . 




Heart Rate {bpm) 
Systolic blood pressure Diastolic blood 
Diet Diet (mmHgl pressure (mmHgl 
LF 574 ± 45 99 ± 5 56 ± 6 
Male 
1 8% 
HF 553 ± 13  1 1 2 ± 1 2  * 63 ± 1 1  
LF 618 ± 23 107 ± 7 62 ± 6 
Female 
HF 521 ± 49 1 1 2 ± 1 4 *  67 ± 1 2  
LF 502 ± 66 1 1 5 ± 25 72 ± 21  + 
Male 
HF 600 ± 21  1 1 4 ± 17  * 68 ± 15 + 
9% 
LF 480 ± 59 1 07 ± 6 66 ± 6 + 
Female 
HF 536 ± 57  120  ± 25  * 71 ± 9 + 
Heart rate and blood pressure measured in oorto of C57BL/6J OlaHsd offspring at 20 weeks of age on low fat 
(LF) or high fat (HF) diet from dams receiving a normal-protein diet ( l 8% casein) or a low protein diet (9% casein) 
during gestation. Data are mean ± SD; N= 6 .  Significant differences of main effects are indicated by: •: p< 0.05 for 
high fat vs control; :): :  p<0.05 for low protein vs control. GLM analysis disclosed a significant interaction between 
prenatal diet and postnatal diet concerning heart rate (p<0.01 ) .  
In utero protein restriction does not influence cholesterol or  triglyceride 
levels in liver or plasma 
Hepatic cholesterol and trig lyceride concentrations  were higher in off­
spring receiving the high fat d iet compared to low fat-fed offspring (+35%, 
p<0 .001 and +90%, p< 0.001 , respectively) (Table 3) . P lasma cholestero l  
and trig lyceride concentrations were h igher in a l l  h igh fat-fed offspring 
compared to low fat-fed offspring (+40%, p<0.001 and +35%, p< 0 .02 ,  re­
spective ly) and in a l l  male offspring compared to females (+35%, p<0.001 
and +35%, p< 0.02, respective ly) . Diet of dams did not influence p lasma 
or hepatic cholesterol or trig lyceride concentrations in offspring (Table 3) . 
The prenata l d iet did not change p lasma FPLC cholestero l  profi les in male 
or female offspring,  nor plasma FPLC trig lyceride profi les in male offspring .  
However, female offspring from low-protein dams showed lower p lasma tri­
g lyceride levels compared to female offspring from normal-protein dams 
on a high fat d iet (Supplementa l Figure 2) . 
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Table 3. Hepatic and plasma cholesterol and triglycerides of offspring 
Perinatal Gender Postnatal Plasma Plasma Hepatic Hepatic Diet diet cholesterol (mM} triglycerides (mM} cholesterol (µmol/gl triglycerides (µmol/gl 
LF 4.89 ± 1 .27 # 1 .08 ± 0.51 # 4.60 ± 1 .43 10.5 ± 3.7 
Male 
HF 6.74 ± 2.69 ·# 1 .37 ± 0.86 .# 7.30 ± 2.97 • 26.6 ± 8.2 • 
1 8% LF 2.93 ± 1 . 1 7  0.8 1 ± 0.60 5.29 ± 1 .35 1 3.5 ± 5.4 
Female 
HF 4.42 ± 1 .88 • 1 . 1 4  ± 0.50 • 7.31 ± 2. 1 0 ' 23.2 ± 5.9 • 
LF 4.39 ± 1 .49 # 0.95 ± 0.48 # 4.76 ± 1 .65 13.3 ± 7.7 
Male 
HF 5.84 ± 1 .66 '# 1 .50 ± 0.91 '# 6.28 ± 2.34 ' 27.0 ± 1 2.2 ' 
9% 
LF 3.52 ± 1 .27 0.80 ± 0.27 5.55 ± 1 .64 1 4.8 ± 6.6 
Female 
HF 5.28 ± 1 .80 • 0.90 ± 0.25 • 6.54 ± 1 .25 ' 22.2 ± 10.0 ' 
Plasma and hepatic cholesterol and triglyceride concentrations in C57BL/6J OlaHsd offspring at 20 weeks of age 
on low fat (LF) or high fat [HF) diet from dams receiving a normal-protein diet ( 1 8% casein) or a low protein diet 
(9% casein) during gestation . .  Values are mean ± SD. N=6 per group. Significant differences of main effects are 
indicated by: •: p< 0.05 for high fat vs control; I; # : p<0.05 for male vs female. 
In utero protein restriction does not significantly influence hepatic steatosis 
at adult age 
We investigated whether receiving a low-protein diet in utero influenced 
the development of hepatic steatosis upon receiving a high-fat diet. HIE 
stained l iver sections of a l l  offspring groups were examined for hepatic 
steatosis . The high-fat d iet caused fat accumulation in a l l  offspring groups, 
independent from the diet of the dam during gestation (F igure 3A to F) . 
Figure 3. (A to H) histological changes in C57BL/6J offspring at 20 weeks of age. The offspring received a ow 
fat or a high fat diet from 6 to 20 weeks of age. Results from male and female offspring from normal prote·n fed 
dams or low protein-fed dams are shown. Histological sections of livers (magnification x20) were prepared and 
stained with Hematoxylin/Eosin or Masson trichrome. (A) low fat-fed male offspring of normal protein dams; [B) 
low fat-fed male offspring of low protein dams; (C) low fat-fed female offspring of normal protein dams; [D) low 
fat-fed female offspring of low protein dams; (E) high fat-fed male offspring of normal protein dams; (F) high fat­
ted male offspring of low protein dams; (G) high fat-fed female offspring of normal protein dams; (H) high fat-fed 
female offspring of low protein dams. 
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In utero protein restriction differentially affects gene expression patterns in 
adult offspring. 
A genome-wide comparison of transcriptional profiles was performed to 
explore global expression differences, using Gene Set Enrichment Analysis 
{GSEA). Instead of using a list of previously selected genes, GSEA uses the 
transcriptional level of the entire array to determine whether a priori de­
fined gene sets are differentially expressed . Gene sets were considered 
as significantly overexpressed at a nominal p-value of <0.01 and an FDR 
of >5%. We compared all high-fat diet groups with their respective low 
fat-fed controls and focused on gene expression sets involved in glucose 
and lipid metabolism. When comparing within gender and within diet of 
the dam, all offspring receiving a high-fat diet showed significant enrich­
ment of the mitochondrial fatty acid oxidation pathway and of the PPAR 
signaling pathway compared to offspring on a low fat diet (Table 4). The 
peroxisomal fatty acid oxidation pathway was enriched in all offspring 
from normal protein dams, and not in offspring from low-protein dams. 
A striking difference was seen regarding expression of genes involved in 
lipid metabolism. The lipogenesis pathway was significantly enriched in all 
offspring groups fed the high fat diet, except in the female offspring on a 
high fat diet from normal protein dams {Table 4). 
Table 4. Pathway enrichment or repression using Gene Set Enrichment Analysis 
Prenalol Diet Gender Pathway name Nominal p-value FOR q-value 
PPAR_SIGNALING_PATHWAY 0.000 0.009 
PEROXISOMAL_FATTY_ACID_OXIOATION 0.000 0,006 
PROTEASOME 0.000 0.005 
Normal NRF2-REGULATED_GENES_COMBINED 0.000 0.01 
Protein 
Mole Enriched 
MITOCHONDRIAL_FATTY_ACID_OXIDATION 0.000 0.01 
LIPOGENESIS 0.000 0,03 
MM_2-TISSUES·MUSCLE_FAT_BONE_AND_CONNECTIVE 0.000 0.04 
FATTY_ACID_METABOLISM 0.002 0.04 
Normal Mole Repres5ed COMPLEMENT_AND_COAGULATION_CASCADES Protein 0.000 0.02 
MITOCHONORIAL_FATTY _ACID_OXIDATION 0.000 0.006 
LIPOGENESIS 0,000 0.004 
MM_FATTY_ACID_SYNTHESIS_BIGCAT 0.000 0.004 
MM_KREBS-TCA_CYCLE 0.000 0.006 
PROPANOATE_METABOLISM 0.000 0.01 
Low Protein Mole Enriched MM_FATTY_ACID_BETA_OXIDATION_META_BIGCAT 0.000 0.01 
MM_FATTY _ACID_BET A_OXIDATION_ I _BIGCAT 0.002 0.02 
MM_ELECTRON_TRANSPORT_CHAIN 0.000 0,03 
MM_MITOCHONDRIAL_FATTY _ACID_BETAOXIDATION 0.000 0.03 
PPAR_SIGNALING_PATHWAY 0.000 0.03 
CITRATE_CYCLE_(TCA_CYCLE) 0.008 0.04 
EGF _SIGNALING_PATHWAY 0.002 0.05 
Low Protein Mole Repressed THE_4-I BB-DEPENDENT_IMMUNE_RESPONSE 0.000 0.03 
MM_SIGNAUNG_OF _HEPATOCYTE_GROWTH_FACTOR_RECEPTOR_BIOCARTA 0.000 0.03 
Long term effects of prenatal protein restriction 
Table 4. (Continued) 
MM_STATIN_PATHWAY_PHARMGKB 0.000 0.002 
Normal MITOCHONDRIAL_FAITT _ACID_OXIOATION 0.000 0.003 
Protein Female Enriched PP AR_SIGNALING_PATHWAY 0.000 0.05 
PEROXISOMAL_FATTY _ACIO_OXIDATION 0.005 0.04 
Normal Female Repressed No repressed pathways Protein 
MM_ELECTRON_TRANSPORT_CHAIN 0.000 0.001 
NRF2-REGULATED_GENES_COMBINED 0.000 0.003 
MM_STATIN_PATHWAY _PHARMGKB 0.000 0.003 
LIPOGENESIS 0.000 0.003 
CHOLESTEROL...SYNTHESIS_ESTERIFICATION 0.000 0.002 
Low Protein Female Enriched OXIDATIVE_PHOSPHORYLATION 0.000 0.003 
UPOPROTEIN_METABOLISM 0.000 0.02 
PPAR_SIGNALING_PATHWAY 0.000 0.03 
CITRATE_CYCLE_(TCA_.CYCLEJ 0.013 0.04 
GL YCINE,_SERINE_ANO_THREONINE_MET ABOLISM 0.000 0.05 
MITOCHONORIAL_FATTY _ACID_OXIDATION 0.01 1 0.05 
COMPLEMENT_AND_COAGULATION_CASCAIDES 0.000 0.002 
MM_IL-4_NETPATH_16  0.000 0.004 
MM_SIGNALING_OF _HEPATOCYTE_GROWTH_FACTOR_RECEPTOR_BIOCARTA 0.000 0.003 Low Protein Female Repressed 
MM_COMPLEMENT_AND_COAGULATION_CASCADES_KEGG 0.000 0.005 
TNFR2_SIGNALING_PATHWAY 0.000 0.005 
NFKB_ACTIV ATION_BY _NONTYPEABLE_HEMOPHILUS_INFLUENZAE 0.002 0.04 
Hepatic gene expression pathway enrichment and repression in C57BL/6J OlaHsd offspring at 20 weeks of age 
on a high-fat diet compared to a control diet, from dams receiving a control diet or a low protein diet during 
gestation. Analysis of pathways is described in the Materials and Methods-section. 
Discussion 
Maternal undernutrition increases the risk of developing the metabolic 
syndrome at a later age, a phenomenon referred to as "metabolic pro­
gramming" (22). Although different rodent models of metabolic program­
ming exist (2, 33), only limited information about gender-specificity in 
the development of metabolic syndrome is available (24). We examined 
whether maternal low protein diet during gestation differentially affects 
glucose and lipid metabolism in male and female mouse offspring. To 
characterize the capability to handle metabolic stress, we applied a sec­
ond hit strategy to the offspring by exposing them to a high-fat diet at adult 
age. A summary of all effects is shown in Figure 4. 
Prenatal protein restriction was favorable to insulin sensitivity in female 
offspring compared to control female offspring on a low fat diet, while 
no effects of protein restriction were seen in male offspring on a low-fat 
diet. Apparently, in utero protein restriction alters the female glucose me­
tabolism towards a more masculine reaction to glucose. In humans, the 
proportion of diabetes is higher in women than men ( 1 5), and high levels 
of estrogens and progesterone are associated with a reduction in insulin 
sensitivity ( 1 ). 
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Figure 4. Summary of all effects in (A) male and (B) female C57BL/6J offspring at 20 weeks of age. 1 8% M LF: low 
fat-fed male offspring of normal protein dams; 9% M LF: low fat-fed male offspring of low protein dams; 1 8% M HF: 
high fat-fed male offspring of normal protein dams; 9% M HF: high fat-fed male offspring of normal protein dams; 
1 8% F LF: low fat-fed female offspring of normal protein dams; 9% F LF: low fat-fed female offspring of low protein 
dams; l 8% F HF: high fat-fed female offspring of normal protein dams; 9% F HF: high fat-fed female offspring of 
normal protein dams. Blue arrows indicate the effects seen when offspring from low-protein dams was compared 
with offspring from normal-protein dams. Red arrows indicate the effects seen when high-fat fed offspring was 
compared with low fat-fed offspring. 
Long term effects of prenatal protein restriction 
Animal studies have shown that females are less sensitive to insulin than 
males, and more rapidly develop severe forms of diabetes than males (32) . 
It has been postulated that sex hormones might decrease the sensitivity of 
insulin in peripheral tissues (25) . Our results might imply that in female off­
spring, sex hormone concentrations are influenced by the in utero protein 
restriction. 
Our results seem to contradict a recent study investigating the develop­
ment of metabolic traits in adulthood after receiving a low-protein diet 
in utero in mice, in which no effects of the low protein diet in the female 
offspring regarding glucose tolerance are described (6) . Methodological 
differences could possibly explain the dissimilar outcome compared to 
our results. In the referenced study an oral glucose tolerance test (OGTT} 
is used to investigate glucose intolerance. We used a very small amount 
of labelled glucose (about 5 % of pool size} to investigate insulin sensitivity 
in conscious mice. This small amount did not change blood glucose nor 
insulin levels and so glucose metabolism is at steady state at basal (fasting} 
levels. In contrast, during OGTT blood glucose as well as blood insulin levels 
rise above basal values and change over time afterwards creating a non­
steady state metabolism. 
To investigate whether a second-hit strategy would ameliorate insulin 
sensitivity, we administered a high-fat diet to offspring from low-protein 
and normal-protein dams. Here, a second sex-specific effect on glucose 
metabolism was observed. Males on a postnatal high fat diet showed lower 
insulin sensitivity, reduced metabolic clearance rate and unchanged rate 
of appearance of glucose compared to low-fat fed males. High-fat fed 
females, however, showed lower insulin sensitivity, unchanged metabolic 
clearance, and higher rate of appearance of glucose upon receiving the 
high-fat diet. This might be an indication of the development of peripheral 
insulin resistance in male offspring (13) , while female offspring seemed to 
be developing hepatic insulin resistance ( 1 0) .  The mechanisms in which sex 
hormone levels influence peripheral or hepatic insulin sensitivity remain to 
be investigated. 
Our results in mice show that only diastolic blood pressure is significantly 
elevated by the prenatal diet, without sex-specific effects present. Our ob­
servations in mice are in accordance with those in rats of Tonkiss et al (29) ,  
who also showed a small increase in diastolic blood pressure in rat offspring 
from low protein dams. 
However, many studies in rats have shown that in utero protein restric­
tion leads to higher systolic blood pressure in adult offspring (7, 1 6-18) . This 
partial discrepancy to the results published for rats (e.g. no effect of the 
prenatal diet on systolic blood pressure in our study} might be due to dif­
ferences in analytical technologies. In most studies described in rats, the 
tail-cuff method is used to determine blood pressure. The aforementioned 
study by Tonkiss et al. shows that rat offspring from low-protein dams are 
more sensitive to stresssors compared to control offspring. Using the tail cuff 
method to measure blood pressure would therefore elicit a stress reaction 
instead of showing blood pressure differences. 
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Feeding a high-fat diet induces hepatic steatosis in mice (14) . We inves­
tigated whether in utero protein restriction programs the development of 
hepatic steatosis in offspring, by examining liver sections of offspring for 
steatosis and by determination of hepatic triglyceride concentrations. He­
patic fat accumulation was higher in high-fat fed offspring with no gender­
differences present, and was independent from receiving the prenatal diet. 
To gain more insight in whether the changes seen on a physiological 
level were also present on a gene expression level, we performed RNA 
m icro arrays on l iver samples of all offspring groups. Our data show that 
exposure to a low protein diet in utero affects gene expression patterns at 
adult age and that these changes are gender-specific. 
GSEA analysis showed that several gene sets were similarly enriched 
in all high-fat fed offspring, regardless of the diet of the dam. However, 
female offspring from low-protein dams displayed a significant enrichment 
of genes involved in lipid metabolism, similar to male offspring, while fe­
male offspring from normal-protein dams did not show this enrichment. This 
may imply that the masculin isation effect of in utero protein restriction in 
female offspring is also present on a gene expression level. 
We conclude that a prenatal low protein diet in mice causes modest 
effects on insulin sensitivity, blood pressure and gene expression patterns 
at adult age. In this respect, our mouse model resembles the well-charac­
terized rat model (2) . However, our data show that female offspring is more 
severely affected by the maternal diet than male offspring. Apparently, the 
regulatory network underlying glucose-and lipid metabolism in females 
is more sensitive to impacts during fetal life than in males. Future experi­
ments are indicated to determine whether the gender specificity is based 
on epigenetic mechanisms (e.g. , by different DNA methylation patterns 
or histone modifications) or on metabolic processes (e.g. by influencing 
sex hormone concentrations) . Hanson and Gluckman proposed that the 
fetal organism is programmed to fit to the anticipated environment in later 
life {Predictive Adaptive Response, (5) ) .  It is tempting to speculate that the 
effects observed in our studies, i.e. a masculinisation of female offspring, 
are aimed to prepare the organism to an environment where resources are 
limited and population density must be reduced. 
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Supplemental Figure 1 .  Weight curves of C57BL/6J offspring from 6 to 20 weeks of age. The offspring received a 
low fat or a high fat diet from 6 to 20 weeks of age. Results from male and female offspring from normal protein­
fed dams ( 1 8%J or low protein-fed dams (9%J are shown. (AJ Growth curves of male offspring, (BJ growth curves 
of female offspring. Black dotted lines: low fat-fed offspring of normal protein dams; black lines: high fat-fed off­
spring of normal protein dams; grey dotted lines: low fat-fed offspring of low protein dams; grey lines: high fat-fed 
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Supplemental Figure 2. Plasma FPLC profiles of C57BL/6J offspring at 20 weeks of age. The offspring received a 
low fat or a high fat diet from 6 to 20 weeks of age. Results from male and female offspring from normal protein­
fed dams ( 1 8%J or low protein-fed dams (9%J are shown. (AJ Triglyceride profile of male offspring, (BJ triglyceride 
profile of female offspring, (C) cholesterol profile of male offspring, (DJ cholesterol profile of female offspring. 
Black dotted lines: low fat-fed offspring of normal protein dams; black lines: high fat-fed offspring of normal 
protein dams; grey dotted lines: low fat-fed offspring of low protein dams; grey lines: high fat-fed offspring of low 







In 1992, the 'Fetal Origins of Health and Disease' hypothesis was 
postulated by Dr. David Barker, stating that ' the relation between retarded 
growth in early life and risk of adult disease is due to long term effects 
on physiology and metabolism imposed by an adverse environment 
during critical periods of development', a process also known as 'metabolic 
programming'{ l ,  10, 28) . Over the years, this hypothesis has been modified 
into the ' Predictive Adaptive Response {PAR) Theory'. Predictive adaptive 
responses describe the processes by which environmental interactions 
in early development lead to changes in the physiological and physical 
phenotype of the developing embryo/fetus/infant, not primarily for 
immediate survival advantage but in expectation of future advantage 
in a particular predicted adult environment (6) . The PAR theory extends 
the Barker hypothesis to a more evolutionary approach. The mechanism 
underlying metabolic programming and PAR is largely unknown. Epigenetic 
modifications could explain fetal adaptations to the uterine environment 
that lead to a metabolism that is mismatched for the future environment, 
predisposing to or increasing the vulnerability to develop certain metabolic 
diseases at a later age. 
In this thesis, two mouse models for metabolic programming are 
described, using either pharmacological or nutritional approaches to 
modify the fetal environment. We determined whether activation of a key 
regulator of cholesterol and fatty acid metabolism, the Liver X Receptor, 
during fetal development modified lipid metabolism immediately and 
on the long-term in the offspring of LXR agonist-treated dams. We also 
investigated the short-and long-term epigenetic and physiological effects 
of a well-known nutritional model for metabolic programming in rodents, 
i.e. feeding a diet low in protein during the gestation to dams. 
Pharmacological intervention - activation of LXR 
We determined whether pharmacological activation of the Liver X 
Receptor influenced fetal cholesterol metabolism and the susceptibility 
to develop cardiovascular diseases at later age. In mice, administration 
of a specific LXR agonist to the dam activated LXR in fetal organs during 
development, resulting in upregulation of LXR target genes, triglyceride 
accumulation in the fetal liver, higher fetal plasma cholesterol concen­
trations and lower fetal hepatic cholesterol content. Effects on fetal lipid 
metabolism were measurable three days after the start of the treatment 
and d iminished when the treatment was stopped. We did not observe 
effects of maternal LXR activation during pregnancy on parameters of 
cholesterol and fatty acid metabolism in the offspring at young-adult age. 
However, we could not exclude that long-term effects on metabolism are 
only present at a more advanced age, i.e. in old mice. Future research 
should therefore include ageing offspring. This would be particularly 
interesting since this would allow determining whether fetel LXR activation 
Chapter 9 
affects the formation of atherosclerotic plaques. 
It could be advantageous for the developing fetus to stimulate 
maternofeta l cholesterol transport by pharmacological means, for 
example in the case of feta l cholesterol biosynthesis defects. Smith-Lemli­
Opitz Syndrome (SLOS) is an inborn error of cholesterol metabolism in 
which the developing fetus is not able to synthesize cholesterol. The SLOS 
phenotype in humans ranges from a mild disorder with behavioural and 
learning problems to a lethal malformation syndrome. We and others were 
able to prove that cholesterol transport to the fetus can be increased by 
administration of the LXR agonist T0901317 to the dam during gestation (20) 
(Plosch in Biological Reproduction, Submitted) . The results a lso indicated, 
however, that the specific compound simultaneously exerted certain 
negative effects which can be detrimental to the mother and to the fetus, 
including hepatic steatosis in both mother and fetus. LXR activation induced 
reverse cholesterol flux, but a lso increased fatty acid synthesis in the liver. 
Long-term effects of hepatic fat accumulation in dam and fetus are 
unknown, but lead to hepatic steatosis and its detrimental consequences 
at a later age (4). An LXR agonist that only activates genes involved in 
cholesterol transport without activating lipid synthesis is presently not 
ava ilable. 
The pathophysiology of the SLOS has not yet been completely 
elucidated. In SLOS there is not only a shortage in cholesterol, but also an 
accumulation of  severa l cholesterol precursors in feta l tissues. I t  is unclear 
to what extent the shortage of cholesterol, the accumulation of these 
precursors, or both factors are responsible to the detrimenta l phenotype 
of SLOS (25, 31, 35) . I ncreasing the cholesterol flux from mother to fetus is 
therefore not expected to ameliorate the pathogenesis of SLOS babies. 
Nevertheless, our data indicate that it is feasible to manipulate at least one 
factor of the pathophysiology of SLOS by an LXR agonist, the maternofetal 
cholesterol transport. 
Nutritional intervention - short term physiological effects 
In a large number of epidemiological studies intrauterine growth 
restriction (IUGR) has consistently been associated with a higher risk of 
cardiovascular diseases at adult age (2, 1 6, 17, 23, 26, 30) . A commonly 
used animal model for I UGR involves feeding a diet low in protein during 
the gestation in rats. We now used the same dietary protocol in mice and 
characterized the effects of this treatment in this species. Dietary low protein 
results in inconsistent birth weight in rodents, varying from a decrease in 
many studies (5, 8, 12, 32-34) , to no change or even an increase in birth 
weight in others (11, 1 5) .  The low protein diet changed the DNA methylation 
status in pups and lowered the insulin sensitivity in adult offspring, even 
despite the similar birth weights observed in our studies. We therefore 
concluded that our mouse model is still relevant for studying metabolic 
programming, despite the absence of intrauterine growth restriction. 
As stated above, undernutrition during gestation seems to affect the 
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development of cardiovascular diseases in humans. Animal studies have 
shown that a low protein diet during gestation increases blood pressure in 
rat offspring (3, 12, 14). We assumed that the low protein diet would affect 
cholesterol metabolism in dam and fetus and investigated whether receiving 
a low protein diet during gestation influenced the cholesterol fluxes from 
dam to fetus. Using stable isotope methodology, however, our data clearly 
showed that the low protein diet did not quantitatively affect maternofetal 
cholesterol fluxes in the mouse. By inference, the low protein diet must have 
influenced the developing fetus on other aspects of metabolism, possibly 
on the development of the kidney, leading to hypertension at adult age. 
Since the focus of our experiments was on lipid metabolism, with the liver 
as central regulator of lipid metabolism, we did not investigate effects of 
the low protein diet on the kidney. However, several studies show that the 
low protein diet lowers nephron numbers in rat offspring, leading to sodium 
retention and subsequently higher mean arterial blood pressure, leading 
to cardiovascular diseases on the long term (13, 21, 22, 24, 34). It is tempting 
to speculate that similar phenomena occur in mice. 
Nutritional intervention - epigenetic modifications 
The mechanism underlying metabolic programming is still unknown. A 
proposed mechanism for metabolic programming involves altering DNA 
methylation state. DNA methylation is one of the mechanisms by which 
epigenetic regulation of gene expression takes place. DNA methylation 
in promoter regions can alter expression of genes without altering DNA 
sequence (7) . In general, DNA methylation causes repression of gene 
transcription while DNA demethylation causes activation of gene 
transcription (9). It has been postulated that a gestational low protein diet 
and, hence, a shortage of methyl group donors during fetal development, 
causes global DNA hypomethylation in offspring (18, 19). 
We showed that administration of a low protein diet to pregnant 
mice leads to specific shifts in genome-wide DNA methylation patterns, 
including both hypo- as well as hypermethylation of CpG-rich areas. 
Apparently, gestational low protein supply results in a relocation of the 
fetal resources, causing particular gene promoters to be methylated and 
others to be demethylated. This subsequently could cause downregula­
tion or upregulation, respectively, of expression of these genes. In this way, 
the fetus could be adapted to the predicted environment after birth by a 
changed DNA methylation status (9). 
Interestingly, we showed in mice that the Liver X Receptor is hyper­
methylated in offspring from low-protein dams, resulting in a reduction in 
expression of LXR and several of its target genes involved in cholesterol 
transport and fatty acid synthesis. The changes in gene expression levels 
during fetal development might have implications for the lipid metabolism 
of the offspring at a later age. However, direct effects of these gene 
expression changes in hepatic and plasma cholesterol and fatty acid 
levels in these fetuses were not detected. Further studies should elucidate 
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whether other epigenetic changes, e.g., histone modifications, are also 
present in offspring from protein restricted dams, and whether these 
changes influence lipid metabolism and the development of cardiovascu­
lar diseases at a later age. 
Nutritional intervention - interpretation of micro array results 
RNA micro arrays are often used to try to identify key genes responsible 
for processes seen on a physiological level. However, widely used software 
packages to calculate changes in gene expression levels (DAVID, GOTM) 
were not suitable for our model because of the relatively mild changes 
induced by our nutritional interventions. DAVI D and GOTM need rather 
robust changes in RNA expression levels to calculate differences in 
individual gene expression levels, after which genes can be allocated to 
different pathways. The Gene Set Enrichment Analysis-method (GSEA) (29) , 
that calculates differences in user-defined gene sets rather than focussing 
on individual genes, did enable us to determine changes in RNA expression 
patterns and to identify affected pathways. Using GSEA, we were able to 
show that feeding a low protein diet to dams during gestation leads to 
gender-specific changes in RNA expression patterns in offspring at 
adult age. We used a second-hit approach to investigate whether the 
gestational low protein diet would influence the coping with a high-fat 
diet at a later age. In all offspring groups receiving the high fat diet, the 
lipogenesis pathway was enriched, except in the female offspring on a 
high fat diet from normal protein-fed dams. This demonstrates that gene 
expression patterns at adult age are indeed influenced by the diet of the 
mothers, corresponding to the concept of metabolic programming. 
Nutrient intervention - long-term physiological effects 
We showed that a maternal low protein diet affects glucose metabolism 
and insulin sensitivity in adult mouse offspring. In fact, differences between 
control and low-protein fed offspring were mainly found on glucose 
metabolism and not, for example, on cholesterol metabolism. Possibly, this 
could be related to the fact that the low protein diet contained higher 
amounts of starch (+6% w/w) and glucose (+3 % w/w) compared to the 
control diet, in order to be isocaloric. A higher dietary glucose load can 
have affected maternal glucose metabolism, leading to effects on glucose 
and fat metabolism but not on cholesterol metabolism in the offspring. 
Higher amounts of starch instead of glucose could be added to the low 
protein diet to overcome effects on glucose and insulin metabolism of the 
dam caused by the higher glucose load of this diet. 
Unexpectedly, the maternal low protein diet during gestation led to 
gender-specific effects in the offspring at a later age. In male offspring, 
the low protein diet did not seem to influence the reaction to a high-fat diet 
at adult age. Female offspring from low-protein dams, however, showed a 
higher susceptibility to develop insulin resistance after receiving a high-fat 
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diet compared to appropriate controls from normal-protein dams. Gender 
differences between the offspring of protein restricted dams are not often 
investigated. Future research should focus on determining whether the 
gender specificity is based on epigenetic mechanisms (e.g., by different 
DNA methylation patterns or histone modifications) or on metabolic 
processes (e.g., by influencing sex hormone concentrations). Histone 
modifications and DNA methylation patterns should be investigated in 
gender specific fashion. In the present thesis we only studied male pups for 
epigenetic modifications. 
Nutritional intervention - use of other models 
Administration of a low protein diet during gestation is a valid model 
to mimic IUGR and its implications for later health. Although IUGR is still 
common in developed countries and a burden for developing countries, 
the majority of modern Western societies have to cope with dietary 
abundance and obesity. Therefore, we would like to propose that future 
research should include the epigenetic and physiological effects of feeding 
diets high in fat and glucose during the gestational period to dams in their 
offspring. Studies that have already been performed in mice show that 
overfeeding of the dam leads to hyperphagia, obesity and hypertension 
in adult offspring (27). Future research should elucidate whether these 
metabolic changes have an epigenetic basis. 
Conclusion 
The aim of the research described in this thesis was to unravel molecular 
mechanisms and physiological consequences of metabolic programming 
in mouse models. We showed in mice that during the gestational period, 
fetal l ipid metabolism can be modulated by administration of a synthetic 
agonist of the Liver X Receptor to the diet of the dam. We also showed 
that a maternal low protein diet during gestation leads to global DNA 
methylation changes in the fetus and that this low protein diet caused gen­
der-specific effects on lipid and glucose metabolism in the offspring. The 
results described in this thesis highlight the fact that maternal diet influences 
the metabolism of the offspring already during fetal development, which 
could predispose to cardiovascular diseases at a later age. Future research 
should focus on the influence of a maternal high-fat diet during gestation 
on health of the male and female offspring. The effects of the maternal 
diet on histone modifications in the offspring should also be investigated 
in male and female offspring separately. Together with DNA methylation, 
these epigenetic modifications could offer, at least in part, an elucidation 
of the mechanism underlying metabolic programming. 
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English Summary 
Human and animal s tudies indicate that the nutritional s tatus of the 
mother during pregnancy affects long-term health of the offspring . This 
process, in which early adaptations to specific nutritional conditions 
permanently change the physiology and metabolism of the organism 
and continue to be expressed even in the absence of the condition 
that initiated them, is termed "metabolic programming". The molecular 
mechanisms of metabolic programming are largely unknown. The aim of 
the research described in this thesis was to unravel molecular mechanisms 
and physiological consequences of metabolic programming. We have 
chosen to obtain metabolic programming by pharmacologically or 
nutritionally influencing the s tatus of the mother during gestation. 
The mechanisms by which fetal and early postnatal environment 
influence l ipid homeostasis in adult life are poorly defined. One of the key 
players in (adult) cholesterol and lipid metabolism is the Liver X Receptor. 
LXR alpha and beta have been shown to be crucially involved in the 
regulation of cellular cholesterol homeostasis in adult mammals, namely in 
the liver, the intestine and in macrophages. In short, the LXRs are activated 
by oxysterols (oxidized cholesterol derivatives) , bind to their heterodimer 
partner Retinoid X-Receptor (RXR) and activate transcription of their target 
genes. Important LXR targets are ATP-binding cassette (ABC) transporters 
involved in cholesterol efflux from cells to the intestinal lumen or bile 
(ABCG5/ABCG8) , or to highdensity lipoproteins (HDL) (ABCAl , ABCGl ) .  
Moreover, the LXRs activate transcription of genes responsible for de nova 
lipogenesis (SREBPl C, FASN) which provides a mean to detoxify choles terol 
by the formation of cholesterylesters. 
The role of LXR in fetal cholesterol and lipid metabolism had not been 
defined so far. In Chapter 2 potential means of cholesterol transport 
across the placenta are reviewed. We discuss how LXR might be involved 
in maternofetal cholesterol transport. We propose here that activation of 
LXR during fetal development might ameliorate the symptoms in patients 
with the Smith Lemli Opitz syndrome (SLOS) , an inborn error of cholesterol 
metabolism. Activation of LXR in the placenta would increase the expression 
of putative cholesterol transport genes and thereby provide a means to 
transfer cholesterol to the fetus. This, hopefully, would limit the severity of 
symptoms caused by the lack of fetal cholesterol synthesis in SLOS. 
In Chapter 3 we describe experimental s tudies in which pharmacological 
activation of LXR influences placental cholesterol transport in human 
placentas, human placental cell lines and in rodent placentas. In these 
studies we analyzed the expression pattern of LXRA and LXRB and their 
target genes during fetal development in the mouse placenta compared 
to the human placenta. In the mouse placenta we could demonstrate that 
both Lxra and Lxrb and their heterodimer partner R xr are constitutively 
expressed throughout the second half of pregnancy. In human placentas 
we demonstrated that both LXRA and LXRB are expressed throughout 
gestation, with higher levels of expression towards the end of pregnancy. 
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Furthermore, gene expression of target genes paralleled that of the LXRs 
and increased during gestation. This study provides information which may 
give us opportunities to influence maternal-fetal cholesterol transport. 
To delineate the functional importance of LXRs in control of fetal 
cholesterol, fatty acid and carbohydrate metabolism, we supplemented 
the diet of pregnant mice with a synthetic LXR ligand, T0901 31 7. In Chapter 
4, we describe the effects of pharmacologically activating Lxr during 
development on fetal cholesterol metabolism. In this study, we present 
for the first time evidence that LXR is functionally active in fetal liver when 
stimulated with the synthetic agonist T0901 31 7. Moreover, the pathways 
controlled by Lxr in adult mouse liver related to maintenance of cholesterol 
homeostasis can be influenced by providing this synthetic agonist via the 
diet of the dam. 
In Chapter 5 we evaluated how this pharmacological activation of Lxr 
during fetal development affected fetal fatty acid and glucose metabolism 
in the mouse. Our data show that this treatment results in acute effects on 
lipid homeostasis in dams and fetuses. Glucose homeostasis in fetuses was 
not affected by T0901 31 7 treatment. 
In both studies described in Chapter 4 and 5 we investigated whether Lxr 
activation byT0901 31 7, which induced profound changes in lipid metabolism 
in prenatal life, also had long-lasting effects in lipid homeostasis, i .e. into 
adulthood. Effects on cholesterol metabolism appeared to be transient 
and activation of Lxr in utero did not evidently affect coping with a H FHC 
diet in adulthood. Effects of  the treatment on fatty acid metabolism during 
adulthood were persistent but relatively minor, and apparently gender­
specific. 
We investigated metabolic programming in mice by nutritionally 
changing the status of the mother during gestation. A well-known model 
to investigate metabolic programming is by providing the dam with a mild 
protein deficient diet containing 9% casein instead of 1 8% casein. A limited 
number of recent studies describe epigenetic changes, e.g. changes in 
DNA methylation status of selected genes, in fetuses from dams receiving 
a protein deficient diet. 
In Chapter 6 we assessed genome-wide changes in DNA methylation 
in livers from pups born from low protein dams, and whether epigenetic 
changes influenced hepatic RNA expression levels of genes involved in 
lipid metabolism. We showed that in protein-restricted pups, the Lxr alpha 
promoter was hypermethylated. Hypermethylation of genes is associated 
with lower expression levels of these genes. As expected, expression 
levels of Lxr target genes involved in cholesterol transport and lipogenesis 
were reduced fetal liver upon maternal protein restriction. Our study 
demonstrated that, in mice, protein restriction during pregnancy interferes 
with DNA methylation in fetal liver. Lxra is a target of differential methylation 
and Lxra transcription is dependent on DNA methylation. It is tempting to 
speculate that perinatal nutrition may influence adult lipid metabolism by 
DNA methylation which may contribute to the epidemiological relation 
between perinatal/neonatal nutrition and adult disease. 
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Since protein restriction in dams led to lower expression levels of several 
genes involved in cholesterol metabolism in the fetal liver, we evaluated in 
Chapter 7 whether a maternal low protein diet during gestation influenced 
cholesterol fluxes from dam to fetus. We demonstrated that matern al 
protein restriction during gestation does not induce immediate, major 
quantitative changes in maternal-fetal cholesterol transport, cholesterol 
biosynthesis or fatty acid biosynthesis in the last stage of pregnancy in mice. 
This observation does not support the hypothesis that programming effects 
of maternal protein restriction during gestation are related to immediate 
changes of fetal lipid metabolism in mice. 
Finally, we determined the long-term effects of receiving a diet low in 
protein during the gestational period (Chapter 8). We examined whether 
maternal protein restriction affects glucose and lipid metabolism, and 
whether coping with a high-fat diet differs between genders. We focused 
on several features of the metabolic syndrome, thereby obtaining a broad 
characterization of our model, including gender-selective programming 
effects. 
Our results indicated that in male mouse offspring, prenatal protein 
restriction does not influence the response to a high-fat diet. In female 
offspring, however, prenatal protein restriction leads to a 'male type' of 
metabolism. Our study suggests that gender-specific factors are critically 
involved in metabolic programming. This finding may have implications for 
future treatment strategies of the metabolic syndrome. 
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Nederlandse Samenvatting 
Ondervoeding van de moeder tijdens de zwangerschap kan hart- en 
vaatziekten en type II diabetes bij hoar kinderen veroorzaken. Dit verband 
tussen prenatale voeding en ontwikkeling van ziekten op latere leeftijd 
wordt oak wel 'meta bole programmering' genoemd. Het doel van het in dit 
proefschrift beschreven onderzoek was om de moleculaire mechanismen 
die ten grondslag liggen aan metabole programmering te ontrafelen 
en de fysiologische consequenties van metabole programmering te 
onderzoeken. 
In het in dit proefschrift beschreven onderzoek zijn verschillende 
muismodellen gebruikt waarin metabole programmering met betrekking 
tot het cholesterol- en vetmetabolisme beschreven wordt. Een belangrijke 
regulator van het cholesterol- en vetmetabolisme is de Lever X Receptor 
(LXR). LXR alpha en beta zijn cruciaal voor de regulatie van de cellulaire 
cholesterol homeostase in volwassen zoogdieren, vooral in de lever, 
dorm en macrofagen. LXRs warden geactiveerd door geoxideerde 
cholesterolderivaten (oxysterolen), binden daarna aan hun heterodimere 
partner RXR en activeren in deze dimeer-vorm transcriptie van hun 
target genen. Belangrijke LXR targets zijn de ATP-binding cassette {ABC) 
transporters, die betrokken zijn bij cholesterol transport vanuit cellen naar 
het darmlumen of de gal {ABCGS/8), of naar HDL (ABCAl en ABCGl ). 
Verder activeren LXRs transcriptie van genen die betrokken zijn bij de nova 
lipogenese (SR EB Pl C, FASN). Activering van LXR veroorzaakt daarom een 
verhoging van het {goede) plasma HDL cholesterol, moor  heeft oak een 
negatieve bijwerking, namelijk vetstapeling in de lever. 
Over de rol van LXR in het foetale cholesterol en lipide-metabolisme was 
tot dusver weinig bekend. In Hoofdstuk 2 bespreken we mogelijke manieren 
van cholesteroltransport door de placenta. We bediscussieren hoe LXR 
betrokken zou kunnen zijn bij het transport van cholesterol van moeder 
naar foetus. Verder stellen we dot activering van LXR tijdens de foetale 
periode de symptomen in patienten met het Smith-Lemli-Opitz Syndroom 
{SLOS) zou kunnen verminderen. SLOS-patienten hebben een aangeboren 
afwijking in het cholesterolmetabolisme waardoor ze geen cholesterol 
kunnen aanmaken. Activering van LXR in de placenta zou de expressie 
van genen betrokken bij het cholesteroltransport kunnen verhogen. Dit 
zou ertoe kunnen leiden dot er meer cholesterol van moeder naar foetus 
getransporteerd wordt. Dit zou mogelijk de ernstige symptomen in SLOS­
patienten, mede veroorzaakt door een gebrek aan cholesterol, kunnen 
verminderen. 
In Hoofdstuk 3 beschrijven we experimentele studies waarin we 
farmacologische activering van LXR op het cholesterol transport in de 
humane placenta, humane placentale cellijnen en muizenplacenta's 
bestudeerd hebben. Genexpressiepatronen van LXRA, LXRB en 
targetgenen in humane en muizenplacenta' s  werden met elkaar 
vergeleken. We laten zien dot Lxra en Lxrb en hun heterodimere partner 
Rxr in de muizenplacenta vanaf de tweede helft van de zwangerschap 
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tot expressie komen. In humane placenta's komen LXRA en LXRB tijdens 
de hele zwangerschap tot expressie, waarbij een verhoogde expressie te 
zien is in het laatste trimester van de zwangerschap. De expressie van de 
targetgenen van LXR volgt eenzelfde patroon. De in deze studie verkregen 
informatie zou mogelijkheden kunnen bieden om het cholesteroltransport 
van moeder naar foetus te be"fnvloeden. 
De LXRs zijn belangrijke regulatoren van het cholesterol-, vetzuur- en 
koolhydraatmetabolisme in volwassen zoogdieren. Om te bepalen of 
LXR deze rol ook heeft tijdens de foetale periode, werd het dieet van 
zwangere muizen verrijkt met een synthetische LXR agonist, T0901317. In 
Hoofdstuk 4 beschrijven we de effecten van deze agonist op het foetale 
cholesterolmetabolisme. In deze studie laten we voorde eerste keerzien dot 
Lxr functioneel is in de foetale lever no stimulatie met T0901317. Bovendien 
kunnen de pathways, die in de volwassen muizenlever gereguleerd word en 
door Lxr en betrokken zijn bij de cholesterolhomeostase, ook in de foetale 
lever be"fnvloed warden door deze synthetische agonist aan het dieet van 
de zwangere muis toe te voegen. 
In de experimenten beschreven in Hoofdstuk 5 onderzochten we hoe 
deze farmacologische activering van Lxr tijdens de zwangerschap het 
vetzuur- en glucosemetabolisme in de muizenfoetus be·,nvloedde. Uit 
onze resultaten blijkt dot de orale toediening van T0901317 sterke, acute 
effecten heeft op het vetzuurmetabolisme van de moeder en foetussen. 
Het glucosemetabolisme van de foetussen wordt daarentegen niet 
be"fnvloed door de T0901317-behandeling. 
In de experimenten beschreven in Hoofdstuk 4 en 5 werd ook bekeken 
of de activering van LXR tijdens de foetale periode effecten had op het 
cholesterol- en vetzuurmetabolisme op jongvolwassen leeftijd van de 
nakomelingen. Effecten op het cholesterolmetabolisme lijken alleen 
op korte termijn (dus tijdens de foetale periode) aanwezig te zijn. De 
prenatale LXR activering had geen invloed op het cholesterolmetabolisme 
van de nakomelingen op latere leeftijd. Ook wanneer we een ' second 
hit' strategie toepasten, waarbij de nakomelingen een aantal weken 
long een dieet verrijkt met verzadigd vet en cholesterol kregen, waren 
er geen verschillen te zien tussen nakomelingen van LXR geactiveerde 
moeders en nakomelingen van controlemoeders betreffende het 
cholesterolmetabolisme. De prenatale activering van LXR had daarentegen 
wel effecten op het vetzuurmetabolime in de volwassen nakomelingen, 
hoewel dit vooral genexpressieverschillen betrof. Ook leek de prenatale 
LXR activering geslachtsspecifieke effecten te bewerkstelligen op het 
vetzuurmetabolime. 
Ook werd een welbekend proefdiermodel gebruikt om metabole 
programmering in nakomelingen te realiseren. Tijdens de zwangerschap 
werd een eiwitarm dieet gegeven aan muizen dot 9% caseine bevatte 
in plaats van 18%. In een aantal studies wordt beschreven dot dit model 
tot epigenetische veranderingen in de nakomelingen leidt. Epigenetische 
veranderingen zijn modificaties van o.a. de methyleringsstatus van het DNA, 
die de expressie van genen, en daarbij het metabolisme, op de langere 
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termijn zouden kunnen be'i"nvloeden. In Hoofdstuk 6 hebben we in muizen 
in het hele genoom de veranderingen van de DNA methyleringsstatus in 
de lever van pups van laag-eiwitdieet moeders , ten opzichte van pups 
van normaal-eiwitdieet moeders bepaald. Verder onderzochten we of 
deze epigenetische veranderingen invloed hadden op de expressie van 
genen betrokken bij het lipidemetabolisme. Het maternale laag eiwitdieet 
veroorzaakte in pups hypermethylering van de Lxr alpha promotor. 
Promotor-hypermethylering wordt geassocieerd met een lagere expressie 
van het betreffende gen. Zoals verwacht kwamen Lxr targetgenen, 
betrokken bij cholesteroltransport en vetzuursynthese, verlaagd tot 
expressie in pups van laag-eiwitmoeders. Deze s tudie loot  zien dot een 
laag-eiwitdieet in zwangere muizen de DNA methyleringsstatus in de 
foetale lever be'i"nvloedt. Deze veranderde methyleringsstatus zou effect 
kunnen hebben op het volwassen cholesterol- en vetzuurmetabolisme, 
en zou een verklaring kunnen geven voor het verband tussen prenatale 
voeding en de ontwikkeling van bepaalde ziekten op latere leeftijd. 
Aangezien hetmaternale laag-eiwitdieetverlaagde expressie van gen en 
betrokken bij het cholesterolmetabolisme veroorzaakte in de lever van de 
pups, bekeken we in Hoofdstuk 7 of deze genexpressieveranderingen het 
cholesteroltransport van moeder naar foetus be'i"nvloedt. Onze data loo t  
zien dot het maternale laag-eiwitdieet in muizen geen directe kwantitatieve 
veranderingen in het maternaal-foetal cholesteroltransport, de foetale 
cholesterol biosynthese of de foetale vetzuursynthese tot gevolg heeft in 
de laatste fase van de zwangerschap. Blijkbaar warden programming­
effecten van het maternale laag-eiwitdieet op het vetzuurmetabolisme 
gemedieerd door complexere routes don door deze parameters. 
In Hoofdstuk 8 behandelen we langetermijneffecten op de 
nakomelingen van een maternaal laag-eiwitdieet in muizen, om een 
volledig model te verkrijgen om metabole programmering te kunnen 
onderzoeken. We analyseerden de invloed van het prenatale dieet op het 
glucose- en vetmetabolisme, en bekeken of de reactie van het glucose­
en vetmetabolisme op een postnataal hoog-vet dieet veranderde 
door het prenatale laag-eiwitdieet. Ook het verschil in reactie op het 
postnatale dieet, tussen de mannelijke en vrouwelijke nakomelingen, werd 
onderzocht. Verschillende aspecten van het metabool syndroom werden 
bekeken, waarbij een brede karakterisatie van ons model verschaft werd, 
inclusief sexe-specifieke effecten van metabole programmering. In de 
nakomelingen van normaal-eiwit moeders zijn er duidelijke verschillen 
te zien tussen mannelijke en vrouwelijke nakomelingen, in de reactie van 
het glucose en vetmetabolisme, op een postnataal hoog-vet dieet. Het 
prenatale laag-eiwitdieet heeft in de mannelijke nakomelingen geen 
invloed op deze reactie. In vrouwelijke nakomelingen daarentegen, zorgt 
het prenatale laag-eiwitdieet wel voor een verandering in deze reactie. 
Deze lijkt nu meer op een mannelijk type reactie. Deze bevindingen 
zouden kunnen impliceren dot de voedingss tatus van de moeder tijdens 
de zwangerschap geslachtsspecifieke effecten heeft op het metabolisme 
van hoar kinderen. 
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En don nu het meest gelezen stukje van elk proefschrift: het dankwoord. 
ledereen die ik in de afgelopen 5 jaar heb leren kennen en die op de een 
of andere manier betrokken was bij mijn onderzoek stoat al genoemd in 
de 'Wardle' op de pagina hiernaast, moor jullie verwachten natuurlijk een 
korte uitleg bij deze namenwolk. Bij deze. 
Ten eerste wil ik graag mijn promotoren Folkert Kuipers en Henkjan 
Verkade bedanken. Folkert, no een gesprek met jou liep ik altijd weer 
gemotiveerd je kamer uit. De opmerkingen die je in de kantlijn van mijn 
stukken plaatste bleken -no decryptie- vaak geniaal. Dank voor je goede 
ideeen en vertrouwen. Henkjan, hoewel je mijn gehele promotietraject 
betrokken was bij mijn onderzoek, heb je me vooral het laatste jaar enorm 
geholpen bij het afronden van mijn stukken. Ons deadline-schema werkte 
zeer motiverend en je scherpe en kritische blik maakten dot ik zelf weer 
met frisse blik (en moed) naar mijn papers kon kijken. Bedankt! 
Zehr geehrte Dr. Plosch, beste Torsten, onze metabole programmerings­
experimenten waren niet de makkelijkst uitvoerbare proeven. 
Nachtbewaker op het dierenlab, pup-verzorger en muizenmelker waren 
oak niet de rollen die jij je voorgesteld had als post-doccer (en nee, we 
waren niet in sloop gevallen!). Onze reisjes naar Praag, Cambridge en 
Maastricht waren erg gezellig en uiteraard leerzaam. Jij bent mede 
verantwoordelijk voor de dikte van dit proefschrift. Heel erg bedankt voor 
alles! 
Verder wil ik graag de leescommissie, prof. Bert Groen, prof. dr. Pieter 
Sauer en prof. dr. Marten Hofker bedanken voor de beoordeling van mijn 
manuscript. 
AIO-zijn is veel leuker als je met z'n alien in hetzelfde schuitje zit. Graag 
wil ik hierbij alle oud-collega's bedanken voor de leuke tijd op het 
lab en alle anekdotes die ik door jullie op papier heb kunnen zetten. lk 
hoop de AIO-quotes ooit nag eens in boekvorm uit te kunnen brengen. 
Mijn oud-kamergenoten Margot (ik heb nag een vraag!), Niels (de 
stereotiepste bioloog), Joana, Wytske, Maaike (als mede ex-Wageninger, 
ex-voedingsmiep en zelfs even huisgenoot, mijn onbewust-grootste 
voorbeeld), Jelske, Leonie, Titia, Anniek W, Martijn en Hans, bedankt 
voor alle vrolijkheid en de gelegenheid om even goed te kunnen zeuren 
wanneer het eens wot minder ging. Henk, je hebt het met ans uitgehouden, 
ik heb diep respect voor je rustige houding tegenover alle kipjes. 
Hester, het heeft even geduurd, moor ans fluxenstuk is nu toch 
eindelijk gesubmit! De resultaten waren misschien niet erg hoopgevend, 
aan de uitvoering heeft het niet gelegen. Bedankt voor alle lab- en 
schrijfgezelligheid (en het wijntje erna). 
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Alie KG-AIO' s, post-doccers en MDL'ers: Sabina (mijn andere grate 
voorbeeld: partyanimal en extreem horde werker), Maxi (wanneer is het 
volgende feestje?), Anke, Annelies, Hilde, Harmen, Jan Freark (het beste 
Sinterklaasgedicht was van jou), Frans C. (er zit iets in je hoar .. . ), Jaap, 
Anniek K. (de recruiter, bedankt! ), Marije, Janine, Marijke, Anja, Yan,  
Miriam, Karin G, Gemma, Jurre, Aldo, Edmond, Thomas, Frans S ,  Klary, Dirk­
Jan ,  Uwe, Robert, Axel, Jannes, Sandra, Krysztof, Antonella, Laura, Han, 
Klaas-Nico, Titia en Elise, bedankt! 
Experimenten zijn  het best uitvoerbaar samen met experts. Juul, 
ongelofelijk bedankt voor alle uren (dagen!) op het dierenlab (termineren 
met chill-out muziek op de achtergrond, wie wil dot nu niet? ! ), de stapels 
coupes die je voor me gekleurd hebt en natuurlijk voor het hardlopen op 
dinsdag. Het was erg gezellig! Vincent, jouw statistisch inzicht heeft me de 
' leukheid' van SPSS doen inzien, en me veel enthousiaster gemaakt over 
mijn micro-array data. Heel erg bedankt! Nicolette, je hebt me ingewijd in 
de geheimen van het kloneren en hebt me zelfs geleerd te 3-punts ligeren 
(ik ben er nag steeds trots op dot het zomaar lukte), bedankt! Theo & Theo, 
een hele tijd leek het er op dot ik geen enkel experiment op het metabole 
lab uit zou voeren, moor gelukkig heb ik in mijn laatste jaar volop gebruik 
kunnen maken van jullie expertise op het gebied van pieken en tluxen. 
Bedankt! ledereen (Jonny, Fjodor, Renze, Rick, Wytse, Janneke, Marianne, 
Manon, Mariska, Janette, Tjasso, Lisette, Fiona, Klaas, Elles, Pim&Pim, Albert, 
Hermie, Conny) op het kindergeneeskunde/ MDL en metabool lab, heel 
erg bedankt voor de goede sfeer op het lab en het voor me klaarstaan als 
ik iets te vragen had. 
De dames van het secretariaat, Hilde R. en Geo, bedankt voor de 
gezelligheid, het tel kens moor weer opnieuw aan me uitleggen hoe de fax 
werkt, en voor alle enveloppen die ik van jullie 'geleend' heb. Els, heel erg 
bedankt voor het reserveren van tijd in Henkjans agenda! ledereen op het 
C D P, en in het bijzonder Sylvia, Yvonne, Natasha, Ralph, Wiebe, Flip en Alex, 
bedankt voor het stroomlijnen van mijn experimenten en het meehelpen 
bij de uitvoering van sommige onmogelijk-lijkende proeven (muizenpups 
geboren zien warden was blijkbaar echt niet voorbestemd voor mij). 
Irma Kuipers, Inge Boudoin en Rudolf de Boer, heel erg bedankt voor 
alle Millar-experimenten, het heeft nag niet geleid tot een publicatie moor 
het kan niet long meer duren. Irma, heel erg veel succes met jouw laatste 
loodjes, het komt goed! Annette Gouw heeft me laten inzien dot er oak 
al heel erg veel te meten is aan een lever voordat je 'm prakt voor RNA­
isolatie. Histologie is zoveel interessanter don ik besefte, bedankt hiervoor! 
Toen mijn tijd bij Kindergeneeskunde erop zat werd ik met open armen 
binnengehaald op het Medische O ncologie lab, waar ik in zeer korte tijd 
klaargestoomd werd voor het betere PET-scan werk (en voor nog een 
heleboel andere soorten scans waar ik daarvoor nag nooit van gehoord 
had). 
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Bij deze wil ik graag Thijs, Wouter, Nienke, S i lke, Hetty, Coby, Steven ,  
Liesbeth, Arne, Bodvael ,  Lina,  Dorenda (bedankt voor het in ju l l ie huisje 
mogen wonen! )  en a l le andere nieuwe col lega ' s  van Medische Oncolg ie 
bedanken voor a l les ,  en voora l voor het bieden van de vrijheid om nag 
aan mijn boekje te kunnen werken .  
Wanneer ik te d iep weg dreigde te zakken in  mijn  onderzoek­
bes lommeringen was er gelukkig a ltijd een fanatiek groepje mensen in 
de buurt dot me dwong om in  gezelschap vreemde series te kijken,  me 
meetrok naar  de bias of ervoor zorgde dot ik uit mijn dak kon goon op 
een technofeest. Bram (De Spi l ) ,  Sabina,  John ,  N iels, Marc,  Laura,  Sarah ,  
MaartendJ,  WouterB, Huygen,  bedankt! Sebastiaan ( 'ze noemen me oak  
wel een creatief genie' ) ,  ongelofel ijk  bedankt voor  het ontwerpen van d e  
omslag van d it proefschift, het ziet e r  geweldig uit! 
Noortje C ,  bedankt voor a l  onze Buckshot-avonden en heel veel  ge luk  
in Kameroen met  Martijn ,  ik  hoop dot ju l l ie d ie  7x  Neder land per  jaar  goon 
ha len want i k  m i s  ju l l ie nu a l !  NoortjevdM, er  wordt te  weinig gebeld tussen 
Utrecht en Groningen,  hier goon we wot aan doen! Mijn paranimfen 
Sabina en Janneke (die dansvloer goat ans nag heel vaa k  terugzien ! ) ,  
heel erg beda n kt dot  ju l l ie me bij wi l len staan vandaag,  ik  hoop op nag  
veel meer feestjes samen in de toekomst! 
Luuk, ik  heb ongelofel ijk  veel  mooie herinneringen aan onze tijd samen 
en ben bl ij dot we e lkaar nag veel  zien .  J ij hebt me meegemaakt in goede 
en minder goede tijden,  bedankt voor a l le keren dot je voor me k laa r  
stand.  
Mijn ' kle ine zusje' Miriam en Joop, bedankt voor het aanhoren van 
mijn A IO-troubles, en za l ik don  nu toch echt een keer naar een wedstrijd 
komen kijken? Pap en mom, ju l l ie hebben me geleerd dot wanneer je iets 
echt wi lt, het oak lukt. Door ju l l ie ben ik de persoon die ik nu ben, bedankt 
daarvoor! 
Maarten ,  we zijn nag helemaal  n iet zo long samen, moor kennen e lkaar  
a l  zo  ongelofel ijk  goed.  Al les wordt makke l ijker wanneer jij in de buurt bent. 
Die laatste loodjes vielen eigenl ijk  best mee, dankjewel dot je er voor m e  
bent! 
Het leven is een feest; dot moet gevierd warden!  
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Curriculum vitae 
Esther Maria Elisabeth van Straten werd op 13 september 1 980 
geboren in Maasbree. Na het behalen van hoar atheneum diploma 
aan het Blariacumcollege te Blerick, began zij in 1998 met de studie 
Voeding en Gezondheid aan Wageningen Universiteit. Haar eerste 
afstudeeronderzoek deed zij bij de vakgroep Fysiologie van Mens en Dier 
van Wageningen Universiteit, onder begeleiding van dr. J.A. Nolles en 
dr. V.V.A.M. Schreurs. Een gedeelte van hoar studie bracht zij in Australie 
door, waar zij in het kader van hoar stage onderzoek deed aan het Child 
Nutrition Research Centre in Adelaide, onder begeleiding van ass. prof. 
R. Gibson. Vervolgens deed zij bij de vakgroep Nutrition, Metabolism and 
Genomics van Wageningen Universiteit een tweede afstudeeronderzoek, 
onder begeleiding van dr. ir. G.J. Hooiveld en prof. dr. M. Muller. Na hoar 
afstuderen in 2003 werkte zij een aantal maanden als onderzoeksassistent, 
wederom bij de vakgroep Nutrition, Metabolism and Genomics 
aan Wageningen Universiteit. In september 2004 began zij aan het 
Universitair Medisch Centrum Groningen bij het Onderzoekslaboratorium 
Kindergeneeskunde met het in dit proefschrift beschreven onderzoek 
naar de mechanismen onderliggend aan metabole programmering van 
het vet- en cholesterolmetablisme, met als promotoren prof. dr. F. Kuipers 
en prof. dr. H.J. Verkade. Van december 2008 tot en met juli 2009 werkte 
zij als onderzoeksassistent bij de vakgroep Medische Oncologie van het 
Universitair Medisch Centrum Groningen. Vanaf september 2009 is zij bij 
deze vakgroep van prof. dr. Liesbeth de Vries gestart als project manager 
van MAMMOTH, een landelijk onderzoeksconsortium binnen het 'Center 
for Translational Molecular Medicine {CTMM) ', dot als doelen het vroeger 
opsporen en beter behandelen van borstkanker heeft. 
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